

**Plaintiff's Objections to Defendants' Exhibit  
List  
EXHIBIT A**

## Plaintiff's Smith Objections To Defendants' Exhibits (4/27/2010)

| Ex#    | Description  | Authenticity | Substantive Objection   |
|--------|--|--------------|---|
| DX0001 | Richard Smith's National Health Laboratories Medical Records.                  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0002 | Richard Smith's Wood, Christopher L. DDS, Dental Records.                      | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0003 | Richard Smith's Berklacich, Frank M. MD, Medical Records.                      | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0004 | Richard Smith's Action Quick Corporation, Medical Records.                     | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0005 | Richard Smith's Baptist Hospital, Medical Records.                             | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0006 | Richard Smith's Blue Cross and Blue Shield of Tennessee, Insurance Records.    | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0007 | Richard Smith's Cardiology Group of Middle Tennessee, Medical Records.         | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0008 | Richard Smith's Centennial Medical Center, Medical Records.                    | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0009 | Richard Smith's Centers for Medicare and Medicaid Services, Insurance Records. | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0010 | Richard Smith's Colon & Rectal Surgery Associates, Medical Records.            | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0011 | Richard Smith's Dyer, David N. MD, Medical Records.                            | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0012 | Richard Smith's Eckerd Drugs, Pharmacy Records.                                | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0013 | Richard Smith's Hampf, Carl MD, Medical Records.                               | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0014 | Richard Smith's Harwell, William B., Jr. MD, Medical Records.                  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0015 | Richard Smith's Heart & Vascular Clinic, Medical Records.                      | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0016 | Richard Smith's Heritage Medical Associates, Medical Records.                  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0017 | Richard Smith's Loden Vision Center, Optometry Records.                        | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0018 | Richard Smith's Nashville Orthopedic Associates, Medical Records.              | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0019 | Richard Smith's Neurological Surgeons, Medical Records.                        | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0020 | Richard Smith's Neurosurgical Associates, Medical Records.                     | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0021 | Richard Smith's Otolaryngology Associates of Tennessee, Medical Records.       | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0022 | Richard Smith's Outpatient Diagnostic Center, Medical Records.                 | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0023 | Richard Smith's Premier Radiology, Medical Records                             | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0024 | Richard Smith's Saint Thomas Hospital, Medical Records.                        | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0025 | Richard Smith's Southern Sports Medicine records.                              | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0026 | Richard Smith's Spalding & Nesbitt Urology Clinic, Medical Records.            | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0027 | Richard Smith's Specialized Assays, Medical Records.                           | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0028 | Richard Smith's Tennessee Orthopedic Alliance, Medical Records.                | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0029 | Richard Smith's University Medical Center, Medical Records.                    | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0030 | Richard Smith's Vanderbilt University Medical Center, Medical Records.         | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |

| Ex#    | Description  | Authenticity | Substantive Objection   |
|--------|--|--------------|---|
| DX0031 | Richard Smith's Willowbrook Home Care Agencies, Medical Records.         | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0032 | Richard Smith's Woods, Christopher L. DDS, Dental Records.               | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0033 | Richard Smith's Plaintiff Produced Records                               | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0034 | Richard Smith's Associated Urologists of Nashville records.              | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0035 | Richard Smith's Powers Chiropractic Clinic records.                      | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0036 | Richard Smith's CVS records.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0037 | Richard Smith's Elite Sports Medicine records.                           | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0038 | Richard Smith's Midstate Cardiology records.                             | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0039 | Richard Smith's Nashville Internal Medicine Associates records.          | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0040 | Richard Smith's Rite Aid records.  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0041 | Richard Smith's Schull, David, M.D. records.                             | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0042 | Richard Smith's Premier Orthopedics and Sports Medicine records.         | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0043 | Richard Smith's Stasko, Thomas records.                                  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0044 | Richard Smith's Urology Associates records.                              | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0045 | Richard Smith's Mohs Micrographic Surgery and Dermatology records.       | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0046 | Richard Smith's Walgreen's records.                                      | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0047 | Richard Smith's McCombs, Paul, M.D. records.                             | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0048 | Richard Smith's Medicare records.  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0200 | Richard Smith's W-2 Forms.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0201 | Richard Smith's Nashville Office Machines, Employment Records.           | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0202 | Richard Smith's IRS Tax Return Records.                                  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0203 | Metropolitan Nashville Police Department, Records.                       | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0204 | Autopsy Records.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0205 | Plaintiff's Response to Defendant's First Set of Interrogatories         | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0206 | Death Certificate  | Admit        |   |
| DX0207 | Suicide Note   | Admit        |   |
| DX0208 | Obituary   | Admit        |   |
| DX0209 | Letters Testamentary   | Admit        |   |
| DX0210 | Letter from M. Richer to A. Seaton re: additional Information            | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0211 | Berklacich, Frank M.D. - Medical Records marked at deposition.           | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0212 | Medical Examination Report marked at the deposition of Gary Wayne Biggs. | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document         |
| DX0213 | Gary Wayne Biggs Notes   | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Relevance |
| DX0214 | Gary Wayne Biggs Investigation Fee Schedule                              | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Relevance |

| Ex#    | Description  | Authenticity | Substantive Objection   |
|--------|--|--------------|---|
| DX0215 | Photograph of Dresser Top with Suicide Note  | Admit        |   |
| DX0216 | Photograph of Dresser Top without Suicide Note   | Admit        |   |
| DX0217 | Photograph of Suicide Note - Close Up  | Admit        |   |
| DX0218 | Metropolitan Police Department Report by Danny Satterfield marked at the deposition of Gary Wayne Biggs. | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0219 | C.V. - Curriculum Vitae of James Cato, M.D.  | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value    |
| DX0220 | Medical records marked at the deposition of James Cato, M.D.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0221 | C.V. - Curriculum Vitae of Carl Hampf, M.D.  | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value    |
| DX0222 | Notice to Take Deposition of Carl Hampf, M.D.  | Admit        | Hearsay; Relevance  |
| DX0223 | Invoice to Richard Smith from Carl Hampf, M.D.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0224 | Medical records marked at the deposition of Carl Hampf, M.D.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0225 | Medical records marked at the deposition of Pamela Krancer, APN  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0226 | Suicide Note   | Admit        |   |
| DX0227 | C.V. - Curriculum Vitae of Feng Li, M.D., J.D., Ph.D.  | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value    |
| DX0228 | Medical records marked at the deposition of Feng Li, M.D., J.D., Ph.D.                                   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0229 | C.V. - Curriculum Vitae of Edward Mackey, M.D.   | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value    |
| DX0230 | Medical records marked at the deposition of Edward Mackey, M.D.  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0231 | Medical records marked at the deposition of Paul R. McCombs, III M.D.                                    | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0232 | McCombs, Paul R. III (M.D.) Deposition - Ex. 3   | Admit        |   |
| DX0233 | Police records marked at the deposition of Danny Satterfield   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0234 | Photograph of Suicide Note - Close Up  | Admit        |   |
| DX0235 | Medical records marked at the deposition of Danny Satterfield  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0236 | Medical records marked at the deposition of Ruth Smith   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0237 | Page from Questionnaire marked at the deposition of Ruth Smith   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0238 | Pharmacy records marked at the deposition of Ruth Smith  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0239 | Pharmacy records marked at the deposition of Ruth Smith  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0240 | Medical records marked at the deposition of Ruth Smith   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0241 | Medical records marked at the deposition of Ruth Smith   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0242 | Expert from Plaintiff's Response to First Set of Interrogatories marked at the deposition of Ruth Smith  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0243 | Pharmacy records marked at the deposition of Ruth Smith  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0244 | Medical records marked at the deposition of Ruth Smith   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0245 | Medical records marked at the deposition of Cindy Smith-Charlton.  | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0246 | Medical records marked at the deposition of Stewart Stowers.   | Admit        | Object Subject To Redactions Of Inadmissible Portions Of The Document |
| DX0247 | C.V. - Curriculum Vitae of Stewart Stowers.  | Admit        | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value    |

| Ex#    | Description  | Authenticity                                       | Substantive Objection   |
|--------|--|--|---|
| DX0248 | Dental records marked at the deposition of Chris L. Wood.  | Admit  | Object Subject To Redactions Of Inadmissible Portions Of The Document   |
| DX0249 | Samples of Neurontin or other medications or containers in possession of the Smith family  | Admit  | Object Subject To Redactions Of Inadmissible Portions Of The Document   |
| DX0250 | Photographs of Neurontin or other medications or containers in possession of the Smith Family to be taken at a future date upon agreement of the parties | Admit  | Object Subject To Redactions Of Inadmissible Portions Of The Document   |
| DX0251 | Audio of 911 call  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX0252 | Transcript of 911 call   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX0253 | Douglas Jacobs, M.D. Expert Report.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0254 | Peter M. Donofrio, M.D. Expert Report.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0255 | Peter M. Donofrio, M.D. CV   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX0256 | Robert P. Granacher, M.D., M.B.A. Expert Report.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0257 | Robert P. Granacher, M.D., M.B.A. CV   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX0258 | Richard Smith's Church of Christ at Trinity Lane records.  | Deny   | Hearsay   |
| DX0259 | Richard Smith's Gilroy Church of Christ records.   | Deny   | Hearsay   |
| DX0260 | Richard Smith's Jackson Park Church of Christ records.   | Deny   | Hearsay   |
| DX0261 | Peter D. Donofrio, M.D. Notes  | Deny   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0262 | Peter D. Donofrio, M.D. Notes  | Deny   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0263 | A 52-Year-Old Suicidal Man by Douglas G. Jacobs JAMA, 2000;283(20);2693-2699   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| DX0264 | List of Documents reviewed by Douglas G.Jacobs, M.D.   | Admit  |   |
| DX0265 | Medical Chronology of Richard Smith  | Deny   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX0266 | Smith: 911 Call Tape Transcript marked at the deposition of Douglas G.Jacobs, M.D.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| JX0300 | Suicide Over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients (Blumenthal, S., et al. American Psychiatric Press, Inc.).     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0301 | Comprehensive Textbook of Suicidology (Ronald W. Maris, et al.).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0302 | Reference Guide on Epidemiology (Green, M., et al. Reference Manual on Scientific Evidence, 2nd ed., 2000).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0303 | Schatzberg, Alan F. M.D., et al., Textbook of Psychopharmacology, 736-739 (Am. Psych. Pub. 3rd ed. 2004) (2000).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0304 | Schatzberg, AF and Nemeroff, C. eds. Textbook of Psychopharmacology, 3rd ed. APA Press, Washington, 2004.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0305 | DSM IV.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0306 | Modern Epidemiology 3rd Edition by Greenland and Rotham.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0307 | Daniel Klein and Alexander Tabarrok, "Who Certifies Off-Label," Regulation 60-63 (Summer 2004).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX0308 | Acosta GB, Losada MEO, Rubio MC (1993): Area-dependent changes in GABAergic function after acute and chronic cold  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | stress. Neuroscience Letters 154:175-178.   |  |                       |
| JX0309 | Acosta GB, Rubio MC (1994): GABAA receptors mediate the changes produced by stress on GABA function and locomotor activity. Neuroscience Letters 176:29-31.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0310 | Ahmad SR, Goetsch RA, Marks NS. Chapter 9, Spontaneous reporting in the United States. In: Pharmacoevidence. 4th Edition. Strom Bed. Wiley & Sons. England. 2005.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0311 | Ahn HS, Choi JS, Choi BH, Kim MJ, Rhie DJ, Yoon SH, et al (2005): Inhibition of the cloned delayed rectifier K <sup>+</sup> channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 133:1007-1019.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0312 | Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, et al (2006): Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319:323-331.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0313 | Ahn SH, Park HW, Lee BS, et al. Gabapentin Effect on Neuropathic Pain Compared Among Patients with Spinal Cord Injury and Different Durations of Symptoms. Spine. 2003; 28(4):341-47.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0314 | Ahrens B et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disorder 1995; 33:67-75.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0315 | Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jr., Jones EG (1995): Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics [see comments]. Archives of General Psychiatr | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0316 | Almenoff, JS., LaCroix, KK., Yuen, NA., Fram, D., DuMouchel, W. Comparative performance of two quantitative safety signaling methods: implications for use in a pharmacovigilance department. Drug Safety 2006; 29(10):875-887.                                 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0317 | Alsheikh-Ali, A., Ambrose, M., Kuvin, J., Karas, R. The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis. Circulation 2005; 111(23):3051-3057.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0318 | Altshuler L. et al. Temporal lobe epilepsy, temporal lobe epilepsy, temporal lobectomy and major depression. J Neuropsychiatry Clin Neurosci 1999; 11 :436-43.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0319 | Altshuler LL, et al.: Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1:61-5, 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0320 | American Academy of Pain Medicine and the American Pain Society. Consensus Statement: The Use of Opioids for the Treatment of Chronic Pain. 1997.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0321 | American Psychiatric Association TFOE (1990): The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Convulsive Therapy 6:85-120.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0322 | American Psychiatric Association. APA Practice Guidelines for the Assessment and Treatment of Patients with Suicidal Behaviors. American Journal of Psychiatry 2004; 160 (11).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0323 | American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Practice Guidelines for Chronic Pain Management. Anesthesiology. 1997; 86:995-1004.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0324 | Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of Gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | Psychopharmacology 2001;157(4):381-387.   |  |                       |
| JX0325 | Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 2004;88:320-325.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0326 | Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry. 1999;60 Suppl 2:57-62.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0327 | Appendix 5, Pfizer Safety and Risk Management Literature Review: Gabapentin Use Among Persons with a History of Psychotic Disorder bearing the bates range Pfizer_Regulatory_000260.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0328 | Apter A, Laufer N, Bar-Sever M, Har-Even D, Ofek H, Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric "inpatients. Biol Psychiatr. 1999 Aug 15;46(4):532-41.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0329 | Arikkath J, Campbell KP. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr Opin Neurobiol 2003; 13(3):298-307.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0330 | Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333:1267-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0331 | Arseneault, L., et al. Causal Association Between Cannabis and Psychosis: Examination of the Evidence, 2 Focus 270 (2007).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0332 | Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of Gabapentin on the Different Components of Peripheral and Central Neuropathic Pain Syndromes: A Pilot Study. Eur. Neural. 1998; 40: 191-200.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0333 | Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000): Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 47:305-313.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0334 | Azbill RD, Mu X, Springer JE (2000): Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 871:175-180.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0335 | Azoulay, Pierre, "Do Pharmaceutical Sales Respond to Scientific Evidence?" Journal of Economics & Management Strategy, Volume 11, No.4, Winter 2002.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0336 | Baastrup, C. and N. B. Finnerup (2008). "Pharmacological management of neuropathic pain following spinal cord injury." CNS Drugs 22(6): 455-75.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0337 | Backonja M, Beydoun A, Edwards KR, et. al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus. JAMA. December 2, 1998; 280(21): 1831-1836.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0338 | Backonja M. Gabapentin Monotherapy for the Symptomatic Treatment of Painful Neuropathy: a Multicenter, Double-Blind, Placebo-controlled Trial in Patients with Diabetes. Epilepsia. 1999; 40 (Suppl. 6):S57-S59.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0339 | Bailey HR, Beck DE, Billingham RP, Binderow SR, Gottesman L, Hull TL, Larach SW, Margolin DA, Milsom JW, Potenti FM, Rafferty JF, Riff DS, Sands LR, Senagore A, Stamos MJ, Yee LF, Young-Fadok TM, Gibbons RD; Fissure Study Group. A study to determine the | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0340 | Baker K, Barkhuizen A. Pharmacologic Treatment of Fibromyalgia. Current Pain and Headache Reports. 2005; 9:301-306.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0341 | Balazsa T, Biro J, Gullai N, Ledent C, Sperlagh B. CB(1)-cannabinoid receptors are involved in the modulation of non-synaptic [(3)h]serotonin release from the rat hippocampus. Neurochem Int 2007.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0342 | Baldessarini RJ, et al. Decreased Risk of Suicides and Attempts During Long-Term Lithium Treatment: A Meta-Analytic Review. Bipolar Disorder 2006; 8:625-639.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0343 | Baldessarini RJ, Pompili M, Tondo L. Suicide in Bipolar Disorder: Risks and Management. CNS Spectr 2006; 11(6):465-471.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0344 | Baldessarini, RJ., Tondo, L. Suicide risk and treatments for patients with bipolar disorder. JAMA 2003; 290:1517-1519.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0345 | Baldessarini, Ross J., "Lithium Treatment and Suicide Risk in Major Affective Disorders: Update and New Findings," Journal of Clinical Psychiatry, 2003:64.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0346 | Baldessarini, Ross, et al., "Treating the Suicidal Patient with Bipolar Disorder Reducing Suicide Risk with Lithium," Annals New York Academy of Sciences, pp.24-43.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0347 | Ballantyne, J.C. and J. Mao (2003). "Opioid therapy for chronic pain." N Engl J Med 349(20): 1943-53.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0348 | Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 2005; 179(1):218-229.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0349 | Bandini F, Castello E, Mazzella L, Mancardi GL, Solaro C. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis? Journal of Neurology, Neurosurgery, and Psychiatry 20 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0350 | Baraclough, B. "Suicide and Epilepsy" in Epilepsy and Psychiatry, ed. Reynold, EH. and Trimble, MR Churchill Livingstone, New York 1981, pp. 72-76.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0351 | Barbul, C., et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 2004; 109:275-78.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0352 | Bartholini G, Lloyd, KG., Morselli, PL. editor (1986): GABA and Mood Disorders: Experimental and Clinical Research, Vol 4. New York: Raven Press.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0353 | Baumeister and Frye. Self-injurious Behavior in Rats Produced by Intracranial Microinjection of GABA Agonists. Pharmacol Biochemical Behavior 1994; 21(1): 89-95.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0354 | Bayer K, Seifollah A, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacol 2004; 46:743-749.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0355 | Bell,GS, Mula, M and Sander, JW. Suicidality in People Taking Antiepileptic Drugs What is the Evidence? CNS Drugs 2009; 23(4):281-291.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0356 | Belliotti T, Ekhatov IV, Capiris T, Kinsora J, Vartanian MG, Field M, Meltzer LT, Heffner T, Schwarz JB, Taylor CP, Thorpe A, Wise L, Su T-Z, Weber ML, Wustrow DJ (2005)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | Structure-activity relationships of pregabalin and analogs that target the $\alpha 2\text{-d}$ prote  |  |                       |
| JX0357 | Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, et al (1985): 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology 24:1085-1092.        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0358 | Benes FM, Berretta S (2001): GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1-27.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0359 | Ben-Menachem E, Hamberger A, Mumford J. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system--a case study. Epilepsy Research 1993; 16(3):241-243.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0360 | Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and Gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of Gabapentin. Epilepsy Research 1992; 11(1):45-49.                              | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0361 | Ben-Menachem E, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. British Journal of Clinical Pharmac | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0362 | Ben-Menachem E, Soderfelt B, Hamberger A, Hedner T, Persson LI. Seizure frequency and CSF parameters in a double-blind placebo controlled trial of Gabapentin in patients with intractable complex partial seizures. Epilepsy Research 1995; 21(3):231-236.     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0363 | Ben-Menachem E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsia 1989; 30 Suppl 3:S12-14.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0364 | Bennett MI, Simpson KH. Gabapentin in the Treatment of Neuropathic Pain. Palliative Medicine. 2004; 18:5-11.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0365 | Benoit E, Escande D (1991): Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflugers Arch 419:603-609.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0366 | Benturquia N, Parrot S, Sauvinet V, Renaud B, Denoroy L. Simultaneous determination of vigabatrin and amino acid neurotransmitters in brain microdialysates by capillary electrophoresis with laser-induced fluorescence detection. Journal of Chromatography 2 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0367 | Benveniste H. Brain microdialysis. Journal of Neurochemistry 1989; 52(6):1667-1679.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0368 | Bergman, U., et al. Epidemiology of adverse drug reactions to phenformin and metformin. Brit Med J 1978; 2:464-66.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0369 | Berlin JA and Kim CJ. Chapter 44. The use of meta-analysis in pharmacoepidemiology. In: Pharmacoepidemiology. 4th Edition. Strom Bed. Wiley & Sons. England. 2005. (electronic version).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0370 | Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000): Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47:351-354.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0371 | Bernasconi, R., "The GABA hypothesis of affective illness: Influence of Clinically Effective Antimanic Drugs on GABA turnover," in: Basic Mechanisms in the Action of Lithium: Proceedings of a Symposium held at Schloss Ringberg, Barvaria, FRG, Oct. 4-6, 19 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0372 | Berndt, Ernst R., "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," The Journal of Economic Perspectives, Fall 2002.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0373 | Berndt, Ernst R., "The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment?" Health Affairs, Volume 20(2), 2001.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0374 | Berndt, Ernst R., Bhattacharja, Mishol, et al An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts, J Ment Health Policy Econ 5, 3-19 (2002).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0375 | Berndt, Pindyck and Azoulay, "Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs," The Journal of Industrial Economics, June 2003.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0376 | Berrettini, et al. Reduced Plasma and CSF Aminobutyric Acid in Affective Illness: Effect of Lithium Carbonate. Biol Psychiat 1983; 18(2):185-194.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0377 | Bert Spilker, Concept of Cause and Effect, in Guide to Clinical Trials 528 (1991).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0378 | Bertrand S, Morin F, Lacaille JC. Different actions of Gabapentin and baclofen in hippocampus from weaver mice. Hippocampus 2003a; 13(4):525-528.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0379 | Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, Lacaille JC, Chronwall BM, Morris SJ. The anticonvulsant, antihyperalgesic agent Gabapentin is an agonist at brain gamma-aminobutyric acid type B r | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0380 | Bertrand S, Nouel D, Morin F, Nagy F, Lacaille JC. Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells. Synapse 2003; 50(2):95-109.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0381 | Besag F. Psychotherapy in people with epilepsy and intellectual disability. J Neurol Neurosurg Psychiatry 2003; 74:1464.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0382 | Besag FM. Behavioral effects of the new anticonvulsants. Drug Saf 2001; 24(7):513-536.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0383 | Besag FM. Behavioral effects of the newer antiepileptic drugs: an update. Expert Opinion on Drug Safety 2004; 3(1):1-8.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0384 | Betty A. Diamond et al., Silicone Breast Implants in Relation to Connective Tissue Diseases and Immunologic Dysfunction. A Report by a National Science Panel to the Honorable Sam C. Pointer Jr., Coordinating Judge for the Federal Breast Implant Multi-Dist | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0385 | Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, et al (2007): Reduction in Occipital Cortex gamma-Aminobutyric Acid Concentrations in Medication-free Recovered Unipolar Depressed and Bipolar Subjects. Biol Psychiatry.                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0386 | Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Watthews PM, Cowen PJ (2004): Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0387 | Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006; 15(6):637-647.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0388 | Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2- | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0389 | Bird SJ, Brown MJ: Diabetic Neuropathies. il Katirji B, Kaminski H, Preston D., Ruff R, Shapiro B (eds.), Neuromuscular Disorders in Clinical Practice, Butterworth-Heinemann, 2002, pp. 598-621.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0390 | Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ, Petty F (2001): Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Research 101:131-136.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0391 | Böhning D, Schlattmann P, Lindsay BG. Re: "A statistical method for evaluating suicide clusters and implementing cluster surveillance". Am J Epidemiol. 1992 Jun; 135(11):1310-4.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0392 | Bone M, Buggy D, Critchley P, Rowbotham D. Gabapentin Monotherapy in Post amputation Phantom Limb and Stump Pain: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study. Regional Anesthesia and Pain Medicine. September-October 2002;27(5):481-486 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0393 | Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A (1988): On the role of endogenous GABA in the forced swimming test in rats. Pharmacology biochemistry & behavior 29:275-279.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0394 | Bosnjak S, Jelic S, Susnajar S, et al. Gabapentin for relief of neuropathic pain related to anticancer treatment: A Preliminary Study. J. Chemother 2002; 14(20):214-9. PPI DN: 182949.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0395 | Bostwck JM, Panatz VS. Affective disorders and suicide risk: a re-examination. Am J " Psychiatry. 200Q Dec;157(12):1925-32.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0396 | Boswell M, Shah R, Everett C, et al. Interventional Techniques in the Management of Chronic Spinal Pain: Evidence-Based Practice Guidelines. Pain Physician. 2005;8:1-47.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0397 | Botts SR, Raskind JL: Gabapentin and lamotrigine in bipolar disorder. Am J Health Syst Pharm 56(19):1939-44, Oct 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0398 | Bourgeois, M. Serotonin, Impulsivity and Suicide. Human Psychopharmacology 1991; 6: S31-36.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0399 | Bourne JA. Intracerebral microdialysis: 30 years as a tool for the neuroscientist. Clinical and Experimental Pharmacology & Physiology 2003; 30(1-2):16-24.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0400 | Bowden CL. The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse. Current Psychiatric Reports 2000; 2:490-494.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0401 | Bowden C, Fawcett J. To the Editor: Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder. JAMA 2004; 291(8):939.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0402 | Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JCY, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipo  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0403 | Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 1993; 33:109-147.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0404 | Bowler JM, Green AR, Minchin MCW, Nutt DJ (1983): Regional GABA concentrations and 3H-diazepam binding in rat brain following repeated electroconvulsive shock. J Neurol Transm 56:3-12.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0405 | Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistic Med 2007; 26:53-77.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0406 | Bradford-Hill, The environment and disease: Association or causation Royal Soc'y Med 295,295-96(1965).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0407 | Bradley S. Galer. Painful Polyneuropathy, in Neurology Clinics 1998. Discusses use of Gabapentin for painful neuropathy (pg. 802).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0408 | Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Molecular Psychiatry 2003;8:721-737.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0409 | Brenner, G. J. and C. I. Woolf(2008). Mechanisms of Chronic Pain. Anesthesiology. D. E. Longnecker, D. L. Brown, M. F. Newman and W. Z. Zapol. New York, McGraw Hill: 2000-2019.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0410 | Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry. 2007 Jul;164(7):989-91.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0411 | Breslau N. Migraine suicidal ideation and suicide attempts. Neurology 1992;42:392-95.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0412 | Bridges et al. Suicide Trends Among Youths Aged 10 to 19 Years in the United States, 1996 - 2005. JAM 2008;300: 1025-6.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0413 | Brock D, "A Model State Act to Authorize and Regulate Physician-Assisted Suicide".  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0414 | Brock D, "Euthanasia".  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0415 | Brown CH, Wyman PA, Brinales JM, Gibbons RD. The role of randomized trials in testing interventions for the prevention of youth suicide. Int Rev Psychiatry 2007 Dec;19(6):617-31.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0416 | Brown J, Randall A. Gabapentin fails to alter P/Q-type Ca2+ channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 2005; 55:262-269.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0417 | Brown JP, et al. Isolation of the [3H]Gabapentin-binding protein/ $\alpha$ 2 $\delta$ CA2+ Channel subunit from porcine brain: development of a radioligand binding assay for $\alpha$ 2 $\delta$ subunits using [3H]leucine. Anal. Biochem. 1998; 255:236-243. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0418 | Bruni, J, and Neon Study Group, Outcome and Evaluation of Gabapentin as Add-on Therapy for Partial Seizures. Can. J Neurol Sci 1998; 25: 134-140.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0419 | Burke, LB., et at. Chapter 9. In: Pharmacoepidemiology an Introduction, 3rd Edition, AG. Harzema, et al., ed. Cincinnati: Whitney Books Company, 1998.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0420 | Busch et al., 1993; Clinical Features of in-patient suicide. Psychiatr. Ann. 23(5): 256-262.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0421 | Busch KA, Fawcett J, Jacobs DG. Clinical Correlates of Inpatient Suicide. J Clin Psychiatry 2003; 64:14-19.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0422 | Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with Neurontin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatr 1999;   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | 60:245-248.   |  |                       |
| JX0423 | Campbell BM, Morrison J-L, Taylor CP (2006) Pregabalin Acts at Calcium Channel Alpha2-Delta ( $\alpha 2-\delta$ ) Type 1 Proteins to Prevent Acute Stress-Induced Increases in Cerebellar cGMP. European Congress on Neuropsychopharmacology.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0424 | Canti C, Davies A, Dolphin AC. Calcium channel alpha2-delta subunits: Structure, functions and target site for drugs. Curr Neuropharmacol 2003; 1(3):209-217.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0425 | Canti C, Nieto-Rostro M, Foucault I, Heblich F, Wratten J, Richards MW, Hendrich J, Douglas L, Page KM, Davies A, Dolphin A. The metal-ion-dependent adhesion site in the Von Willebrand factor-A domain of subunits is key to trafficking voltage-dependent Ca                             | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0426 | Caraceni A, Zecca E, Bonezzi C, Bennett MI. Gabapentin significantly improves analgesia in people receiving opioids for neuropathic cancer pain. Cancer Treat Rev 2005; 31(1):58-62.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0427 | Caraceni A, Zecca E, Martini C, DeConno F. Differences in Gabapentin efficacy for cancer pain more apparent than real? Journal of Pain and Symptom Management 2001; 21(Feb):93-4.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0428 | Caraceni A, Zecca E, Martini C, DeConno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999; 17(Jun):441-5 .   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0429 | Carlson PJ, Singh JB, Zarate CA, Jr., Drevets WC, Manji HK (2006): Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 3:22-41.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0430 | Carta et al., The Clinical Use of Gabapentin In Bipolar Spectrum Disorders. Journal of Affective Disorders, 75:83-91 (2003).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0431 | Castle, K., Duberstein, PR., Meldrum, S., Conner, KR., Conwell, Y. Risk Factors for Suicide in Blacks and Whites: An Analysis of data from the 1993 National Mortality Followback Survey. Am J Psychiatry 2004; 161(3): 452-458.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0432 | Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacological Reviews 2005; 54:411-425.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0433 | Cavanaugh S, Clark DC, Gibbons RD. Diagnosing depression in the hospitalized medically ill. Psychosomatics. 1983 Sep;24(9):809-15.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0434 | Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WSQARS) (online) (2004 Data Analysis) Available from URL: <a href="http://www.cdc.gov/ncipc/wisgars">www.cdc.gov/ncipc/wisgars</a> . | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0435 | Centers for Disease Control and Prevention. National Vital Statistics Reports (NSS). Deaths: Preliminary Data for 2002: Vol. 52, No. 13, Washington: Public Health Service, February 11, 2004.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0436 | Chandler A, Williams IE. Gabapentin, an Adjuvant Treatment for Neuropathic Pain in a Cancer Hospital (Letters). Journal of Pain and Symptom Management. Aug 2000; 20(2):82-86.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0437 | Chang L, Cloak CC, Ernst T. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J. Clin. Psychiatry 2003 ;64 Supp. 3:7-14.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0438 | Charney DS, Manji HK. Life stress, genes, and depression:   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004.   |  |                       |
| JX0439 | Chen, H., et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid Population. Pharmacoeconomics & Drug Safety 2005; 14:629-38.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0440 | Cheng JK, Chen CC, Yang JR, Chiou LC. The antiallodynic action target of intrathecal gabapentin: Ca2+ channels, KATP channels or N-methyl-D-aspartic acid receptors? Anesthes. Analges. 2006;102:182-187.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0441 | Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of Gabapentin. Journal of Pharmacological Sciences 2006; 100(5):471-486.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0442 | Cheng JK, Lee SZ, Yang JR, Wang CH, Liao YY, Chen CC, Chiou LC. Does Gabapentin act as an agonist at native GABAB receptors? Journal of Biomedical Science 2004; 11(3):346-355.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0443 | Cheng VY, Bonin RP, Chiu MW, Newell JG, MacDonald JF, Orser BA. Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology 2006; 105(2):325-333.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0444 | Cheramy A, Barbeito L, Godeheu G, Glowinski J (1992): Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209-212.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0445 | Chiaramonti R, Lori S, Baggione CM, et al. Nociceptive Reflex of the Short Femoral Biceps in Patients with Painful Diabetic Neuropathy Treated with Gabapentin (GBP). Neurology. 52:A169- 170, 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0446 | Ching, Andrew, and Masakazu Ishihara, "The Effects of Detailing on Prescribing Decisions under Quality Uncertainty," Draft Paper, August 2006.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0447 | Cho SW, Cho EH, Choi SY. Activation of two types of brain glutamate dehydrogenase isoproteins by Gabapentin. FEBS Lett 1998; 426(2):196-200.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0448 | Chou, R., A. Qaseem, et al. (2007). "Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society." Ann Intern Med 147(7): 478-91.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0449 | Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al (2005): Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102:15653-15658. Epub 12005 Oct 15617. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0450 | Chouinard G, Beaclair L, Belanger MC. Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998; 43(3):305.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0451 | Christensen et al., Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007 6:693-698.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0452 | Chu, L. F., M. S. Angst, et al. (2008). "Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations." Clin J Pain 24(6): 479-96.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0453 | Clark DC, Gibbons RD, Fawcett J, Aagesen CA, Sellers D. Unbiased criteria for severity of depression in alcoholic inpatients. J Nerv Ment Dis. 1985 Aug;173(8):482-7.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0454 | Clark DC, Gibbons RD, Fawcett J, Scheftner WA. What is the mechanism by which suicide attempts predispose to later suicide  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | attempts? A mathematical model. J Abnorm Psychol. 1989 Feb;98(1):42-9.  |  |                       |
| JX0455 | Clark DC, Gibbons RD, Haviland MG, Hendryx MS. Assessing the severity of depressive states in recently detoxified alcoholics. J Stud Alcohol. 1993 Jan;54(1):107-14.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0456 | Clark DC, Gibbons RD. Does one nonlethal suicide attempt increase the risk for a subsequent nonlethal attempt? Med Care 1987 Dec;25(12 Suppl):S87-9.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0457 | Clark DC, vonAmmon Cavanaugh S, Gibbons RD. The core symptoms of depression in medical and psychiatric patients. J Nerv Ment Dis. 1983 Dec;171(12):705-13.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0458 | Cockerell OC, Moriarty J, Trimble M, Sander JW, Shorvon DS. Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Res 1996; 25(2):119-131.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0459 | Coderre TJ, Kumar N, Lefebvre CD, Yu JSC. Evidence that Gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94:1131-1139.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0460 | Collins JC, McFarland BH (2007): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0461 | Compton, P., V. C. Charvastra, et al. (2001). "Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent." Drug Alcohol Depend 63(2): 139-46.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0462 | Congressional Budget Office. Research and Development in the Pharmaceutical Industry, October 2006 (www.cbo.gov/ftpdocs/76xx/doc761S/10-02-DrugR-D.pdf.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0463 | Cooper JR, Bloome FE & Roth RH, The Biochemical Basis of Neuropharmacology 8th ed. 2003.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0464 | Coric V, Milanovic S, Wasyluk S, Patel P, Malison R, Krystal JH (2003): Beneficial effects of the ant glutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 167:219-220.     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0465 | Coscelli, Andrea, and Matthew Shum, "An Empirical Model of Learning and Patient Spillovers in New Drug Entry," Journal of Econometrics, Volume 122(2), 2004.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0466 | Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Everall I (2002): The density and spatial distribution of GABAergic neurons, labeled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar d | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0467 | Crafford, Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-1273.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0468 | Cramer, J.A., De Rue, K., Devinsky, O., Edrich, P. and Trimble, M.R. (2003). "A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials." Epilepsy Behav 4(2): | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0469 | Cuignet, O., Pirson J., et al. (2007). "Effects of Gabapentin on morphine consumption and pain in severely burned patients." Burns 33(1): 81-6.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0470 | Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RSG. Dual effects of Gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
|        | Neurosci 2004; 20(6):1566-1576.  |  |                       |
| JX0471 | Currie, S., et al., Clinical Course and Prognosis of Temporal Lobe Epilepsy: A Survey of 666 Patients. Brain 1971; 94:173-90.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0472 | Dalby N. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000; 39(12):2399-2407.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0473 | Dalocchio C, Buffa C, Ligure N, et al. Gabapentin Versus Amtrpyline in Painful Diabetic Neuropathy. Neurology. 50:A102-3, 1998.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0474 | Dalocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs. Amtrpylie in Painful Diabetic Neuropathy. Journal of Pain and Symptom Management. 20:280-285, 2000.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0475 | Dang K, Bowery N, Sugiyura T, Urban L. Sustained depolarization of the ventral root following washout of GABAB receptor agonists in a novel juvenile mouse hemisectioned spinal cord preparation: Is this due to desensitization? American Pain Society Abstracts. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0476 | Darel A. Regier & Jack D. Burke, Jr., 5.1 Epidemiology, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Volume I, 500 (Benjamin J. Sadock & Virginia A. Sadock eds., 7th ed. 2000).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0477 | Davies A, Douglas L, Hendrich J, Wratten J, Tran Van Minh A, Foucault I, Koch D, Pratt WS, Saibil HR, Dolphin AC. The calcium channel alpha2delta-2 subunit partitions with CaV2.1 into lipid rafts in cerebellum: implications for localization and function..    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0478 | Davies, A., J. Hendrich, et al. (2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels." Trends Pharmacol Sci 28(5): 220-8.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0479 | Davis JM, Janicak PG, Wang Z, Gibbons RD, Sharma RP. The efficacy of psychotropic drugs: implications for power analysis. Psychopharmacol Bull. 1992;28(2):151-5.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0480 | Davis JM, Koslow SH, Gibbons RD, Maas JW, Bowden CL, Casper R, Hanin I, Javaid JI, Chang SS, Stokes PE. Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls. Arch Gen Psychiatry. 1988 Aug;45(8):705-17.                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0481 | Debono MW, Le Guern J, Canton T, Doble A, Pradier L (1993): Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 235:283-289.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0482 | Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000; 61 Suppl 6:7-11.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0483 | de-Paris F, Sant'Anna MK, Vianna MR, Barichello T, Busnello JV, Kapczinski F, Quevedo J, Izquierdo I. Effects of Gabapentin on anxiety induced by simulated public speaking. Journal of Psychopharmacology (Oxford, England) 2003; 17(2):184-188.                  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0484 | Department of Health and Human Services, The Surgeon General's Call to Action to Prevent Suicide (1999).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0485 | Devulder J, Lambert J, Naeyaert JM. Gabapentin for pain control in cancer patients' wound dressing care. J. Pain Symptom Manage 2001; 22(1)(Jul):622-6.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0486 | Diamond KR, Pande AC, Lamoreaux L, Pierce MW (1996): Effect of Gabapentin (Neurontin®) on Mood and Well-Being in Patients with Epilepsy. Prog Neuro-Psychopharmacol & Biol Psychiat 20: 407-17.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0487 | Doble A, Hubert JP, Blanchard JC (1992): Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 140:251-254.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0488 | Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of Gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45(3):171-190. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0489 | Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by Gabapentin and Pregabalin. J Pharmacol Exp Ther 2000; 296(3):1086-1098.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0490 | Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by Gabapentin. Neurosci Lett 2000; 280(2):107-110.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0491 | Dooley DJ, Suman Chauhan N, Madden Z. Inhibition of K+-evoked [3H]noradrenaline release from rat neocortical slices by the anticonvulsant Gabapentin. Soc Neurosci Abstr 1996; 22:1992-1992.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0492 | Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel $\alpha 2\text{-}\delta$ ligands: Novel modulators of neurotransmission. Trends in Pharmacological Sciences 2007;28(2):75-82.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0493 | Dorus W, Kennedy J, Gibbons RD, Ravi SD. Symptoms and diagnosis of depression in alcoholics. Alcohol Clin Exp Res. 1987 Apr;11(2):150-4.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0494 | Drugan RC, Maier SF, Skolnick P, Paul SM, Crawley JN (1985): An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur J Pharmacol 113:453-457.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0495 | Duner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disorders 2005; 7:307-325.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0496 | Dunlop J, Beal McIlvain H, She Y, Howland DS (2003): Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 23:1688-1696. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0497 | Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M (2000): The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 57:906-912.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0498 | Dworkin RH, Backonja M, Rowbotham M, et al. Advances in Neuropathic Pain. Arch. Neural. 2003; 60: 1524-1534.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0499 | Dworkin, R. H., A. B. O'Connor, et al. (2007). "Pharmacologic management of neuropathic pain: evidence-based recommendations." Pain 132(3): 237-51.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0500 | Eckhardt, K., S. Ammon, et al. (2000). "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91(1): 185-91.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0501 | Edwards, RR., Smith, MT., Kude1, I., Haytorntwaite, J. Pain-related catastrophizing as a risk factor for suicidal ideation in chronic pain. Pain 2006; 126:272-279.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0502 | Eichler, H-G, Abadie, E., Raine, J. And Salmonson, T. Safe Drugs and the Cost of Good Intentions. New Eng. J. Med. 2009 360:1378 – 1380.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0503 | Eisenberg, E., E. D. McNicol, et al. (2005). "Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials." JAMA 293(24): 3043-52.                  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0504 | Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, Hedeker D. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol. 199 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0505 | Epstein B, Childers MK. The use of Gabapentin for neuropathic and musculoskeletal pain: a case series. J Neurol Rehabil 1998; 12(2):81-5.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0506 | Erfurth A, Kammerer C, Grunze H, et al. An open label study of Neurontin in the treatment of acute mania. J Psychiatry Res 1998; 32:261-264.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0507 | Errante LD, Petroff OAC. Acute effects of Gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003; 12:300-306.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0508 | Errante LD, Williamson A, Spencer DD, Petroff OA. Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Research 2002; 49(3):203-210.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0509 | Essentials of Epidemiology in Public Health. Ann Aschengrau, George R. Seage, ScD, Editors. Jones & Barlett 2nd ed. 2007.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0510 | Evans, S., Waller, P., Davis, S. Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10:483-486.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0511 | Faich GA., et al. National adverse drug reaction surveillance. 1986. Arch Intern Med 1988; 148:785-87.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0512 | Fathalla MF. A Practical Guide for Health Researchers (2004). Nasr City, Cairo:WHO Regional Publications.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0513 | Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbons RD. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987 Mar;44(3):248-56.                                      | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0514 | Fawcett J, Clark DC, Gibbons RD, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, Stutzman D. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984 Dec;45(12):494-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0515 | Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983 Jan;40(1):79-84.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0516 | Fawcett J, Scheftner WA, Fogg L; Clark DC, Young MA, Hedeker D, Gibbons R. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990 Sep; 147(9): 1189-94.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0517 | Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann NY Acad Sci. 2001. Apr; 932:94-105.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0518 | FDA Reviews Data on Anticonvulsants for Suicide Risk (Carroll, L. Neurology Today, June 2005).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0519 | FDA. FDA Drug Safety Newsletter Fact Sheet. FDA Drug Safety Newsletter.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0520 | Fehrenbacher JC, et al. Pregabalin and Gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003; 105:133-144.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0521 | Feld M, Horstmann H, Koehlhofer U, Mahlmann H, Most M, Schneider F, Verma V, Reimann W. Effect of Gabapentin, G $\bar{o}$ 4942 and valproate on GABA content in mouse brain nerve endings. Pfizer Research Report 1985; RR-No. 4192-0189.                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0522 | Feng MR, Turluck D, Burleigh J, Lister R, Fan C, Middlebrook A, Taylor CP, Su TZ (2001). Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur Journal of Drug Metabolism and Pharmacokinetics 26:123-128.                                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0523 | Feng Y, Cui M, Willis WD. Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology 1998; 98(3):729-733.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0524 | Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioral reactions to vigabatrin: a review. Acta Neurol. Scan. 1996; 93(a):1-8.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0525 | Ferrier IN: Lamotrigine and gabapentin. Alternatives in the treatment of bipolar disorder. Neuropsychobiology 38(3):192-7, 1998.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0526 | Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Dolphin AC, Hendrich J, Webb T, Williams D. Identification of the alpha 2-delta-1 subunit of voltage dependent calcium channels as a novel molec | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0527 | Field MJ, Holloman EF, McCleary S, Hughes J, Singh L. Evaluation of Gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther 1997; 282(3):1242-1246.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0528 | Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999; 80(1-2):391-398.                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0529 | Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. British Journal of Pharmacology 1997; 121(8):1513-1522.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0530 | Figiel G, et al., Electroconvulsive Therapy, p. 523 in: The American Psychiatric Press Textbook of Psychopharmacology (Schatzberg A, Nemeroff C, eds., 2d ed. 1998).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0531 | Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. Inhibition of neuronal Ca <sup>2+</sup> influx by Gabapentin and pregabalin in the human neocortex. Neuropharmacol 2002; 42:229-236.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0532 | Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca <sup>2+</sup> influx by Gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000; 130(4):900-906.                                      | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0533 | Fink K, Schmitz V, Boing C, Gothert M. Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via alpha 2-heteroreceptors. Naunyn-Schmiedeberg's Archives of Pharmacology 1995; 352(4):394 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0534 | Finlay & Abercrombie. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neurosci. 1995; 64:619-628.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0535 | Finnerup, N. B., M. Otto, et al. (2005). "Algorithm for neuropathic pain treatment: an evidence based proposal." Pain 118(3): 289-305.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0536 | Fiordell E et al. Epilepsy and psychiatric disturbance: a cross sectional study. Br J Psychiatry 1993;163:446-50.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0537 | Fishbain DA et al. Completed suicides in chronic disease. Clin J Pain 1991;7:29-36.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0538 | Fishbain DA, Cuter R, Rosomoff HL, Rosomoff RS. Chronic Pain-Associated Depression: Antecedent or Consequence of Chronic Pain? A Review. Clinical Journal of Pain 1997; 13(2):116-137.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0539 | Fishbain DA. Current research on chronic pain and suicide. American Journal of Public Health. 1996;86:1320-1321.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0540 | Fishbain, D.A. Association of chronic pain and suicide. Seminars in Clinical Neuropsychiatry 4:221-27 (1999).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0541 | Fisher, et al., "Suicidal intent in patients with chronic pain," Pain 89 (2001) 199-206.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0542 | Flattery KV, Spero L. Chapter 18: Drugs acting on adrenergic neurons (adrenergic neuronal blocking drugs). In: Principles of Medical Pharmacology, Fourth Edition. Kalant H, Roschlau WHE, Selle EM (Eds.). Department of Pharmacology, Faculty of Medicine,    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0543 | Foley KM. Controlling Cancer Pain. Hospital Practice. April 15, 2000: 101-112.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0544 | Forde, G. (2007). "Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles." J Fam Pract 56(2 Suppl Pain): 3-12.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0545 | Forman, EM., Berk, MS., Henriques, GR., Brown, GK, Beck, AT. History of Multiple Suicide Attempts as a Behavioral Marker of Severe Psychopathology. Am J Psychiatry 2004; 161(3): 437-443.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0546 | Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ. Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. British Journal of Pharmacology 1999; 126(7):1634-1638.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0547 | Frederick K. Goodwin, M.D., "Impact of Formularies on Clinical Innovation", 64 J. Clin Psychiatry 11 (2003)..   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0548 | Freiman, Modulation of K+ -evoked (3H)-noradrenaline release from rat and human brain slices by Gabapentin: involvement of KATP channels. Naunyn-schmiedeber's Arch Pharmacol 2001; 363: 537-42.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0549 | Freyenhagen, Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind multicenter, placebo-controlled trial of flexible and fixed-dose regimens. Pain 2005; 115: 254-263.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0550 | Friedman, Seth, et al. Lithium and Valproic Acid Treatment Effects on Brain Chemistry in Bipolar Disorder. Biol Psychiat 2004; 56(5): 340-348.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0551 | Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Locatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607-14, De   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0552 | Furberg, Class Effects and Evidence-Based Medicine, Clin. Cardiol. 2000;23;7 Suppl 4:IV15-19, at IV-15.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0553 | Furberg et al., Class Effects: Are Drugs within a Class Interchangeable?, Lancet 1999;354:1202-04, at 1202.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0554 | Furberg & Pitt, Are All Angiotensin-Converting Enzyme Inhibitors Interchangeable?, J. Am. Coll. Cardiol. 2001;37:1456-60, at 1456.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0555 | Furberg & Psaty, Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a "Class of Agents"?, Circulation 2003;108:2608-10, at 2610.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0556 | Galer BS. Painful Polyneuropathy. Neurologic Clinics. 16:791-811, 1998.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0557 | Galli T, Haucke V. Cycling of synaptic vesicles: how far? how fast! Sci STKE. 2004; 2004(264):re19.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0558 | Garnett, William R, "New Opportunities for the Treatment of Epilepsy," Am. J. Health Systems Pharm., Vol. 52, Jan. 1, 1995.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0559 | Gatti A, Jann S, Sandro B, Manuela B. Gabapentin in the Treatment of Distal Symmetric Axonopathy in HIV Infected Patients. Neurology. 50:A216, 1998.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0560 | Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, Gabapentin (Neurontin), binds to the $\alpha 2\delta$ subunit of a calcium channel. J. Biol. Chem. 1996; 271(10):5768-5776.                                 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0561 | Gerner R, Fairbanks, L., Anderson, M., Young, JG., Scheinin, M., Linnoila, M., Hare, TA., Shaywitz, BA., Cohen, DJ. (1984): CSF neurochemistry in depressed, manic and schizophrenic patients compared with normal controls. American Jrn of Psychiatry 141:153 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0562 | Gerner R, Hare, TA. (1981): CSF GABA levels in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. American Jrn Psychiatry 138:1098-1101.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0563 | Ghaemi SN, Goodwin FK: Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord 65(2):167-71, 2001.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0564 | Ghaemi SN, HSU DJ, Solda F, Goodwi FK. Antidepressants in Bipolar Disorder: The Case for Caution. Bipolar Disorder 2003; 5(6):421-33.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0565 | Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK: Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 59:426-9, 1998.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0566 | Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007 Sep;164(9):1356-63.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0567 | Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007 Jul;164(7):1044-9.                                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0568 | Gibbons RD, Clark DC, Davis JM. A statistical model for the classification of imipramine response in depressed inpatients. Psychopharmacology (Berl).1982;78(2):185-9.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0569 | Gibbons RD, Clark DC, Fawcett J. A statistical method for evaluating suicide clusters and implementing cluster surveillance. Am J Epidemiol. 1990 Jul;132(1 Suppl):S183-91.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0570 | Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res. 1993 Jul-Sep;27(3):259-73.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0571 | Gibbons RD, Clark DC, VonAmmon Cavanaugh S, Davis JM. Application of modern psychometric theory in psychiatric research. J Psychiatr Res. 1985;19(1):43-55.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0572 | Gibbons RD, Davis JM, Hedeker DR. A comment on the selection of 'healthy controls' for psychiatric experiments. Arch Gen Psychiatry. 1990 Aug;47(8):785-6.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0573 | Gibbons RD, Davis JM. The price of beer and the salaries of priests: analysis and display of longitudinal psychiatric data. Arch Gen Psychiatry. 1984 Dec;41(12):1183-4.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0574 | Gibbons RD, Dorus E, Ostrow DG, Pandey GN, Davis JM, Levy DL. Mixture distributions in psychiatric research. Biol Psychiatry. 1984 Jul;19(7):935-61.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0575 | Gibbons RD, Hedeker D, Davis JM. Regression toward the mean: more on the price of beer and the salaries of priests. Psychoneuroendocrinology. 1987;12(3):185-92.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0576 | Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collabor | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0577 | Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005 Feb;62(2):165-72.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0578 | Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006 Nov;163(11):1898-904.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0579 | Gibbons RD, Lavigne JV. Emergence of childhood psychiatric disorders: a multivariate probit analysis. Stat Med. 1998 Nov 15;17(21):2487-99.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0580 | Gibbons RD, Rush AJ, Immekus JC. On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. J Psychiatr Res. 2009 Jan;43(4):401-10. Epub 2008 Jun 12.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0581 | Gibbons RD, Segawa E, Karabatsos G, Amatya AK, Bhaumik DK, Brown CH, Kapur K, Marcus SM, Hur K, Mann JJ. Mixed-effects Poisson regression analysis of adverse event reports: The relationship between antidepressants and suicide. Stat Med. 2008 May 20; 27.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0582 | Gibbons Replies to Wohlfarth, Jureidini and Olfson. Am J Psychiatry. 2007 Dec;164(12):1908-10.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0583 | Gibbons, RD & Davis, JM. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. Acta psychiatr scand 1986; 74(1): 8-12.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0584 | Gibbons, RD, Amatya, A.K., Brown, C.H., Hur, K., Marcus, S.M., Bhaumik, D.K., Mann, J.J. Post-approval drug safety surveillance. Annual Review of Public Health, in press.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0585 | Gibbons, R.D., Hur, K., Brown, C.H., Mann, J.J. The Relationship Between Antiepileptics and Suicide Attempts in Patients with Bipolar Disorder, Arch Gen Psychiatry. 2009;66(12):1354-1360.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0586 | Gilliam, et al., "Depression in Epilepsy: Ignoring Clinical Expression of Neuronal Network Dysfunction?" Epilepsia, 45 (Suppl. 2): 28-33, 2004.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0587 | Gilron L, Orr E, Dongsheng T, O'Neil, Zamora J, Bell A. A Placebo- Controlled Randomized Clinical Trial of Perioperative Administration of Gabapentin, Rofecoxib and Their Combination for Spontaneous and Movement-Evoked Pain After Abdominal Hysterectomy. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0588 | Gilron, L. (2007). "Gabapentin and pregabalin for chronic neuropathic and early post surgical pain: current evidence and future directions." Curr Opin Anaesthesiol 20(5): 456-72.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0589 | Gilron, L., J. M. Bailey, et al. (2005). "Morphine, Gabapentin, or their combination for neuropathic pain." N Engl J Med 352(13): 1324-34.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0590 | Girard M, Conclusiveness of rechallenge in the interpretation of adverse reactions. Br J Clin Pharmac., 1987; 23:73-79.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0591 | Girard, M. Oral Provocation Limitations. Sem Dermatol 1989; 8(3):192-195.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0592 | Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, et al (2001): Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Archives of General Psychiatry 58:556-561.                      | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0593 | Goddard AW, Mason GF, Rothman DL, Behar KL, Petroff OA, Krystal JH (2004): Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder. Neuropsychopharmacology 29:639-640.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0594 | Gold B, Bowers, MB., Roth RH., Sweeney, DW. (1980): GABA levels in CSF of patients with psychiatric disorders. American Jrn Psychiatry 137:362-364.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0595 | Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL (1995): Effects of anticonvulsant drug Gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 22:1-11.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0596 | Goldsmith SK. Pellmar TC, Klein AM, Bunney WE (E). Reducing Suicide: A National Imperative (2002). Washington, DC: National Academies Press.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0597 | Gong HC, Hang J, Kobler W, Li L, Su TZ. Tissue-specific expression and Gabapentin-binding properties of calcium channel $\alpha 2\delta$ subunit subtypes. J Membrane Biol. 2001; 184:35-43.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0598 | Gonul, Fusun, F. et al., "Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," Journal of Marketing, Volume 65, 79-90, July 2001.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0599 | Goodman, M. and Nordin, J. Vaccine Adverse Event Reporting Source: A Possible Source of Bias in Longitudinal Studies. Pediatrics 2006; 117:387-90.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0600 | Goodwin FK, et al., Manic-depressive illness. New York: Oxford University Press, 1990.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0601 | Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression (2007). New York, New York: Oxford University Press, Inc; 247-269.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0602 | Goodwin, F.K., 1999. Anticonvulsant therapy and suicide risk in affective disorders. J. Clin. Psychiatry 60 (Suppl. 2), 89-93.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0603 | Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J. Revicki, D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290:1467-1473.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0604 | Gorson KC, Schott C, Herman R, Ropper A. Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo Controlled, Double Blind, Crossover J Neurol. Neurosurg. Psychiatry. February 1999; 66(2):251-252.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0605 | Gorson KC, Schott C, Rand WM, et al. Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo-Controlled, Double-Blind, Crossover Trial. Neurology. 1998; 50:A103, 1998.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0606 | Gottesfeld, Z. Effect of Lithium and Other Alkali Metals on Brain Chemistry and Behavior: I Glutamic Acid and GABA in Brain Regions. Psychopharmacologia Berl. 1976; 45(3): 239-242.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0607 | Grabowska-Grzyb, et al., "Risk factors for depression in patients with epilepsy," Epilepsy & Behavior 8 (2006) 411-417.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0608 | Greenland S. Relation of probability of causation to relative risk and doubling dose: a methodologic error that has become a social problem. Am J Public Health. 1999 Aug;89(8):1166-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0609 | Greenland, S. Can Meta-analysis Be Salvaged? Am. J. Epidemiol. 1994;140: 783-787.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0610 | Groh, CL Poverty, Mental Health, and Women: Implications for Psychiatric Nurses in Primary Care Settings. Journal of the American Psychiatric Nurses Association 2007; 13(5):267-274.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0611 | Gronseth, G., G. Cruccu, et al. (2008). "Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Fed | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0612 | Grunze H, Greene RW, Moeller H-J, Meyer T, Walden J. Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res. 1998;791:330-334.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0613 | Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003;23:7069-7074.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0614 | Gu Y, Huang LYM. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain. 2001; 93:85-92.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0615 | Gu Y, Huang LYM. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neurosci Lett. 2002; 324:177-180.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0616 | Hahn RA. The Nocebo Phenomenon: Concept, Evidence, and Implications for Public Health. Preventive Medicine 26, 607–611 (1997).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0617 | Hainline B. Chronic Pain: Physiological, Diagnostic, and Management Considerations. Psychiatr. Clin. N. Am. 2005; 28:713-735.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0618 | Hall RC, Platt DE, Hall RC. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics. 1999 Jan-Feb; 40(1):18-27.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0619 | Halonen T, Pitkanen A, Saano V, Riekkinen PJ. Effects of vigabatrin (gamma-vinyl gaba) on neurotransmission-related amino acids and on gaba and benzodiazepine receptor binding in rats. Epilepsia 1991; 32(2):242-249.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0620 | Ham, BJ et al., Decreased GABA Levels in Anterior Cingulate and Basal Ganglia in Medicated Subjects with Panic Disorder: A Proton Magnetic Resonance Spectroscopy (H-MRS) Study. Progress Neuropsychopharmacol Biologic Psychiatry 2007; 31: 403-411.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0621 | Hamad, T. Relationship between psychotropic drugs and pediatric suicidality. U.S. Food and Drug Administration, August 16, 2004.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0622 | Hanley MA, Ehde D, Campbell KM, Osborn B, Smith D. Self-Reported Treatments Used for Lower-Limb Phantom Pain: Descriptive Findings. Arch. Phys. Med. Rehabilitation February 2006;87:270-277.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0623 | Hanna, M., O'Brien C, et al. (2008). "Prolonged-release oxycodone enhances the effects of existing Gabapentin therapy in painful diabetic neuropathy patients." Eur J Pain 12(6): 804-13.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0624 | Harden C et al. Mood disorders in patients with epilepsy. CNS Drugs 2002;15:291-302.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0625 | Harris EC, Baraclough B. Suicide as an Outcome for Mental Disorders. A Meta Analysis. Br. J. Psychiatry 1997; 170:205-228.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0626 | Harrison's Online. Par 14: Neurologic Disorders: Section 5; Chapter 385: Anxiety Disorders. McGraw-Hill Companies, 26 Sept 2002. Available at URL: <a href="http://www.harrisons.accessmedicine.com/serverjava/Arknoide/madeharrisons/chapters/ch385/ch385_01.htm?searchter">http://www.harrisons.accessmedicine.com/serverjava/Arknoide/madeharrisons/chapters/ch385/ch385_01.htm?searchter</a> | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0627 | Hashimoto K, Sawa A, Iyo M (2007): Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0628 | Hasler G, van der Veen JW, Tuminis T, Meyers N, Shen J, Drevets WC (2007): Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64:193-20  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0629 | Hauben & Aronson. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Safety 32:99 - 110 (2009).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0630 | Hauben & Bate. Decision support methods for the detection of adverse events in post-marketing data. Drug Discovery Today 14:343 - 357 (2009).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0631 | Hauben, et al. Evaluation of Suspect Adverse Drug Reactions. JAMA, March 16, 2005 - Vol. 293, No. 11, pg. 1324.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0632 | Hauben, M., Horn, S., Reich, L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Safety 2007; 30(2):143-155.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0633 | Hauben, M., Patadia, V., Gerrits, C., Walsh, L., Reich, L. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Safety 2005; 28(10):835-842.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0634 | Hauben, M., Reich, L., Chung, S. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. European Journal of Clinical Pharmacology 2004; 60(10):747-50.    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0635 | Hauben, M., Reich, L., Gerrits, CM. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study. Pharmacoepidemiol Drug Safety 2006; 15(11):775-783.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0636 | Hauben, M., Reich, L., Van Puijenbroek, EP., Gerrits, CM., Patadia, VK. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 2006; 62(11):967-970.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0637 | Hauben, M., Zhou, X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26(3):159-186.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0638 | Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66(6):693-704.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0639 | Hayashida KI, Degoes S, Curry R, Eisenach JC. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiol. 2007;106(3):557-562.                                     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0640 | Hebert T, Drapeau P, Pradier L, Dunn RJ (1994): Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45:1055-1060.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0641 | Heblich, F., A. Tran Van Minh, et al. (2008). "Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin." Channels (Austin) 2(1): 4-9.                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0642 | Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad. Sci. USA 2008;105:3628-3633. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0643 | Hendrich, J., A. T. Van Minh, et al. (2008). "Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin." Proc Natl Acad Sci U S A 105(9): 3628-33.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0644 | Hendricson AW, Sibbald JR, Morrisett RA. Ethanol alters the frequency, amplitude, and decay kinetics of Sr2+ - supported, asynchronous NMDAR mEPSCs in rat hippocampal slices. J Neurophysiol 2004; 91:2568-2577.                     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0645 | Herman JP, Mueller NK, Figueiredo H (2004): Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration. Ann N Y Acad Sci 1018:35-45.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0646 | Hill A.B., The Environment and Disease: Association or Causation? (1965) Proceedings of the Royal Society of Medicine: 58: 295-300, reprinted in Bulletin of the WHO, Oct. 2005; 83(10):796-798.                                      | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0647 | Hill DR, Suman CN, Woodruff GN. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993; 244(3):303-309.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0648 | Hitchcock LS et al. The experience of chronic nonmalignant pain. J Pain Symptom Manage. 1994;9:312-18.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0649 | Honig A, Bartlett JR, Bouras N, Bridges PK. Amino acid levels in depression: a preliminary investigation. Journal of Psychiatric Research 1988;22(3):159-164.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0650 | Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 1995a; 20(3):193-202.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0651 | Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant Gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995b; 692(1-2):273-277.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0652 | House, JS., Strecher, V., et al. Occupational Stress and Health Among Men and Women in Tecumseh Community Health Study. J Health Soc Behav 27: 62, 1986.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0653 | Hua, et al., An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiology and Drug Safety 2005; 14: 629-638.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0654 | Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T (1997): Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 282:1280-1290.                                  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0655 | Hurley RW, Chatterjea D, Feng MR, Taylor CP, Hammond DL. (2002) Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiol 97:1263-1273.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0656 | Hurley, R. W., S. P. Cohen, et al. (2006). "The analgesic effects of perioperative Gabapentin on postoperative pain: a meta-analysis." Reg Anesth Pain Med 31(3): 237-47.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0657 | Hutson SM, Berkich D, Drown P, Xu B, Aschner M, LaNoue KF. Role of branched-chain aminotransferase isoenzymes and Gabapentin in neurotransmitter metabolism. J Neurochem 1998; 71(2):863-874.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0658 | Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. Journal of Nutrition 2001; 131(3):846S-850S.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0659 | Hwang JH, Yaksh TL. Effect of subarachnoid Gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg Anesthesia 1997; 22(3):249-256.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0660 | Institute of Medicine report on Causal Assessment.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0661 | Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, Shuaib A, Hasan Rajput A. Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res 2002; 946(2):162- | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0662 | Isenberg K, Zorumski C. Chapter 31, Electroconvulsive Therapy, in: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol. II, pp. 2503-2507 (Sadock B, Sadock V, eds., 7th ed. 2000.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0663 | Jackson & Turkington, "Depression and Anxiety in Epilepsy," J   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | Neurol. Neurosurg. Psychiatry 2005; 76 (Suppl. I): i45-i47.   |  |                       |
| JX0664 | Jacobs DG (Ed.) The Harvard Medical School Guide to Suicide Assessment and Intervention (1999). Jossey-Bass: New York, New York.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0665 | Jacobs DG, Deutch NL, Brewer M. Suicide, Depression and Isotretinoin: Is There a Causal Link? J Am Acad Dennatol 2001; 45:S168-75.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0666 | Jacobs DG. A 52-Year-Old Suicidal Man. JAMA 2000; 283(20):2693-2699.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0667 | Jacobs, D, Brewer, M. APA Practice Guideline Summary: Recommendations for Assessing and Treating Patients with Suicidal Behaviors. Psychiatric Ann 2004; 34 (5): 373-380.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0668 | Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61 Suppl. 9:47-51.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0669 | Janakiramaiah N, Gangadhar BN, Naga VMPJ. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: A randomized comparison with electroconvulsive therapy (ECT) and imipramine. Journal of Affective Disorders 2000;47:255-259.                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0670 | Jancsar SM, Leonard BE (1984): Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog Neuropsychopharmacol Biol Psychiatry 8:263-269.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0671 | Janicak PG, Davis JM, Gibbons RD, Ericksen S, Chang S, Gallagher P. Efficacy of ECT: a meta-analysis. Am J Psychiatry 1985 Mar;142(3):297-302.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0672 | Jehle T, Bauer J, Blauth E, Hummel A, Darstein M, Freiman TM, Feuerstein TJ (2000):Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 130:1227-1234.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0673 | Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, Abrahamsen B, Mattsson JP, Lehmann A, Bettler B, Braeuner-Osborne H. The anticonvulsant Gabapentin (Neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol 20 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0674 | Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and ltp: Do pain and memory share similar mechanisms? Trends Neurosci 2003; 26(12):696-705.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0675 | Jones JE et al. Rates and risks for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy and Behavior 2003;S31-38.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0676 | Joshi I, Taylor CP (2005) Pregabalin action at a model synapse: binding to presynaptic ( $\alpha 2$ - $\delta$ ) subunit reduces neurotransmission in mice. Soc. Neurosci. Abstr.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0677 | Joshi I, Taylor CP (2006) Pregabalin action at a model synapse: binding to presynaptic Ca <sup>2+</sup> -channel $\alpha 2$ -delta ( $\alpha 2$ - $\delta$ ) subunit reduces neurotransmission in mice. For Eur J Pharmacol. 553:82-88.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0678 | Jureidini J. The black box warning: decreased prescriptions and increased youth suicide? Am J Psychiatry. 2007 Dec;164(12):1907; author reply 1908-10.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0679 | Juonk, DN, Herman, N, Szalai, JP, Kopp, A, Redelmeier, DA. Medical illness and the Risk of Suicide in the Elderly. Arch Int Med June 2004; 64: 1179-1184.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0680 | Kalinin V. Suicidality and antiepileptic drugs: Is there a link? Drug Safety 2007; 30(2):123-142.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0681 | Kandel ER, Schwartz JH, Jessell TM (eds.). Principles of Neural Science, 4th Edition. New York: McGraw-Hill, 1414 1991.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0682 | Kandel ER, Seigelbaum SA. Transmitter release. Chapter 14 in: Principles of Neural Science, 4th edition, Kandel ER, Schwartz JH, Jessell TM (eds.), McGraw-Hill, New York, 2001.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0683 | Kanemoto K, Kawas J, Mori E. Violence and Epilepsy: A Close Relation Between Violence and Postictal Psychosis. Epilepsia 1999; 40(1):107-109.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0684 | Kaner AM, Stagno S, Kotaal P, Morris HH. Postictal Psychiatric Events During Prolonged Video-Electroencephalographic Monitoring Studies. Arch Neurol 1996 Mar; 53(3):258-63.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0685 | Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vols. I and II (B. Sadock & V. Sadock eds., 7th ed. 2000).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0686 | Kaplan et al., Physical illness, functional limitations, and suicide risk: a population-based study. Am J Orthopsychiatry 2007; 77:56-60.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0687 | Kasa K, Otsuki, S., Yamamoto, M., Sato, M., Kuroda, H., Ogawa, N. (1982): Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biological Psychiatry 17:877-883.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0688 | Kasper S, Olie JP (2002): A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 17 Suppl 3:331-340.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0689 | Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K (2002): Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB Journal 16:1328-13 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0690 | Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(suppl. 2):53-67.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0691 | Kellner C, Fink M, Knapp R, Petrides G, Husain M, Rummans T, Mueller M, Bernstein H, Rasmussen K, O'Connor K, Smith G, Rush AJ, Biggs M, McClintock S, Bailine S, Malur C. Relief of Expressed Suicidal Intent by ECT: A Consortium for Research in ECT Study.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0692 | Kelly KM (1998): Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 38:139-144.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0693 | Kendler KS (2005): Toward a philosophical structure for psychiatry. Am J Psychiatry 162:433-440.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0694 | Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005): Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0695 | Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the united states at the beginning of the twenty-first century. Annual Review of Clinical Psychology 2007;3:137-158.                                 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0696 | Kessler, RC, Berglund, ZP., Borges, G., Nock, M., Wang, PS. Trends in Suicide Ideation: Plans, Gestures and Attempts in the U.S. 1990-1992 to 2001-2003. JAMA 2005; 293:2487-2495.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0697 | Kessler, RC., Borges, G., Walters, EE. Prevalence of and Risk Factors for Lifetime Suicide Attempts in the National Comorbidity Survey. Arch Gen Psych 1999; 56: 617-626.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0698 | Khan A et al. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J of Affective Disorders 2002;68:183-90.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0699 | Khan A, Warner HA, Brown W A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000 Apr;57(4):311-7. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0700 | Khan RB, Hunt DL, Thompson SJ. Gabapentin in control seizures in children undergoing cancer treatment. J Child Neurol 2004; 19(2)(Feb):97-101.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0701 | Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0702 | King, Charles (2002). "Marketing, Product Differentiation, and Competition in the Market for Antiulcer Drugs," HBS Working Paper 01-014.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0703 | Klein D, Strom BL, Wang P, Cunningham F, Herings RMC, O'Brien CP. (2007): The Future of Postmarketing Surveillance of Psychotropic Medications. CNS Spectr 12: 9(Suppl 16)1-20.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0704 | Knowles SR, Uetrecht JP, Shear NH. Confirming false adverse reactions to drugs by performing individualized, randomized trials. Can J Clin Pharmacol 2002; 9(3): 149-53.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0705 | Kocsis JD, Honnmu O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994; 169(1-2):181-184.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0706 | Kocsis JD, Mattson RH. GABA levels in the brain: a target for new antiepileptic drugs. Neuroscientist 1996; 2:326-334.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0707 | Korf J, Venema K (1983): Desmethylinipramine enhances the release of endogenous GABA and other neurotransmitter amino acids from the rat thalamus. J Neurochem 40:946-950.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0708 | Kraemer, H.C., Gibbons, R.D. Where do we go wrong in assessing risk factors, diagnostic and prognostic tests? The problems of two-by-two association.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0709 | Kramer MS, Algorithm for the operational assessment of adverse drug reactions. JAMA, Vol. 242 No. 7, 623-632 (1979).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0710 | Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al (2002): Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 7:S71-80.                            | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0711 | Kubota, K., Koide, D., Hirai, T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiology & Drug Safety 2004; 13(6):387-94.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0712 | Kugaya A, Sanacora G (2005): Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10:808-819.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0713 | Kung, H., et al. Deaths: Preliminary Data for 2005.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0714 | Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, Hetherington H (2002): Modulation of cerebral GABA by topiramate, lamotrigine, and Gabapentin in healthy adults. Neurology 58:368-372.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0715 | Kuzniecky RI, Hetherington HP, Ho S, Pan JW, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. <i>Neurol</i> 1998; 51:627-629.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0716 | La Spina I, Porrazzi D, Maggiolo F, et al. Gabapentin (GBP) in Painful. AIDS-Related Neuropathy. <i>Neurology</i> . 1999; 52:A190.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0717 | Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, Charles KJ, Wood M, Davies CH, Pangalos MN. Gabapentin is not a GABAB receptor agonist. <i>Neuropharmacology</i> 2001; 41(8):965-975.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0718 | Leach JP, Sills GJ, Butler E, Forrest G, Thompson GG, Brodie MJ. Neurochemical actions of Gabapentin in mouse brain. <i>Epilepsy Research</i> 1997; 27(3):175-180.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0719 | Leckman JF, King RA. A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. <i>Am J Psychiatry</i> . 2007 Sep; 164(9):1304-6.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0720 | Levendoglu F, Ogun, CO, Ozerbil O, Ogun TC, Ugulu H. Gabapentin is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury. <i>Spine</i> . 2004; 29(7):743-751.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0721 | Levine, JG., Tonning, JM., Szarfman, A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned (comment) (erratum appears in <i>Br J Clin Pharmacol</i> 2006; 61 (1):.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0722 | Levinson DE, Devinsky O. Psychiatric adverse events during vigabatrin therapy. <i>Neurology</i> 1999; 53(7):1503-1511.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0723 | Levitt AJ. Psychogenic panic after zidovudine therapy: the therapeutic benefit of an N of 1 trial. <i>Can Med Assoc J</i> 1990; 142 (4) 341-342.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0724 | Levy DL, Dorus E, Shaughnessy R, Yasillo NJ, Pandey GN, Janicak PG, Gibbons RD, Gaviria M, Davis JM. Pharmacologic evidence for specificity of pursuit dysfunction to schizophrenia. Lithium carbonate associated with abnormal pursuit. <i>Arch Gen Psychiatry</i> . 1 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0725 | Levy DL, Yasillo NJ, Dorus E, Shaughnessy R, Gibbons RD, Peterson J, Janicak PG, Gaviria M, Davis JM. Relatives of unipolar and bipolar patients have normal pursuit. <i>Psychiatry Res</i> . 1983 Dec; 10(4):285-93.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0726 | Lewis DA, Volk DW, Hashimoto T (2004): Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. <i>Psychopharmacology (Berl)</i> 174:143-150.                              | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0727 | Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson AH, Feng G, Luo ZD. Calcium channel alpha2delta1 subunit mediates spinal hyper excitability in pain modulation. <i>Pain</i> 2006; 125(1-2):20-34.                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0728 | Li Z et al. Poster presented at Society for Neuroscience 32nd Annual Meeting. Abstract 798.1, 2002. Gabapentin Inhibits ERK MAP Kinase Phosphorylation in NK1 Expressing Cells.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0729 | Liccardia, et al. Evaluation of the placebo effect during oral challenge in patients with adverse drug reactions. <i>J Invest Allergol Clin Immunol</i> 2004; Vol. 14(2): 104-107.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0730 | Linthorst AC, Reul JM. Stress and the brain: Solving the puzzle using microdialysis. <i>Pharmacol Biochem Behav</i> 2007.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0731 | Lloyd and colleagues. Biochemical Evidence of Dysfunction of Brain Neurotransmitters in the Lesch-Nyhan Syndrome. NEJM 1994; 305(19): 1106-11.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0732 | Lloyd KG, Morselli PL, Bartholini G (1987a): GABA and affective disorders. Med Biol 65:159-165.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0733 | Lloyd KG, Morselli PL, Depoortere J, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacology | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0734 | Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G (1987b): Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 241:245-250.                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0735 | Löffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R, Feuerstein TJ. Dopamine release in human neocortical slices: Characterization of inhibitory auto receptors and of nicotinic acetylcholine receptor-evoked release. Brain Research Bulletin 2006;  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0736 | Loscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neuroscience Letters 1991;128(2):150-154.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0737 | Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res. 2006; 69:183-272.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0738 | Lotarski SM, Kinsora J. Behavioral characterization of pregabalin in congenic 2- -1(R217A) mouse mutants in models of anxiety and side effects. Soc Neurosci Abstr 2006 (program number 829.3).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0739 | Lubell, et al. Suicide Trends Among Youths and Young Adults Aged 10--24 Years ---United States, 1990-2004. MMWR. September 7,2007/56(35):905-908.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0740 | Lumley, CD., et al. The under-reporting of adverse drug reactions seen in general practice. Pharmaceut Med 1986; 1:205-12.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0741 | Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR. Injury type-specific calcium channel alpha-2-delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of Gabapentin. J Pharmacol Exp Ther.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0742 | Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion alpha-2-delta calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21(6):1868-1875.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0743 | Lydiard RB. Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Anxiety. 1996;2(2):61-70.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0744 | Magée WJ et al. Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996;53:159-68.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0745 | Magni G et al. Suicidality in chronic abdominal pain: an analysis of the Hispanic Health and Nutritional Examination   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | Survey (NS). Pain 1998;76:137-144.  |  |                       |
| JX0746 | Magni G, Garreau M, Orofiamma B, Palminteri R (1989): Fengabine, a new GABA-mimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology 20:126-131.                                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0747 | Maier SF, Busch CR, Maswood S, Grahn RE, Watkins LR (1995): The dorsal raphe nucleus is a site of action mediating the behavioral effects of the benzodiazepine receptor inverse agonist DMCM. Behav Neurosci 109:759-766.                                      | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0748 | Mairs, RW. Social and Familial Risk Factors in Suicidal Behavior. Suicide 1997; 20(3): 519-551.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0749 | Manchanda R et al. Psychiatric disorders in candidates for epilepsy surgery. J Neurol Neurosurg Psychiatry 1996;61 :82-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0750 | Manchikanti L, Singh V. Managing phantom pain. Pain Phys 2004; 7(3):365-75.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0751 | Manchikanti L, Singh, V, Kloth D, Slipman W. Et al. Interventional Techniques in Management of Chronic Pain: Part 2.0. Pain Physician. 2001; 4(1):24-98.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0752 | Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by Gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. British Journal of Pharmacology 2004; 141(4):574-579.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0753 | Maneuf YP, Gonzalez MI, Sutton KG, Chung FZ, Pinnock RD, Lee K. Cellular and molecular action of the putative GABA-mimetic, Gabapentin. Cell Molec Life Sci 2003; 60(4):742-750.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0754 | Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001; 93(2):191-196.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0755 | Maneuf YP, McKnight AT. Block by Gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001; 134(2):237-240.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0756 | Maneuf, Y. P., Z. D. Luo, et al. (2006). "alpha2delta and the mechanism of action of Gabapentin in the treatment of pain." Semin Cell Dev Biol. 17(5): 565-70.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0757 | Mann, J. J. Searching for Triggers of Suicidal Behavior. Am J Psychiatry 2004; 161(3): 395-397.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0758 | Mann, J.J. and Gibbons R.D. SSRIs and the risk of suicide attempt and completion: a systematic review of observational studies. Canadian Medical Association Journal, in press.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0759 | Manor D, Rothman DL, Mason GF, Hyder F, Petroff OA, Behar KL. The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA). Neurochemical Research 1996; 21(9):1031. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0760 | Marangell L et al., Psychopharmacology and Electroconvulsive Therapy, p. 1025 in: The American Psychiatric Press Textbook of Psychiatry (Hales R, et al., eds.) 3rd ed. 1999.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0761 | Marcangelo, M. Psychiatric Aspects of Epilepsy. Psychiatr Clin N Am 30 (2007) 781-802.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0762 | Maris, R. Suicide. Lancet 2002; 360:319-26.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0763 | Maris, RW. Social and Familial Risk Factors in Suicidal Behavior. Suicide 1997; 20(3): 519-551.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0764 | Maris, RW. Suicide Prevention in Adults (age 30-65). Suicide and Life Threatening Behavior 1995; 25(1): 171-179.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0765 | Marsteller DA, Barbarich-Marsteller NC, Patel VD, Dewey SL (2007): Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and gamma-amino butyric acid levels. Synapse 61:877-881.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0766 | Martin D, Thompson MA, Nadler JV (1993): The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 250:473-476.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0767 | Martin DJ, McClelland D, Herd MB, Sutton KG, Hall MD, Lee K, Pinnock RD, Scott RH. Gabapentin-mediated inhibition of voltage-activated Ca-2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0768 | Mason G, Watzl J, Gomez R, Krystal J, Rothman D, Sanacora G. Effects of light deprivation on brain GABA and glutamate in healthy and depressed individuals. Neuropsychopharmacology 2006;31:S160.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0769 | Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005): Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379-2381.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0770 | Matthews, W. and Barabas, G. Suicide and epilepsy: A review of the literature. Psychosomatics 1981; 22:515-24.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0771 | Matthews, SC., Dimsdale, JE. Priapism after a Suicide Attempt by the Ingestion of Olanzapine and Gabapentin. Psychosomatics 2001; 42(3): 280-281.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0772 | Mattson RH, Petroff OA, Rothman D, Behar K. Vigabatrin: Effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol. Scand. Suppl. 1995;162:27-30.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0773 | Mauri MC, et al.: Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium. Clin Drug Invest 21(3):169-74, 2001.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0774 | Max MB, Culname M, Schafer SC, et al. Amtrptyline relieves diabetic neuropathic pain in patients with normal or depressed mood. Neurology. 1987; 37:589-590.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0775 | Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991; 45:3-5.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0776 | McCleane G. Pharmacological Strategies in Relieving Neuropathic Pain. Expert Opin. Pharmacother. 2004; 5(6):1299-1312.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0777 | McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of Gabapentin and pregabalin on the electrophysiological properties of cultured DRUG neurones from neonatal rats. BMC Pharmacol 2004; 4:14-24.                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0778 | McElroy SL, Keck PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biological Psychiatry 48(6):539-57, Sep 15 2000.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0779 | McElroy SL, Soutulo CA, Keck PE Jr., et al. A pilot trial of adjunctive Neurontin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9:99-103.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0780 | McEwen BS, Olie JP (2005): Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 10:525-537.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0781 | McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus-Miller L, Bernstein P, Rose-Legatt A. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia 1999;40(7):965-72.                     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0782 | McKenna KF, McManus DJ, Baker GB, Coutts RT (1994): Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm 41S:115-122.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0783 | McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF (1992): Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-Transaminase activity in rat brain. Biochem Pharmacol 43:2486-2489.                                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0784 | McPhee SJ, Papadaks MA and Tierney LM. Neuropathic Pain. In Current Medical Diagnosis and Treatment, McGraw Hill Medical, New York. 2007, pp. 68-86.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0785 | McQuay, H. J., K. H. Poon, et al. (2008). "Acute pain: combination treatments and how we measure their efficacy." Br J Anaesth 101(1): 69-76.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0786 | Meder WP et al, Modulation of K+-induced synaptosomal calcium influx by Gabapentin. Brain Res. 2000; 875: 157-159.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0787 | Medical Uses of Statistics, 2nd Edition.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0788 | Meinzinger, MM. and Bar, WS. Prospective Study of the Influence of the Media on Reporting Medical Events. Drug Inf J 1990; 24:575-77.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0789 | Meldrum, B. S. and M. A. Rogawski (2007). "Molecular targets for antiepileptic drug development." Neurotherapeutics 4(1): 18-61.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0790 | Mellegars MA, Furlan AD, Mailis A. Gabapentin for Neuropathic Pain: Systematic Review of. Controlled and Uncontrolled Literature. Clin. J. Pain. 2001; 17(4):284-295.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0791 | Mellick GA, Mellick LB. Reflex Sympathetic Dystrophy Treated With Gabapentin. Arch. Phys. Med. Rehabil. 1997; 78:98-105.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0792 | Mendez, MF., et al. Depression in Epilepsy: Significance and Phenomenology. Arch Neurol 1986; 43(8):766-70.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0793 | Menigaux C, Adam F, Guignard B, Sessler D, Chauvin M. Preoperative Gabapentin Decreases Anxiety and Improves Early Functional Recovery From Knee Surgery. Anesth. Analg. 2005; 100:1394-1399.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0794 | Mera J, Martinez-Castrillo JC, Mariscal A, Herrero A, Alvarez-Cemeno JC. Autonomous stump movements responsive to Gabapentin. J Neurol 2004; 25(3)(Mar):346-7.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0795 | Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Cancer 2001; 9(3)(May):205-6.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0796 | Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfeleiderer B (2003): Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychological Med | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0797 | Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006; 70(2):467-476.  |  |                       |
| JX0798 | Miller RG, Mitchell JD, Lyon M, Moore DH (2007): Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev:CD001447.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0799 | Milstein JR, et al. Factors affecting physician reporting of adverse drug reactions. Drug Inf J 1986; 20:157-64.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0800 | Mirchandani GR, Agulian S, Abi-Saab W, Tyrrell L, Mattson RH, Kocsis JD. Vigabatrin increases total GABA levels in rat optic nerve while Gabapentin and pregabalin do not. Soc Neurosci Abstr 1999; 25:1868-1868.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0801 | Mizik, Natalie, and Jacobson, Robert, "Are Physicians 'Easy Marks'?" Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science, Volume 50, Dec. 2004.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0802 | Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, et al (1985): 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology 24:767-773.            | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0803 | Moghaddam B, Jackson M (2004): Effect of stress on prefrontal cortex function. Neurotox Res 6:73-78.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0804 | Mongeau R, De Montigny C, Blier P. Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. European Journal of Pharmacology 1994; 271(1):12 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0805 | Moore, N., et al. Biases Affecting the Proportional Reporting Ratio (PRR) in Spontaneous Reports Pharmacovigilance Databases: the Example of Sertindole. Pharmacopeidemiology and Drug Safety 2003; 12(4):271-81.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0806 | Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain. Arch. Int. Med. September 13, 1999;159:"1931-1937.                 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0807 | Morilak DA, Barrera G, Echevarria DJ, Garcia AS, Hernandez A, Ma S, Petre CO. Role of brain norepinephrine in the behavioral response to stress. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005;29(8):1214-1224.                             | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0808 | Morse R. Search script for the COSTART Thesaurus of Adverse Reaction Jan 1994. Available at: <a href="http://hedwig.mgh.harvard.edu/biostatistics&amp;iode/17">http://hedwig.mgh.harvard.edu/biostatistics&amp;iode/17</a> ).                                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0809 | Morrell, MJ. Dosing to Efficacy with Neurontin: The STEPS Trial. Epilepsia 1999; 40 (supp 6): S23-26.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0810 | Morrell MJ, Mclean MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus L, Bernstein P, Rose-Legatt A. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure-European Journal of Epilepsy 2000;9(Jun):241-8.               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0811 | Moscicki E. Epidemiology of suicide. In: Goldsmith S, ed. "Risk factors for Suicide" Washington, DC: National Academy Press, 2001:10-12.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0812 | Mosholder AD, C. Pamer. "Postmarketing Surveillance of Suicidal Adverse Events with Pediatric Use of Antidepressants." Journal of Child and Adolescent Psychopharmacology 16(2006): 33-36.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0813 | Moulin DE. Peripheral Neuropathic Pain Disorders. In Noseworthy JH (00.), Neurologic Therapeutics: Principles and Practice, Marn Dunitz, London. 2003, pp. 222-229.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0814 | Moulin, D. E., A. J. Clark, et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society." Pain Res Manag 12(1): 13-21.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0815 | Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety 2007; 30(7):555-567.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0816 | Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 2007 Jun;68(6):908-16.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0817 | Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T (1996): Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 709:21 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0818 | Namaka M, Gramlich CR, Ruben D, Melanson M, Sutton I, Major J. A Treatment Algorithm for Neuropathic Pain. Clin. Therapeutics. 2004; 26(7):951 -979.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0819 | Nasr SJ, Gibbons RD. Depressive symptoms associated with dexamethasone resistance. Psychiatry Res. 1983 Nov;10(3):183-9.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0820 | Neal, A., Huntly, K., Doan, V., Zielonka, J. MedDRA and pharmacovigilance - the way forward. DIA annual meeting. June 27-July 1999. Slide # 7.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0821 | Nemeroff, CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37(4):133-146.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0822 | Neugebauer V, Carlton SM. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opinion on Therapeutic Targets 2002; 6(3):349-361.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0823 | Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE. Gamma-aminobutyric acid type B receptors with specific heterodimer composition and post | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0824 | Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunbauer A, et al (2003): Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23:155-168.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0825 | Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001; 87(1):107-16.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0826 | Nilsson Let al. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002;43:644-51.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0827 | Nodera H, ReDmann DN. A Diagnostic and Treatment Approach to Painful Neuropathy. In Bromberg MB, Smith AG (eds.), Handbook of Peripheral Neuropathy, Taylor & Francis,  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | Boca Raton. 2005.   |  |                       |
| JX0828 | O'Brien RF. Medical Conditions with Psychiatric Manifestations. <i>Adolesc Med</i> 17 (2006) 49–77.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0829 | O'Connell KA, Wilkin JK, Pitts M. Isotretinoin (Accutane) and Serious Psychiatric Adverse Events. <i>J Am Acad Dermatol</i> 2002; 48(2): 306-308.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0830 | Ohayon, "Specific Characteristics of the Pain/Depression Association in the General Population," <i>J Clin Psychiatry</i> 2004; 65 (suppl 12): 5-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0831 | Ohayon, et al., "Using Chronic Pain to Predict Depressive Morbidity in the General Population," <i>Arch Gen Psychiatry</i> 2003; 60:39-47.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0832 | Ohring R, Apter A, Ratzoni G, Weizman R, TyanoS, Plutchik R. State and trait anxiety in adolescent suicide attempters. <i>J Am Acad child Adolesc Psychiatry</i> . 1996 Feb;35(2):154-7.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0833 | Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T. A comparison of Ca2+ channel blocking mode between Gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. <i>British Journal of Pharmacology</i> 2003a; 39(2):435-443. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0834 | Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T. Gabapentin blocks L-type and P/Q-type Ca2+ channels involved in depolarization-stimulated nitric oxide synthase activity in primary cultures of neurons from mouse cerebral cortex. <i>Pharm Res</i> 2003; 20(6):897-899.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0835 | Olfson M, Shaffer D. SSRI prescriptions and the rate of suicide. <i>Am J Psychiatry</i> . 2007 Dec;164(12):1907-8; author reply 1908-10.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0836 | Olsen RW, Ticku MK, Van Ness PC, Greenlee D (1978): Effects of drugs on gamma-aminobutyric acid receptors, uptake, release and synthesis in vitro. <i>Brain Res</i> 139:277-279.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0837 | Oquendo MA, Malone KM, Ellis SP, Sackeim HA, Man JJ. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. <i>Am J Psychiatry</i> . 1999 Feb;156(2):190-4.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0838 | Ostrow DG, Halaris A, DeMet E, Gibbons RD, Davis JM. Ion transport and adrenergic function in major affective disorder. <i>Biol Psychiatry</i> . 1982 Sep;17(9):971-80.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0839 | Page ME, Abercrombie ED. An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. <i>Neuropsychopharmacology</i> 1997; 6(6):419-425.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0840 | Pande AC, Crockett JG, Janney CA, Worth JL, Tsamoucha O. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. <i>Bipolar Disord</i> 2000; 220:(3 Pt 2): 249-255.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0841 | Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with Gabapentin: A placebo-controlled study. <i>J Clin Psychopharmacol</i> 1999; 19(4):341-348.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0842 | Pande AC, Pollack MH, Crockett J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovit T. Placebo-controlled study of Gabapentin treatment of panic disorder. <i>J Clin Psychopharmacol</i> . 2000 Aug;20(4):467-71.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0843 | Pandey CK, Sahay S, Gupta D, et al. Preemptive Gabapentin Decreases Postoperative Pain After Lumbar Discectomy. Regional Anesthesia and Pain. Can J. Anesth. 2004; 51(10):986-989.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0844 | Pandey CK. Does Preemptive use of Gabapentin Have No Effect on Postoperative Pain and Morphine Consumption Following Lumbar Laminectomy and Discectomy (Correspondence). Neurosurg. Anesthesiol. July 2005; 17(3): 172-173.                                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0845 | Pape HC (2005): GABAergic neurons: gate masters of the amygdala, mastered by dopamine. Neuron 48:877-879.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0846 | Parent MB, Master S, Kashlub S, Baker GB (2002): Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenyl ethylamine hydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol 63:57-64. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0847 | Parker DA, Ong J, Marino D, Kerr DI. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur J Pharmacol 2004; 495(2-3):137-143.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0848 | Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology 1999; 38(6):735-767.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0849 | Paslawski TM, Sioley BD, Baker GB. Effects of the mao inhibitor phenelzine on glutamine and gaba concentrations in rat brain. Progress in Brain Research 1995; 106:181-186.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0850 | Patel GJ, Schatz RP, Constantinides SM, Lal H (1975): Effect of desipramine and pargyline on brain gamma-aminobutyric acid. Biochem Pharmacol 24:56-60.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0851 | Patel S, Naeem S, Kesingland A, Froestl W, Capogna M, Urban L, Fox A. The effects of GABA(b) agonists and Gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. Pain 2001; 90(3):217-226.                          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0852 | Pentien J. Back pain and risk of suicide among Finnish farmers. Am J Public Health 1995 ;85: 1452-53.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0853 | Perry TL, Hansen S (1973): Sustained drug-induced elevation of brain GABA in rat. J Neurochem 21:1667-1175.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0854 | Perry, CFS amino acids and plasma CSF amino acid ratios in adults. J Neurochem 1975; 24: 587-89.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0855 | Perugi G, et al.: Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 32:136-41, 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0856 | Perugi G, Toni C, Frare F, Ruffulo G, Moretti L, Torti C, Akiskal HS (2002):Effectiveness of adjunctive Gabapentin in Resistant Bipolar Disorder: Is It Due to Anxious-Alcohol Abuse Comorbidity? J Clin Psychopharmacol 22(6): 584-91.                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0857 | Petroff OA, Behar KL, Mattson RH, Rothman DL. Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. J Neurochem 1996; 67(6):2399-2404.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0858 | Petroff OA, Hyder F, Collins T, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999; 40(7):958-964.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0859 | Petroff OA, Hyder F, Mattson RH, Rothman D. Topiramate increases brain GABA, homocarnosine and pyrrolidinone in patients with epilepsy. <i>Neurology</i> 1999; 52:473-478.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0860 | Petroff OA, Hyder F, Rothman DL, Collins TL, Mattson RH. Gabapentin increases human brain GABA within one hour. <i>Epilepsia</i> 1998; 39(Suppl. 6):71.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0861 | Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of Gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. <i>Epilepsia</i> 2000; 41(6):675-680.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0862 | Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. <i>Neurology</i> 1996; 47(6):1567-1571.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0863 | Petroff OA, Rothman DL, Behar KL, Hyder F, Mattson RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. <i>Seizure</i> 1999; 8(2):120-127.     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0864 | Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of Gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. <i>Ann Neurol</i> 1996; 39(1):95-99.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0865 | Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. <i>Mol Neurobiol</i> 1998; 16(1):97-121.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0866 | Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate and glutamine in human brain. <i>Epilepsia</i> 1995; 36(5):457-464. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0867 | Petty F (1994): Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? <i>Clin Chem</i> 40:296-302.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0868 | Petty F, Kramer GL, Hendrickse W (1993): GABA and depression. In: Mann JJ, Kupler DJ editors. <i>Biology of depressive disorders, Part A: A systems perspective</i> . New York: Plenum Press, pp 79-108.                                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0869 | Petty F, Sherman AD (1981): GABAergic modulation of learned helplessness. <i>Pharmacol Biochem Behav</i> 15:567-570.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0870 | Petty, F, et. al, Plasma GABA Predicts Acute Response to Divalproex in Mania. <i>Biol Psychiatry</i> 1996; 39(4): 278-284.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0871 | Petty, F, Schlessner, MA Plasma GABA in Affective Illness: Preliminary Investigation <i>J Aff Dis</i> 1981; (3): 339-43.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0872 | Petty, F, Sherman, AD. Plasma GABA Levels in Psychiatric Illness. <i>J Aff Dis</i> 1984; (6): 131-38.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0873 | Piazza-Hepp, TO. and Kennedy, DL. Reporting of Adverse Events to MedWatch. <i>Am J Health-Syst Pharm</i> 1995; 52:1436-39.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0874 | Pile A, Lloyd KG (1984): Chronic antidepressants and GABA receptors: A GABA hypothesis of antidepressant drug action. <i>Life Sci</i> 35:2149-2154.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0875 | Pittaluga A, Raiteri L, Longordo F, Luccini E, Barbiero VS, Racagni G, et al (2007): Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. <i>Neuropharmacology</i> 53:27-36.       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0876 | Polydefkis M. Painful Neuropathy. In Johnson RT, Griffin JW, McArthur JC (eds.), <i>Current Therapy in Neurologic Disease</i> , 6th Edition, Mosby, St Louis. 2002, pp. 373-375.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0877 | Poncelet M, Martin P, Danti S, Simon P, Soubrie P (1987): Noradrenergic rather than GABergic Processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals. Pharmacol Biochem & Behavior 28:321-326.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0878 | Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of H-channels reduces the excitability of pyramidal neuron dendrites. Nature Neurosci. 2002;5:767-774.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0879 | Popov N, Matthies H (1969): Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 16:899-907.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0880 | Posner K, Oquendo MA, Gould M, Stacey B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA's Pediatric Suicidal Risk Analysis of Antidepressants. Am J Psychiatry 2007; 164:1035-1043.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0881 | Pugsley TA, Whetzel SZ, Dooley DJ. Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by Gabapentin. Psychopharmacology Berlin 1998; 137(1):74-80.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0882 | Putzke JD, Richards JS, Kezar L, Hicken BL, Ness TJ. Long-term use of Gabapentin for treatment of pain after traumatic spinal cord injury. Clin J. Pain 2002; 18(2)(Mar/Apr):16-21.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0883 | Quanebeck, C. Forensic Psychiatric Aspects of Inpatient Violence. Psychiatr Clin N Am 29 (2006) 743-760.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0884 | Quetsch RM, Achor RWP, Litin EM, Faucett RL. Depressive reactions in hypertensive patients: A comparison of those treated with rauwolfia and those receiving no specific antihypertensive treatment. Circulation 1959; 19:366-375.                             | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0885 | Radley DC, Finkelstein SN, Stafor RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0886 | Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ (2007): GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 32:471-482.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0887 | Rao ML, Clarenbach P, Vahlensieck M, Kratzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J. Neural. Transm. 1998; 73:129-134.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0888 | Rawlins, MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol. 1988 Jul; 26(1):1-5.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0889 | Reeves RR. Nocebo effects with antidepressant clinical drug trial placebos. General Hospital Psychiatry 29 (2007) 275- 277.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0890 | Reimann W, Zumstein A, Jackisch R, Starke K, Hertting G. Effect of extracellular dopamine on the release of dopamine in the rabbit caudate nucleus: Evidence for a dopaminergic feedback inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology 1979; 306. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0891 | Reimann W. Inhibition by GABA, baclofen and Gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Europe J Pharmacol 1983; 94:341-344.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0892 | Rice ASC, Maton S. Gabapentin in Post-Herpetic Neuralgia: a Randomized, Double-Blind, Placebo Controlled Study. Pain.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | 2001; 94(2):215-224.  |  |                       |
| JX0893 | Rickels, Pregabalin for the treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat 2005; 62: 1022-30.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0894 | Rihmer Z et al. Bipolar II disorder and suicidal behavior. Psychiatry Clin North Am 1999;22:667-73.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0895 | Rizzo, J., "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs, "Journal of Law and Economics, 42:1, 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0896 | Robert M. Kaplan & Igor Grant, 5.2 Statistics and Experimental Design, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Volume 1, (Benjamin I. Sadock & Virginia A. Sadock eds., 7th ed. 2000) 522.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0897 | Robertson MM. Suicide parasuicide and epilepsy. In: Engel J et al. eds. Epilepsy: a Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1997 :2141-51.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0898 | Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993; 16(2):89-98.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0899 | Rogawski MA, Taylor CP. Section 2.4.2. Potential new targets for development of anti-ictal drugs: How to improve efficacy versus tolerability? Ion channels. In: Schmidt D, Loescher W. Critical review: Drug resistance in epilepsy: Putative neurobiologic an | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0900 | Rogawski, M. A. and W. Loscher (2004). "The neurobiology of antiepileptic drugs." Nature Reviews Neurosci 5: 553-564.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0901 | Rogers, AM., et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 1988; 148:1596-1600.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0902 | Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, et al (1998): Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155:910-913.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0903 | Roose SP, Glassman AH, Walsh BT, Woodring S, Vitas-Herne J. Depression, delusions, and suicide. Am J Psychiatry. 1983 Sep;140(9):1159-62.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0904 | Rorarius MGF, Mennander S, Suimien P, et al. Gabapentin for the Prevention of Postoperative Pain After Vaginal Hysterectomy. Pain. 2004; 110: 175-181.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0905 | Rosenblatt JE, Rosenblatt, NC: Gabapentin for bipolar disorder. Currents in Affective Illness 15(6):2-3, 1996.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0906 | Rossi AR., et al. The importance of physician adverse reaction reporting: suprofen and the flank pain syndrome. JAMA 1988; 259:1203-04.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0907 | Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proceedings of the National Academy of Sciences of the United States of America 1993; 90(12):5662-5666.                          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0908 | Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Lippincott, Williams and Wilkins, Philadelphia, 1998.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0909 | Rothman, Greenland & Lash Modern Epidemiology, 3rd Edition. Lippincott Williams & Wilkins. 2008. Philadelphia,  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | PA.   |  |                       |
| JX0910 | Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Mier L. Gabapentin for the Treatment of Postherpetic Neuralgia: a Randomized Controlled Trial. JAMA. December 2,1998; 280(21):1837-1842.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0911 | Rowbotham MC. Mechanisms and Pharmacologic Management of Neuropathic Pain. In Dyck PJ, Thomas PK (eds.), Peripheral Neuropathy, Four Edition, Elsevier Saunders, New York. 2005, pp. 2637-2652.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0912 | Ruhe HG, Mason NS, Schene AH (2007): Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331-359.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0913 | Rush AJ (2007): STAR*D: What have we learned? Am J Psychiatry 164:201-204.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0914 | Sachs, GS, et al.: Expert Consensus Guideline Series-medication treatment of bipolar disorder 2000. Postgraduate Med Apr:1-104, 2000.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0915 | Saks MJ, Faigman DL, Kaye DH, Sanders J (Eds). Annotated Reference Manual on Scientific Evidence (2005-2006). St. Paul, Minnesota: Thomson West;526-535.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0916 | Salas, et al. Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. American Journal of Epidemiology 1999; 149(11):981-983.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0917 | Salzman C. Treatment of the Suicidal Patient with Psychotropic Drugs and ECT, p. 272 in: Harvard Medical School Guide to Suicide Assessment and Intervention (Jacobs D, ed.) 1999.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0918 | Sanacora G, Gueorgieva R, Epperson CN, Wu Y-T, Appel M, Rothman DL, et al (2004): Subtype-specific alterations of GABA and glutamate in major depression. Archives of General Psychiatry 61:705-713.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0919 | Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007): Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822-825.                           | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0920 | Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic Function in Depression: New Insights from Neuroimaging. Critical Reviews of Neurobiology 2000;14:23-45.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0921 | Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, et al (1999): Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of General Psychiatry 56:1043-1047. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0922 | Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased cortical GABA concentrations in depressed patients receiving ECT. Amer. J. Psychiat. 2003;160(3):577-579.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0923 | Sanacora G, Mason GF, Rothman DL, Krystal JH (2002): Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. American Journal of Psychiatry 159:663-665.                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0924 | Sanacora G, Saricicek A (2007): GABAergic contributions to the pathophysiology of depression and the mechanism of   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
|        | antidepressant action. CNS Neurol Disord Drug Targets 6:127-140.   |  |                       |
| JX0925 | Sander JM, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry 1991; 54(5):435-439.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0926 | Sander JM, Hart YM. Vigabatrin and behavior disturbances. Lancet 1990; 335(8680): 57.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0927 | Saper CB. Brain stem modulation of sensation, movement and consciousness. Chapter 45 in: Principles of Neural Science, 4th edition, Kandel ER, Schwartz JH, Jessell TM (eds.), McGraw-Hill, New York, 2001.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0928 | Sapolsky RM (2000): The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biological Psychiatry 48:755-765.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0929 | Sartorius A, Mahlstedt MM, Vollmayr B, Henn FA, Ende G (2007): Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. Neuroreport 18:1469-1473.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0930 | Sator-Katzenschlatger SM, Schiesser AQ, Kozek-Langenecker SA, Benetka G, Langer G, Kress HG Does pain relief improve pain behavior and mood in chronic pain patients? Anesth Analg 2003; 97(3)(Sep):791-7.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0931 | Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung 1994; 44(3):261-266.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0932 | Scatton B, Lloyd KG, Zivkovic B, Dennis T, Claustre Y, Dedek J, et al (1987): Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther 241:251-257. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0933 | Schatz RA, Lal H (1971): elevation of brain GABA by Pargyline: A possible mechanism for protection against oxygen toxicity. J Neurochem 18:2553-2555.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0934 | Schatzberg AF, Nemeroff CB. Depression and gamma-aminobutyric acid, page 736 in: The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd Ed. 2004.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0935 | Schatzberg, "The Relationship of Chronic Pain and Depression," J. Clin. Psychiatry 2004; 65 (suppl 12).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0936 | Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE et al. Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRX 2005;2:590-611.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0937 | Schlicker E, Brandt F, Classen K, Gothert M. Serotonin release in human cerebral cortex and its modulation via serotonin receptors. Brain Research 1985; 331:337-341.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0938 | Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneim Forsch - Drug Res 1985; 35(9):1347-1349.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0939 | Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006; (47) (supp. 2):28-33.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0940 | Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 (Supp. 10):S65-S70.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0941 | Schmitz EB, Robertson J, Trimble MR Depression and Schizophrenia in Epilepsy: Social and Biological Risk Factors: Epilepsy Research 1999; 35 :59-68.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX0942 | Schnyder U, Valach L, Bichsel K, Michel K. Attempted suicide. Do we understand the patients' reasons? Gen Hosp Psychiatry. 1999 Jan-Feb; 21(1):62-9.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0943 | Scholz, J. and C. J. Woolf (2002) "Can we conquer pain?" Nat Neurosci 5 Suppl: 1062- 7.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0944 | Scott, HS., et at. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA 1990; 263:1785-88.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0945 | Selai C, Bannister D, Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 2005; 46(Suppl. 4):50-57.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0946 | Serpell MG, Neuropathic Pain Study Group. Gabapentin in Neuropathic Pain Syndromes: a Randomized, Double-Blind, Placebo-Controlled Trial. Pain. 2002; 99(3):557-566.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0947 | Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J. Enzyme Inhib. Med. Chem. 2008;23:271-276.                                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0948 | Shawn J. Bird and Mark J. Brown, Diabetic Neuropathies, in Neuromuscular Disorders in Clinical Practice. 2002.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0949 | Sherman AD, Petty F (1980): Neurochemical basis of the action of antidepressants on learned helplessness. Behav Neural Biol 30:119-134.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0950 | Sherman AD, Petty F (1982): Additivity of neurochemical changes in learned helplessness and imipramine. Behav Neural Biol 35:344-353.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0951 | Sheth RD, Buckley D, Penney S, Hobbs GR. Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. Clin Neuropharmacol 1996; 19 (4):297-304.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0952 | Shiah I, Yatham LN. GABA function in mood disorders: An update and critical review. Life Sciences 1998;63:1289-1303.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0953 | Shimizu S, Honda M, Tanabe M, Oka J-I, Ono H. Endogenous GABA does not mediate the inhibitory effects of Gabapentin on spinal reflexes in rats. J Pharmacol Sci 2004a; 94:137-143.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0954 | Shimizu S, Honda M, Tanabe M, Ono H. GABAB receptors do not mediate the inhibitory actions of Gabapentin on the spinal reflex in rats. J Pharmacol Sci 2004b; 96(4):444-449.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0955 | Short C, Cooke L: Hypomania induced by gabapentin. Br J Psychiatry 166:679-680, 1995.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0956 | Shukla G et al. Psychiatric manifestations in temporal lobe epilepsy: a controlled study. Br J Psychiatry 1979; 135:411-7.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0957 | Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. Vigabatrin, but not Gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 2003; 44(7):886-892. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0958 | Sills GJ. Not another Gabapentin mechanism! Epilepsy Currents / American Epilepsy Society 2005; 5(2):75-77.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0959 | Sills GJ. The mechanisms of action of Gabapentin and pregabalin. Current Opinion in Pharmacology 2006; 6(1):108-113.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0960 | Silverman MM., Mars, RW. The Prevention of Suicidal Behaviors: an Overview. Suicide and Life Threatening Behavior 1995; 25(1): 10-20.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX0961 | Silverman RB, Andruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG. 3-alkyl-4-aminobutyric acids: The first class of anticonvulsant agents that activates l-glutamic acid decarboxylase. Journal of Medicinal Chemistry 1991;34:2295-2298.                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0962 | Silverstone PH, Silverstone T: A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 19(3):13-24, May 2004.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0963 | Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007 Jul;164(7):1029-34.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0964 | Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent Gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacol 1996; 127(1):1-10.               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0965 | Smith L, Price-Jones M, Hughes K, Egebjerg J, Poulsen F, Wiberg FC, Shank RP. Effects of topiramate on kainite- and domoate-activated [14C]guanidinium ion flux through GluR6 channels in transfected BHK cells using Cytostar-T scintillating microplates. Epi | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0966 | Smith MT., Edwards RR., et al. Suicidal ideation, plans, and attempts in chronic pain patients: factors associated with increased risk. Pain 2004; 111(1-2):201-8.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0967 | Smith, et al., "Suicidal Ideation in Outpatients With Chronic Musculoskeletal Pain; An Exploratory Study of the Role of Sleep Onset Insomnia and Pain Intensity," Clin J Pain 2004; 20:111-118.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0968 | Smolders I, Khan GM, Lindekens H, Prikken S, Marvin CA, Manil J, Ebinger G, Michotte Y. Effectiveness of vigabatrin against focally evoked pilocarpine-induced seizures and concomitant changes in extracellular hippocampal and cerebellar glutamate, gamma-am | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0969 | Sokolski KN, Green C, Maris DE, DeMet EM: Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 11(4):217-22, 1999.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0970 | Song C, Leonard BE (2005): The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627-647. Epub 2005 Apr 2025.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0971 | Spafford & Zamponi, Functional interactions between presynaptic calcium channels and the neurotransmitter release machinery. Curr. Opin Neurobiology 2003; 13: 308-314.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0972 | Stahl, S. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd ed., Cambridge University Press, New York, 2000, pp. 135-197.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0973 | Starke K, Reimann W, Zumstein A, Hertting G. Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology 1978; 305(1):27-36.                             | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0974 | Stefani A, et al. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology.1998; 37:83-91.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0975 | Stefani A, Spadoni F, Bernardi G (1997): Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | strategies. Exp Neurol 147:115-122.   |  |                       |
| JX0976 | Stein MB et al. Social Anxiety disorder and the risk of depression. Arch Gen Psychiatry 2001; 58:251-56.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0977 | Stenager E et al. Attempted suicide, depression and physical disease: a one year follow up study. Psychother Psychosom. 1994 ;61:65-73.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0978 | Stone, MB, Jones, ML. Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults, U.S. Food and Drug Administration, November 17, 2006.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0979 | Streeter CC, Hennen J, Ke Y, Jensen JE, Sarid-Segal O, Nassar LE, et al (2005): Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment. Psychopharmacology (Berl):1-11.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0980 | Streeter CC, Jensen JE, Perlmutter RM, Cabral HJ, Tian H, Terhune DB, Ciraulo DA, Renshaw PF. Yoga Asana sessions increase brain GABA levels: A pilot study. Journal of Alternative and Complementary Medicine (New York, NY 2007; 13(4):419-426. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0981 | Stringer JL, Arihi AM. Modulation of the in vivo effects of Gabapentin by vigabatrin and SKF89976A. Epilepsy Research 2002; 52(2):129-137.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0982 | Stringer JL, Lorenzo N. The reduction in paired-pulse inhibition in the rat hippocampus by Gabapentin is independent of GABA(B) receptor activation. Epilepsy Research 1999;33(2-3):169-176.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0983 | Strom B and Melmon KL. Chapter 40. The use of pharmacoepidemiology to study beneficial drug effects. In: Pharmacoeidemiology. 3rd Edition. Strom Bed. Wiley & Sons. England. 2002 (electronic version).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0984 | Strom B and Melmon KL. Chapter 40. The use of pharmacoepidemiology to study beneficial drug effects. In: Pharmacoeidemiology. 4th Edition. Strom Bed. Wiley & Sons. England. 2005 (electronic version).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0985 | Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA, 2004, 292:2643-2626.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0986 | Strom BL. Chapter 2. Study design available for pharmacoepidemiology studies. In: Pharmacoeidemiology. 4 Edition. Strom Bed. Wiley & Sons. England. 2005. (electronic version).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0987 | Strom, BL "Evaluation of Suspected Adverse Drug Reactions – Reply," JAMA 293:1324 – 1325 (2005).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0988 | Su TZ, Lunney E, Campbell G, Oxender DL. Transport of Gabapentin, a gamma-amino acid drug, by system I alpha-amino acid transporters: A comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem 1995; 64(5):2125-2131.          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0989 | Suicide Trends Among Youths and Young Adults Aged 10-24 - United States, 1990-2004. MMWR. September 7, 2007/56(35):905-908.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0990 | Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN. Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993;  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | 244(3):293-301.   |  |                       |
| JX0991 | Sung B, Lim G, Mao J (2003): Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 23:2899-2910.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0992 | Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. British Journal of Pharmacology 2002; 135(1):257-265.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0993 | Sutton KG, Snutch TP. Gabapentin: a novel analgesic targeting voltage- gated calcium channels. Drug Development Research 2002; 54(3):167-172.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0994 | Tabarrok, A.T., "Assessing the FDA via the Anomaly of Off-Label Drug Prescribing," Independent Review, Volume 5(1), Summer 2000.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0995 | Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, Delissa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: A prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002; 25(2)(summer):100-5.                  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0996 | Takasu K, Ono H, Tanabe M. Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. J. Neurochem. 2008;105:933-942.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0997 | Takeuchi Y, Takasu K, Honda M, Ono H, Tanabe M. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur. J. Pharmacol. 2007;556(1-3):69-74.                          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0998 | Tamez-Perez HE, Rodriguez AM, Gomez DO. Use of Gabapentin on Neuropathic Pain. Med. Intern Mex. 1998; 14:251-253.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX0999 | Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of Gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharma | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1000 | Tanabe, M., K. Takasu, et al. (2008). "Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury." J Neurosci Res.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1001 | Taney BL. Psychiatric Diagnoses and Suicide, In Mars, R.W. et al, eds., Comprehensive Textbook of Suicidology. New York: Guilford, 2000:311-41.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1002 | Tang NK., Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med. 2006 May; 36(5):575-86.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1003 | Taylor CP (2002) Chapter 8, Sodium and calcium channel blockers, pp. 209-244 in: Marcoux FW, Choi DW (eds.) Handbook of Experimental Pharmacology: CNS Neuroprotection. Heidelberg, Germany: Springer Verlag.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1004 | Taylor CP, Donevan SD. Summary of preclinical pharmacological studies with gabapentin (CI 0945, PD 0087842 0000) in vitro and in laboratory animals, Section 5 [from May 2001 gabapentin neuropathic pain sNDA application], Pfizer Research Report RR 740-0355 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX1005 | Taylor CP, et al. A summary of mechanistic hypotheses of Gabapentin pharmacology. <i>Epilepsy Research</i> 1998; 29(3):233-249.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1006 | Taylor CP, Garrido R, Joshi I, Budzyn B, Arneric S. (2006) Immunoreactivity for calcium channel alpha2-delta (α2-δ) type 1 protein is localized at glutamate synaptic endings in rat brain and neuronal cell cultures. <i>Amer. Acad. Neuropsychopharmacol. Abstra</i> | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1007 | Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (α2-δ) type 1 protein. <i>Neurosci.</i> 2008;155:510-521.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1008 | Taylor CP, Narasimhan LS. Sodium channels and therapy of central nervous system diseases. <i>Adv. Pharmacol.</i> 1997;39:47-98.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1009 | Taylor CP, Offord J, Su T-Z, Baron S, Kinsora J, Vartanian MG, Bian F, Li Z, Dooley D, Wustrow DJ, Belliotti T, Schwarz J, Thorpe A, Donevan S, Field MJ. (2005) Contribution of high-affinity binding at calcium channel α2-d proteins to the Analgesic, Antic        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1010 | Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman RB. 3-alkyl GABA and 3-alkylglutamic acid analogues: Two new classes of anticonvulsant agents. <i>Epilepsy Research</i> 1992;11(2):103-110.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1011 | Taylor CP. Emerging perspectives on the mechanism of action of Gabapentin. <i>Neurology</i> 1994;44(6 Suppl 5):10-16.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1012 | Taylor CP. Gabapentin: Mechanisms of action. In: RH Levy, RH Mattson, BS Meldrum (editors) <i>Antiepileptic Drugs</i> , 4th Edition, New York, NY, Raven Press 1995, pp 829-41.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1013 | Taylor CP. Gabapentin: Mechanisms of action. In: RH Levy, RH Mattson, BS Meldrum (editors) <i>Antiepileptic Drugs</i> , 5th Edition, New York, NY, Raven Press 2002, pp 321-34.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1014 | Taylor CP. (2004) Meeting Report: The biology and pharmacology of calcium channel(α2-δ) proteins - Pfizer satellite symposium to the 2003 Society for Neuroscience meeting. <i>CNS Drug Rev</i> 10:183-188.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1015 | Taylor, CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. <i>Epilepsy Research</i> 2007a;73:137-150.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1016 | Taylor, CP. (2009). "Mechanisms of analgesia by gabapentin and pregabalin – Calcium channel α2-d [CaVa2-d] ligands." <i>Pain</i> 142: 13-16.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1017 | Taylor, CP. and R. Garrido (2008). "Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (α2-δ) type 1 protein." <i>Neuroscience</i> 155: 510-521.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1018 | Tayoshi, S et al. Lithium Effects on Brain Glutamatergic and GABAergic Systems of Healthy Volunteers as Measured by Proton Magnetic Resonance Spectroscopy. In Press: <i>Progress Neuropsychopharmacol Biologic Psychiatry</i> 2007.                                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1019 | Teasdale RD, Smith BP, Koman LA. Complex regional pain syndrome (reflex sympathetic dystrophy) <i>Clin Sports Med</i> 2004; 23(1):145-55.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX1020 | Thase, M. Chapter 14.1, Mood Disorders: Neurobiology, in: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol. I, pp. 1318-1328 (Sadock B, Sadock V, eds., 7th ed. 2000).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1021 | The Empirical Foundations of Suicidology in Ronald W. Maris, Alan L. Berman & Morton M. Silverman, Comprehensive Textbook of Suicidology (2000).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1022 | The Theoretical Component in Suicidology in Ronald W. Maris, Alan L. Berman & Morton M. Silverman, Comprehensive Textbook of Suicidology (2000).   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1023 | Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behavior disorders: a retrospective survey. Epilepsy Res. 1996; 25(1):21-27.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1024 | Thomas S. A phenomenologic study of chronic pain. Western Journal of Nursing Research 2000; 22:683-705.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1025 | Thompson SO. Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-1355.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1026 | Thompson, P., Clarkson, P., Karas, R. Statin-Associated Myopathy. JAMA 2003; 289(13):1681-1690.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1027 | Thorpe A, Taylor CP, Barta NS, Donevan SD (2006) Case histories: Alpha2-delta ligands: Gabapentin and pregabalin, in: Comprehensive Medicinal Chemistry, Vol. 8, eds. Triggle DJ, Taylor JB (Elsevier, Oxford) p. 227-246. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1028 | Tidemalm, Dan, et al. "Risk of Suicide After Suicide Attempt According to Coexisting Psychiatric Disorder: Swedish Cohort Study with Long Term Follow up." BMJ (2008): Print.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1029 | Tiippana, E. M., K. Hamunen, et al. (2007). "Do surgical patients benefit from perioperative Gabapentin/pregabalin? A systematic review of efficacy and safety." Anesth Analg 104(6): 1545-56, table of contents.          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1030 | Timmerman W, Bouma M, De Vries JB, Davis M, Westerink BH (2000): A microdialysis study on the mechanism of action of Gabapentin. Eur J Pharmacol 398:53-57.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1031 | To TP, Lim TC, Hill St, Frauman AG, Cooper N, Kirsas SW, Brown DJ. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord 2002; 40(6)(Jun):282-5.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1032 | Todorov A, Kolchev C, Todorov A Tiagabine and Gabapentin for the Management of Chronic Pain. Clin. J. Pain. July/August 2005; 21(4):358-361.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1033 | Tohen M et al. Epidemiology of bipolar disorder. In: Tsuang MT et al, eds. Psychiatric Epidemiology. New York, NY: Wiley-Liss; 2002:427-44.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1034 | Tollefson GD, Rosenbaum JF, Selective serotonin reuptake inhibitors, pp 219-234 in: The American Psychiatric Press Textbook of Psychopharmacology, 2nd edition. (Schatzberg AF, Nemeroff CB, eds.) 1998.                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1035 | Tondo L et al. Suicidal behavior in bipolar disorder: risk and prevention. CNS Drugs 2003;17:491-511.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1036 | Traa, B. S., J. D. Mulholland, et al. (2008). "Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia." Pediatr Res 64(1): 81-5.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1037 | Trescott-A, Boswell M, Atluri S, et al. Opioid Guidelines in the Management of Chronic Non-Cancer Pain. Pain Physician. 2006; 9:1-40.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX1038 | Triggle DJ. Calcium-channel antagonists: mechanisms of action, vascular selectivity, and clinical relevance. Cleve Clin J Med. 1992; 59(6):617-27.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1039 | Trimble MR. Anticonvulsant-induced psychiatric disorders. The role of forced normalization. Drug Safety 1996; 15(3):159-166.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1040 | Trimble MR. Biological Psychiatry, Second Edition.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1041 | Trimble MR. Neuropsychiatric consequences of pharmacotherapy. In: Engel J, Pedley TA, eds, Epilepsy. A comprehensive textbook. Philadelphia, New York: Lippincott-Raven, 1997, pp. 2161- 2170.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1042 | Trimble MR New antiepileptic drugs and psychopathology. Neuropsychobiology. 1998 Oct;38(3):149-51.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1043 | Trimble MR, Rusch N, Betts T, Crawford PA. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9:249-254.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1044 | Tuncer S, Bariskaner H, Reisli R, Sarkiar G, Cicekci F, Otelcioglu S Effect of Gabapentin on postoperative pain: A randomized, placebo-controlled clinical study. Pain Clin. 2005; 17(1):95-9.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1045 | Tunnicliff G, Malatynska E. Central GABAergic systems and depressive illness. Neurochemical Research 2003;28:965-976.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1046 | Turan A, Karamanlioglu B, Memis D, et al. Analgesic Effects of Gabapentin After Spinal Surgery. Anesthesiology. 2004; 100(4):935-938.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1047 | Turan A, Kararanlioglu B, Memis D, et al. The Analgesic Effects of Gabapentin After Total Abdominal Hysterectomy. Anesth. Analg. 2004; 98:1370-3.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1048 | Turk, D. C., K. S. Swanson, et al. (2008). "Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis." Clin J Pain 24(6): 497-508.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1049 | Tutka P, Olszewski K, Wozniak M, Kleinrok Z, Czuczwar SJ, Wielosz M. Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electro convulsions in mice. Eur Neu | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1050 | Tzellos, T. G., G. Papazisis, et al. (2008). "Efficacy of pregabalin and Gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature." Eur J Clin Pharmacol 64(9): 851-8.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1051 | U.S. Department of Health and Human Services. Mental Health: a Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, Nation | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1052 | U.S. Dep't of Health, Educ. & Welfare, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service 20 (1964).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1053 | U.S. Surgeon General, The Health Consequences of Involuntary Exposure to Tobacco Smoke (2006)..   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1054 | Urbani A, Belluzzi O (2000): Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12:3567-3574.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX1055 | Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998): Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proceedings of the Nat | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1056 | van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomized controlled trial of Gabapentin in Complex Regional Pain Syndrome type 1. BMC Neurology 2004; 4(1)(29 Sep):13.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1057 | Van Elstraete, A. C., P. Sitbon, et al. (2008). "Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats." Anesthesiology 108(3): 484-94.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1058 | van Hooft JA, Dougherty JJ, Endeman D, Nichols RA, Wadman WJ. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449(3):221-228.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1059 | van Reekum et al., Applying Bradford Hill's Criteria for Causation to Neuropsychiatry: Challenges and Opportunities, The Journal of Neuropsychiatry and clinical Neurosciences 2001; 13:318-325.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1060 | Vartanian M, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, Taylor CP (2006) Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68:189-205.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1061 | Vartanian MG, Donevan SD, Weber ML, Stoehr SJ, Dooley DJ, Taylor CP, Donevan SD. Gabapentin does not interact with the GABAB receptor. Soc Neurosci Abstr 2002; 31:603.603.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1062 | Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, Parker EM, Hunter JC, Higgins GA, Reggiani A, Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1063 | Venkoba RA. Physical illness, pain and suicidal behavior. Crisis 1990; 11 :48-56.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1064 | Verkuyt JM, Karst H, Joels M (2005): GABAergic transmission in the rat paraventricular nucleus of the hypothalamus is suppressed by corticosterone and stress. Eur J Neurosci 21:113-121.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1065 | Verona, E., Sachs-Ericsson, N., Joiner, TE. Suicide Attempts Associated with Externalizing Psychopathology in an Epidemiological Sample. Am J Psychiatry 2004; 161(3): 444-451.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1066 | Victoroff J. DSM - III -R psychiatric diagnoses in candidates for epilepsy surgery: lifetime prevalence. Neuropsychiatry Neuropsychol Behav Neurol 1994;7:87-97.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1067 | Victoroff JI, Benson F, Grafon ST, Engel J Jr, Mazotta JC. Depression in Complex Partial Seizures. Electroencephalography and Cerebra Metabolic Correlates. Arch Neurol 1994 Feb; 51(2):155-163.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1068 | Vieta E, Goikolea JM, Martinez-Aran A et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive Neurontin for bipolar disorder. J Clin Psychiatry 2006; 67:473-477.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1069 | Vieta E, Martinez-Aran A, Nieto E, et al. Adjunctive Neurontin treatment of bipolar disorder. Eur Psychiatry 2000; 15:433-437.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX1070 | Vilhjalmsson, R., Krstjandottir, G., et al. Factors associated with suicide ideation in adults. Soc Psychiatry Psychiatry Epidemiol 1998; 33(3): 97-103.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1071 | Wagstaff AJ, Ormrod D, Spencer CM (2001): Tianeptine: a review of its use in depressive disorders. CNS Drugs 15:231-259.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1072 | Wamil AW, McLean MJ. Limitation by Gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res. 1994; 17:1-11.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1073 | Watson CJ, Venton BJ, Kennedy RT. In vivo measurements of neurotransmitters by microdialysis sampling. Analytical Chemistry 2006; 78(5):1391-1399.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1074 | Weiner N. Drugs that block adrenergic nerves and receptors. Chapter 9 In: AG Gilman, LS Goodman, A Gilman (ed.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed., 1980, MacMillan Publishing Co., New York, NY, 1843 pp.                                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1075 | Weintraub D, Buschbaum R, Resor SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior 2007; 10:105-110.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1076 | Weisberg, HI, Hayden, VC, Pontes, VP. Selection Criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant- induced suicidality? Clin Trials 2009; 6: 109-118.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1077 | Weiss S.R, Gogolak V, Chung S., Deshpande G. Assessing data mining approaches to drug safety. In: Best Practices in Data Mining Thin Tan Meeting. Shady Grove, MD. June 2008. At: <a href="http://www.unaryland.edu/datamining.html">http://www.unaryland.edu/datamining.html</a> . | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1078 | Weiss Smith, S. Chapter Title: Pharmacoepidemiology. In: Encyclopedia of Epidemiology. Editor: Boslaugh S. Publisher: Sage Publications Inc. 2007.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1079 | Werner MU, Perkins FM, Holte K, Pedersen JL, Kehlet H. Effects of Gabapentin in acute inflammatory pain in humans. Reg Anesth Pain Med 2001; 26(4)(Jul/Aug):322-8.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1080 | White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41 Suppl 1, S17-20.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1081 | White SJ et al. Anticonvulsant drugs and cancer: a cohort study in patients with severe epilepsy. Lancet 1979;2:458-60.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1082 | White, J. M. (2004). "Pleasure into pain: the consequences of long-term opioid use." Addict Behav 29(7): 13 1-24.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1083 | Whitworth TL, Quick MW. Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma-aminobutyric acid derivatives. Biochem Soc Transactions 2001; 29(6):736-741.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1084 | Wiffen PJ, McQuay HJ, Edwards, JE, Moore RA. Gabapentin for Acute and Chronic Pain (Review). Cochrane Database of Systematic Reviews. 2005, Issue 3, Ar. No.: CDOO5452. DOI: 10.1002/11465 1858.CD005452.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1085 | Wiffen, P. J., H. J. McQuay, et all. (2005). "Gabapentin for acute and chronic pain." Cochrane Database Syst Rev(3): CD005452.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
| JX1086 | Wilde MI, Benfield P (1995): Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. <i>Drugs</i> 49:411-439.                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1087 | Williams et al., Psychology and suicidal behavior: elaborating the entrapment model. In <i>Prevention and Treatment of Suicidal Behavior: From Science to Practice</i> (ed. K Hawton), pp. 71-89. Oxford University Press: Oxford, UK. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1088 | Wilton, LV. and Shakin, S. A Postmarketing surveillance Study of Gabapentin as Add-on Therapy for 3,100 Patients in England. <i>Epilepsia</i> 2002 Sep; 43(9):983-92.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1089 | Wodarski, R., A. K. Clark, et al. (2008). "Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats." <i>Eur J Pain</i> .  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1090 | Wohlfarth T, Boer F, van den Brink W. Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents. <i>Am J Psychiatry</i> . 2007 Dec;164(12):1908; author reply 1908-10. | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1091 | Wolf M, Eberhart A, Glossmann H, Striessnig J, Grigorieff N. Visualization of the domain structure of an L-type Ca <sup>2+</sup> channel using electron cryo-microscopy. <i>J Mol Biol</i> 2003; 332:171-182.                          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1092 | Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. <i>Nature</i> 1983; 306(5944):686-688.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1093 | Working Group on Meta-Analysis in Environmental Epidemiology (1995). Guidelines for application of meta-analysis in environmental epidemiology. <i>Regulatory toxicology and Pharmacology</i> , 22, 189-197.                           | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1094 | Wu Y, Wang W, Richerson GB. GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux through reversal of the GABA transporter. <i>J Neurosci</i> 2001; 21(8):2630-2639.                         | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1095 | Xiong Z-Q, Stringer JL. Effects of felbamate, Gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. <i>Epilepsy Res</i> 1997; 27:187-194.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1096 | Xu L, Enyeart JA, Enyeart JJ (2001): Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. <i>J Pharmacol Exp Ther</i> 299:227-237.                   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1097 | Yaksi, A., L. Ozgonenel, et al. (2007). The efficiency of Gabapentin therapy in patients with lumbar spinal stenosis." <i>Spine</i> 32(9): 939-42.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1098 | Yang J, Shen J (2005): In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. <i>Neuroscience</i> 135:927-937.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1099 | Yoshimoto K, Ueda S, Kato B, Takeuchi Y, Kawai Y, Noritake K, Yasuhara M. Alcohol enhances characteristic releases of dopamine and serotonin in the central nucleus of the amygdale. <i>Neurochem Int</i> , 2000; 37:369-376.          | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1100 | Young LT, Robb JC, Hasey GM, MacQueen GM, Patelis-Siotis I, Marriott M, Joffe RT. Gabapentin as an adjunctive treatment in bipolar disorder. <i>J of Affect Disord</i> 1999; 55:73-77.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1101 | Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with Neurontin. <i>Biol Psychiatry</i> 1997;   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |



| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | 42:851-853.   |  |                       |
| JX1102 | Yourick DL, Repasi RT, Rittase WB, Staten LD, Meyerhoff JL. Ifenprodil and arcaine alter amygdala-kindling development. European Journal of Pharmacology 1999; 371(2-3):147-152.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1103 | Zarate CA, Jr., Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al (2004): An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 161:171-174.                                       | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1104 | Zarate CA, Jr., Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al (2005): An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry 57:430-43 | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1105 | Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al (2006): A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.                                     | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1106 | Zheng GZ, Bhatia P, Daanen J, Kolasa T, Patel M, Latshaw S, El Kouhen OF, Chang R, Uchic ME, Miller L, Nakane M, Lehto SG, Honore MP, Moreland RB, Brioni JD, Stewart AO. Structure-activity relationship of triazafluorenone derivatives as potent and selecti | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1107 | Zielinski JJ. Epilepsy and mortality rate and cause of death. Epilepsia 1974;15:191-201.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1108 | A.K. MacLeod et al., Hopelessness and Positive and Negative Future Thinking in Parasuicide, 44 Brit. J. Clinical Psychology 495 (2005)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1109 | A.L. Chapman et al., Factors Associated with Suicide Attempts in Female Inmates, Acgemony of Hopelessness, 35 Suicide & Life-Threatening Behav. iii (2005)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1110 | A.P. Chioqueta & T.C. Stiles, The Relationship Between Psychological Buffers, Hopelessness, and Suicidal Ideation: Identification of Protective Factors, 28 Crisis 67 (2007)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1111 | B.R. Sommer et al., Safety and Efficacy of Anticonvulsants in Elderly Patients with Psychiatric Disorders: Oxcarbazepine, Topiramate, and Gabapentin, 6 Expert Opinion in Drug Safety 133 (2007)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1112 | C. Born et al., Newer Prophylactic Agents for Bipolar Disorder and Their Influence on Suicidality, 9 Archives Suicide Res. 301 (2005)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1113 | C.A. Langford & B.C. Gilliland, Fibromyalgia, in Harrison's Principles of Internal Medicine (A.S. Fauci et al. eds., 17th ed. 2008)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1114 | C.L. Ernst & J.F. Goldberg, Anti-suicide Properties of Psychotropic Drugs: A Critical Review, 12 Harv. Rev. Psychiatry 317 (2004)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1115 | Chou R, Norris S, Carson S, Chan BKS. Drug Class Review for Neuropathic Pain. 2007.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1116 | D. Jacobs & M. Klein-Benheim, The Psychological Autopsy: A Useful Tool for Determining Proximate Causation in Suicide Cases, 23 Bull. Am. Acad. Psychiatry & Law 165 (1995)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1117 | D. Lester & R.L. Walker, Hopelessness, Helplessness, and Haplessness as Predictors of Suicidal Ideation, 55 Omega 321   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
|        | (2007)  |  |                       |
| JX1118 | D. McMillan et al., Can We Predict Suicide and Non-Fatal Self-Harm with the Beck Hopelessness Scale? A Meta Analysis, 37 Psychological Med. 769 (2007)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1119 | D.G. Blazer, Treatment of Seniors, in American Psychiatry Publishing Textbook of Psychiatry (R.E. Hales et al. eds., 5th ed. 2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1120 | D.G. Jacobs, Review of Navy Investigation of U.S.S. Iowa Explosion, Joint Hearings Before the Investigations Subcommittee and the Defense Policy Panel of the Committee on Armed Services, U.S. House of Representatives (Dec. 21, 1989)                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1121 | D.M. Reith & L. Edmonds, Assessing the Role of Drugs and Suicidal Ideation and Suicidality, 21 CNS Drugs 463 (2007)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1122 | D.W. Black & G. Winokur, Suicide and Psychiatric Diagnosis, in Suicide Over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients 135 (S.J. Blumenthal & D.J. Kupfer eds. 1990)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1123 | Dale C. Hesdorffer and Andres M. Kanner, "The FDA Alert on suicidality and antiepileptic drugs: Fire or false alarm?", Epilepsia, 50(5):978-986, 2009 (April 27, 2009)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1124 | E. Robins et al., Some Clinical Considerations in the Prevention of Suicide Based on a Study of 134 Successful Suicides, 49 Am. J. Pub. Health 888 (1959)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1125 | E.K. Moscicki, Epidemiology Surveys as Tools for Studying Suicidal Behavior: A Review, 19 Suicide & Life-Threatening Behav. 131 (1989)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1126 | Ajtai 2008 Hopelessness in Patients Presenting to Their Family Physician.pdf Segatore 1994 Understanding Chronic Pain after Spinal Cord Injury.pdf  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1127 | G. Ratcliffe, Chronic Pain Conditions and Suicidal Ideation and Suicide Attempts: An Epidemiological Perspective, 23 Clinical J. Pain 204 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1128 | G. Ratcliffe, Chronic Pain Conditions and Suicidal Ideation and Suicide Attempts: An Epidemiological Perspective, 23 Clinical J. Pain 204 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1129 | G.J. Macfarlane et al., Widespread Body Pain and Mortality: Prospective Population Based Study, 323 BMJ 662 (2001)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1130 | Gilron I, Orr E, Tu D, Mercer CD, Bond D. A randomized, double-blind, controlled trial of perioperative administration of gabapentin, meloxicam and their combination for spontaneous and movement-evoked pain after ambulatory laparoscopic cholecystectomy. A | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1131 | J. Avorn, Drug Warnings That Cause Fits. Communicating Risks in a Data-Poor Environment, 359 New Eng. J. Med. 991 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1132 | J. Neill, Meta-Analysis Research Methodology, <a href="http://wilderdom.com/research/meta-analysis.html">http://wilderdom.com/research/meta-analysis.html</a> , Internet site visited October 31, 2008.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1133 | J.Arheit-Treichel, Some Chronic Pain Patients at Increased Suicide Risk, 41 Psychiatric News 25 (2006)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1134 | J.G. Abbey et al., Hopelessness at the End of Life: The Utility of the Hopelessness Scale with Terminally Ill Cancer Patients,  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
|        | 11 Brit. J. Health Psychology 173 (2006)   |  |                       |
| JX1135 | J.K. Hirsch & K.R.Conner, Dispositional and Explanatory Style Optimism as Potential Moderators of the Relationship Between Hopelessness and Suicidal Ideation, 36 Suicide & Life-Threatening Behav. 661 (2006) | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1136 | J.P. Lepine & M. Briley, The Epidemiology of Pain and Depression, 19 (Suppl. 1) Hum. Psychopharmacology S3 (2004)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1137 | L. Lawhorne, Depression in the Older Adult, 32 Primary Care 787 (2005)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1138 | M. Burgy, Phenomenological Investigation of Despair and Depression, 41 Psychopathology 147 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1139 | M. Miller & D. Hemenway, Guns and Suicide in the United States, 359 New Eng. J. Med. 989 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1140 | M. Pompili et al., Depression, Hopelessness, and Suicide Risks Among Patients Suffering from Epilepsy, 43 Annali dell'Institute Superiore di Sanita 425 (2007)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1141 | M. Pompili et al., Hopelessness and Suicide Risks Emerge in Psychiatric Nurses Suffering from Burnout and Using Specific Defense Mechanisms, 20 Archives Psychiatric Nursing 135 (2006)                        | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1142 | M. Segatore, Understanding Chronic Pain After Spinal Cord Injury, 26 J. Neuroscience Nursing 230 (1994)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1143 | M. Theodoulou et al., Pain and Deliberate Self-Harm: An Important Association, 58 J. Psychosomatic Res. 317 (2005)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1144 | M.D. Rudd, Suicide Warning Signs in Clinical Practice, 10 Current Psychiatry Rep. 87 (2008)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1145 | M.I. Bennett, Gabapentin Significantly Improves Analgesia in People Receiving Opioids for Neuropathic Cancer Pain, 31 Cancer Treatment Rev. 58 (2005) [summary of A. Caraceni et al. 2004 article]             | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1146 | Medical Research Council Tuberculosis Chemotherapy Trials Committee, The Treatment of Pulmonary Tuberculosis with Isoniazid, 2 Brit. Med. J. 735 (1952)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1147 | Medical Research Council Whooping-Cough Immunization Committee, The Prevention of Whooping-Cough by Vaccination, 1 Brit. Med. J. 1463 (1950)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1148 | N. Billig, Attitude and Burden in Families of Depressed Elderly Patients: Strategies for Care, 84 S. Med. J. 225 (1991)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1149 | P. Sokero et al., Decline and Suicidal Ideation Among Patients with MDD Is Predicted by Decline in Depression and Hopelessness, 95 J. Affective Disorders 95 (2006)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1150 | P.K. Grewal & J.E. Porter, Hope Theory: A Frame work for Understanding Suicidal Action, 31 Death Studies 131 (2007)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1151 | R. Doll, People of Consequence: Sir Austin Bradford Hill and the Progress of Medical Science, 305 BMJ 1521 (1992)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1152 | R. Roy, Chronic Pain, Loss and Suffering: A Clinical Perspective (2004)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1153 | R. Schiffer et al., Neuropsychiatry (2003)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1154 | R. Weiner, Pain Management: A Practical Guide for Clinicians (6th ed. 2002)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1155 | R.B. Khan et al., Gabapentin to Control Seizures in Painful AIDS-Related Neuropathy, 52 Neurology A190 (1999)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description   | Authenticity                                       | Substantive Objection |
|--------|---|--|-----------------------|
| JX1156 | R.E. McKeown et al., U.S. Suicide Rates by Age Group, 1970-2002: An Examination of Recent Trends, 96 Am. J. Pub. Health 1744 (2006)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1157 | S.A.W. Shakir, Thoughts on Signal Detection in Pharmacovigilance (Abstract), <a href="http://www.haiweb.org/medicineprices/2410/contributions/saadshakir.doc">www.haiweb.org/medicineprices/2410/contributions/saadshakir.doc</a> , Site visited 9/08/08.               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1158 | T.W. Meeks et al., Chronic Pain and Depression Among Geriatric Psychiatry Inpatients, 23 Int'l J. Geriatric Psychiatry 637 (2008)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1159 | Wiffen PJ, McQuay HJ, Rees J, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005452 DOI: 10.1002/14651858.CD005452. Published in Issue 1, 2010   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1160 | Y. Levi et al., Mental Pain and Its Communication in Medically Serious Suicide Attempts and "Impossible Situation," J. Affective Disorders ePub (Apr. 22, 2008)   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1161 | Z. Bajwa et al., Antiepileptic Drugs in the Treatment of Neuropathic Pain, in UpToDate (B.D. Rose ed. 2008), available at <a href="http://www.uptodate.com">http://www.uptodate.com</a>   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1162 | Mokhber N, Lane CJ, Azarpazhooh MR, Salari E, Fayazi R, Shakeri MT, Young AH, Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran. Neuropsychiatr Dis Treat. 2008 Feb.;4(1):227-34                               | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1163 | Gorson et al., Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo-Controlled, Double-Blind, Crossover Trial, 66 J. Neurology, Neurosurgery & Psychiatry 251 (Feb. 1999)  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1164 | Di Trapani, G. et al.: Gabapentin in the Prophylaxis of Migraine: A Double-Blind Randomized Placebo-Controlled Study, 151 Clin. Ter. 145 (2000).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1165 | Spira, P.J. et al.: Gabapentin in the Prophylaxis of Chronic Daily Headache: A Randomized, Placebo-Controlled Study, 61 Neurology 1753 (2003).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1166 | Zona C. et al. (1998) Riluzole interacts with voltage activated sodium and potassium currents in cultered rat cortical neurons Neuroscience 85:931-938  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1167 | Goodman F, Glassman P, Maglione M. Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia. <a href="http://www.ohsu.edu/drugeffectiveness/reports/final.cfm">http://www.ohsu.edu/drugeffectiveness/reports/final.cfm</a> | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1168 | Editorial in JAMA, Dec 2, 1998 Vol 280, No 21 "Symptomatic Treatment of Painful Neuropathy" by Phillip Low, MD and Rose M Dotson MD.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1169 | Schatzberg, AF and Nemeroff, C. eds. Textbook of Psychopharmacology, 3rd ed. APA Press, Washington, 2004  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1170 | Rowbotham, M. et al.: Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial, 280 JAMA 1837 (1998).  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1171 | Maizels, M., "The Patient with Daily Headaches," American Family Physician, 70(12):2299-2306, Dec. 15, 2004   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1172 | Reducing Suicide: A National Imperative, National Academies Press; 1 edition, By Board on Neuroscience and Behavioral   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection |
|--------|--|--|-----------------------|
|        | Health   |  |                       |
| JX1173 | Backonja, M. and R.L. Glanzman, Gabapentin Dosing for Neuropathic Pain: Evidence from Randomized, Placebo-Controlled Clinical Trials, Clin. Ther. 2003; 25:81-104  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1174 | Guille et al., Gabapentin Versus Placebo As Adjunctive Treatment for Acute Mania and Mixed States in Bipolar Disorder, in Am. Psych. Ass'n, New Research Abstracts, available at <a href="http://archive.psych.org/edu/other_res/lib_archives/archives/meetings/1999">http://archive.psych.org/edu/other_res/lib_archives/archives/meetings/1999</a> | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1175 | Abstract of T. Gordh, A Stubhaug et al., Gabapentin in Chronic Peripheral Postoperative and Posttraumatic Neuropathic Pain, included in "Abstracts of the 10th World Congress on Pain," IASP, San Diego, Aug 17-22, 2002   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1176 | "Warner-Lambert Neurontin Promotions Under Investigation By U.S. Attorney", The Pink Sheet, April 3, 2000  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1177 | Davidson JRT, Connor KM, Sutherland SM. Panic Disorder and social phobia: current treatments and new strategies. Cleve Clin J Med 1998;65(Suppl 1):S139-S147   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1178 | Mosciki EK. Identification of Suicide Risk Factors Using Epidemiological Studies, Psychiar. Clin. North AM. 1997; 20:499-517   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1179 | Schmader, KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002; 18:350-354.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1180 | Delgado-Rodriguez M. Systematic reviews of meta-analyses: applications and limitations. J Epidemiol Comm. Health 2006; 60:90-92.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1181 | Greenland S. Invited commentary: A critical look at some popular meta-analytic methods. Am J Epi 1994; 140(3):290-295.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1182 | Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epi, 2000; 151(5):531-539.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1183 | Greenland S. Multiple-bias modeling for analysis of observational data. JR Statist Soc A 2005; 168(2):267-306.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1184 | Greenland S. Meta-analysis. In: Rothman KJ, Greenland S, Editors. Modern Epidemiology, Second Edition. Philadelphia: Lippincot, Williams & Wilkins; 1998: p. 643-673.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1185 | Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60:82-91.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1186 | Shapiro S. Meta-analysis/shmeta-analysis. Am J Epi 1994; 140(9):771-778.   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1187 | Petitti DB. Of babies and bathwater. Am J of Epi 1994; 140(9): 779-782.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1188 | Shapiro S. Is there or is there ain't no baby?: Dr. Shapiro replies to Drs. Petitti and Greenland. Am J Epi 1994; 140(9):788-791.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |
| JX1189 | Harden CL, Pick LH. Alterations in mood and anxiety in epilepsy patients treated with gabapentin [abstract]. Epilepsia   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay               |

| Ex#    | Description  | Authenticity                                       | Substantive Objection   |
|--------|--|--|---|
|        | 1996; 37 (5): 137  |  |   |
| JX1190 | Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. <i>Epilepsia</i> 1999; 40: 1129-34  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX1191 | Dodrill CR, Arnett JL, Hayes AG, et al. Cognitive abilities adjustment with gabapentin: results or multi-site study. <i>Epilepsy Res</i> 1999; 35: 109-2   | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX1192 | Hudson, JI & Pope, HG. Affective Spectrum Disorder: Does Antidepressant Response Identify a Family of Disorders with a Common Pathophysiology? <i>Am J Psychiatry</i> 1990; 147: 552-564.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX1193 | Bridge, JA, Iyengar, S, et. al., Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressants Treatment: A Meta-analysis of Randomized Controlled Trials. <i>JAMA</i> 2007; 297 (15): 1683-1696.                    | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX1194 | Kaizar, E., Greenhouse, JB, et.al. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. <i>Clin Trials</i> . 2006; 3: 73-98.  | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| JX1195 | Rowbotham, M. Gabapentin in the Management of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathic Pain of Varying Etiology: Overview of Results from 5 Placebo-Controlled Trials, Fourth International Conference on the Mechanisms and treatment of | Documents Are Self-Authenticating Under F.R.E. 902 | Hearsay   |
| DX7000 | Gabapentin Draft Label, Draft 3, 1989 bearing the bates range Pfizer_TMF_CRF_052223 - 38.  | Admit  |   |
| DX7001 | Gabapentin Draft Label, Draft 4, 1989 bearing the bates range Pfizer_TMF_CRF_052206 - 22.  | Admit  |   |
| DX7002 | Gabapentin Draft Label, Draft 5, 1989.   | Admit  | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7003 | Neurontin Draft Label 1992.  | Admit  |   |
| DX7004 | Neurontin Annotated Label 1992 bearing the bates range Pfizer_LCastro_0039686 - 718.   | Admit  |   |
| DX7005 | Neurontin Revised Label 1993 bearing the bates range WLC_CBU_118838 - 57.  | Admit  |   |
| DX7006 | Neurontin Revised Label 1993 bearing the bates range WLC_CBU_122636 - 57.  | Admit  |   |
| DX7007 | Neurontin Draft Label 1993 bearing the bates range WLC_CBU_120352 - 407.   | Admit  |   |
| DX7008 | Neurontin Approved Label 1993.   | Admit  | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7009 | Neurontin Approved Label 1994.   | Admit  |   |
| DX7010 | Neurontin Approved Label 1994.   | Admit  |   |
| DX7011 | Neurontin Approved Label 1997.   | Admit  |   |
| DX7012 | Neurontin Approved Label 1998.   | Admit  |   |
| DX7013 | Neurontin Approved Label 1998.   | Admit  |   |
| DX7014 | Neurontin Draft Label 1999 bearing the bates range Pfizer_CTaylor_0012930 - 976.   | Admit  |   |
| DX7015 | Neurontin Approved Label 2000.   | Admit  |   |
| DX7016 | Neurontin Approved Label 2000.   | Admit  |   |



| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7017 | Neurontin Approved Label 2000.  | Admit   |   |
| DX7018 | Neurontin Annotated Label with Proposed Revisions 2001 bearing the bates range Pfizer_LAlphs_0080550 - 643.           | Admit   |   |
| DX7019 | Neurontin Approved Label 2001.  | Admit   |   |
| DX7020 | Neurontin Draft Label 2002 bearing the bates range Pfizer_LKnapp_0066072 - 107.                                       | Admit   |   |
| DX7021 | Neurontin Revised Draft Label, Draft 2, 2002 bearing the bates range Pfizer_RGlanzman_0057487 - 523.                  | Admit   |   |
| DX7022 | Neurontin Approved Label 2002.  | Admit   |   |
| DX7023 | Neurontin Revised Label 2003 bearing the bates range Pfizer_AMishra_0005337 - 63.                                     | Admit   |   |
| DX7024 | Neurontin Revised Label 2004.   | Admit   |   |
| DX7025 | Neurontin Approved Label 2005.  | Admit   |   |
| DX7026 | Neurontin Approved Label 2005.  | Admit   |   |
| DX7027 | Neurontin Approved Label 2007.  | Admit   |   |
| DX7028 | Memo from Jan Turner to John Howard, Lena Ulrich, and Harry Okerfell bearing the bates range WLC_CBU_119977 - 120015. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7029 | Conditional Approval Letter from Robert Temple to Janeth Turner bearing the bates range WLC_CBU_119980 - 120015.      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7030 | Original Approval Letter (NDA 20-235) bearing the bates range Pfizer_LCastro_0035910 - 46.                            | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7031 | Original Approval Letter (NDA 20-235).  | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7032 | Supplement 6 Non-Approval Letter (NDA 20-235) bearing the bates range WLC_FRANKLIN_0000090128 - 30.                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7033 | Supplement 011 - Approval Letter (NDA 20-235).  | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7034 | Original Approval Letter (NDA 20-882) bearing the bates range WLC_CBU_140528 - 30.                                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7035 | Supplement 015 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_LCastro_0072758 - 61.                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7036 | Supplement 022 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_JSu_0031427 - 29.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7037 | Original Approval Letter (NDA 21-397) bearing the bates range Pfizer_JSu_0019183 - 85.                                | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7038 | Supplement 023 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_TMF_CRF_001074 - 76.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7039 | Original Approval Letter (NDA 21-397, 21-423, 21-424) bearing the bates range Pfizer_ELuczak_0000005 - 6.             | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7040 | Original Approval Letter (NDA 20-882) bearing the bates range Pfizer_BParsons_0106370 - 72.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7041 | Supplement 029 - Approval Letter (NDA 20-235).  | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7042 | Supplement 035 - Approval Letter (NDA 20-235).  | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7043 | Letter from Mary Ann Evertsz to Russell Katz bearing the bates range Pfizer_MEvertsz_0079493 - 94.                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7044 | Summary of Proposed Labeling bearing the bates range Pfizer_CGrogan_0012493 and 0012541.                              | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7045 | Neurontin Indication Status Spreadsheets bearing the bates range Pfizer_MDL_0008198 - 408.            | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance   |
| DX7046 | NDA Reviewer's Guide: Content and Format.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7047 | NDA 20-235 Cover Letter bearing the bates range Pfizer_LCastro_0039684 - 85.                          | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7048 | Epilepsy NDA Index bearing the bates range Pfizer_LCastro_0066749 - 808.                              | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7049 | Neurontin IND/NDA Periodic and Annual Reports.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7050 | MedWatch Reports.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7051 | NDA Narratives in Epilepsy NDA.   | Deny  | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7052 | FDA letter to Janeth Turner.  | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7053 | Epilepsy ISE bearing the bates range Pfizer_Raltevotg_0000008 - 259.                                  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7054 | Epilepsy ISS bearing the bates range Pfizer_MPatel_0239370 - 40396.                                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7055 | Appendix B.2, Epilepsy ISS bearing the bates range Pfizer_MPatel_0239655 - 64.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7056 | Appendix B.5 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239680 - 99.                         | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7057 | Appendix B.13 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239801 - 34.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7058 | Appendix B.30, Epilepsy ISS bearing the bates range Pfizer_MPatel_0239956 - 58.                       | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7059 | Appendix B.33 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239968 - 76.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7060 | Appendix B.34 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239977 - 96.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7061 | Appendix C.1 to Epilepsy ISS bearing the bates range Pfizer_MPatel_0240009 - 52.                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7062 | Appendix C.3 to Epilepsy ISS bearing the bates range Pfizer_MPatel_0240057 - 141.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7063 | Appendix C.4, Epilepsy ISS bearing the bates range Pfizer_MPatel_0132429 - 60.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7064 | Table 14, Epilepsy ISS bearing the bates range WLC_CBU_117908.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7065 | Table 15, Epilepsy ISS bearing the bates range WLC_CBU_117910.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7066 | Table 41, Epilepsy ISS bearing the bates range WLC_CBU_117990.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7067 | Epilepsy ISS, page 135 bearing the bates range WLC_CBU_117998.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7068 | First Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0149430 - 72.                | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7069 | Appendix C.4, First Safety Update (Epilepsy NDA) bearing the bates range Pfizer_LAlphs_0066259 - 315. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7070 | First Safety Update (Epilepsy NDA) Table 8 bearing the bates range Pfizer_MPatel_0153669.             | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |

| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
| DX7071 | First Safety Update (Epilepsy NDA) Table 9 bearing the bates range Pfizer_MPatel_0153670.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7072 | Second Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0148429 - 85.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7073 | Appendix C, Second Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0155170 - 201.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7074 | Third Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_120469 - 518.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7075 | Appendix B.3, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MClaussen_0011908 - 09.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7076 | Appendix B.6, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MEvertsz_0021265 - 308.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7077 | Appendix B.7, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MClaussen_0011956 - 80.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7078 | Third Safety Update (Epilepsy NDA)--Review and Analysis of Clinical Data bearing the bates range Pfizer_LAlphs_0059899 - 917.                                | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7079 | Fourth Safety Update (Epilepsy NDA) bearing the bates range Pfizer_RAltevogt_0002091 - 138.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7080 | Appendices to Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_064286 - 648.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7081 | Appendix B.1 Fourth Safety Update (Epilepsy NDA) bearing the bates range Pfizer_LAlphs_0081418 - 564.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7082 | Appendix B.9, Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_057070 - 156.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7083 | Appendix B.10, Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_057157 - 63.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7084 | Fourth Safety Update (Epilepsy NDA)--Review and Analysis of Clinical Data bearing the bates range Pfizer_LLaMoreaux_0031627 - 34.                            | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7085 | PHN Safety Update bearing the bates range Pfizer_LCastro_0024697 - 810.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7086 | PHN ISE bearing the bates range Pfizer_Azeuscher_0005442 - 728.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7087 | PHN ISS bearing the bates range Pfizer_AGarrity_0007313 - 93.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7088 | Appendix A.9 Pain ISS bearing the bates range Pfizer_AGarrity_0007565.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7089 | Pain ISE bearing the bates range Pfizer_Sdoft_0001870 - 944.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7090 | Neuropathic Pain ISS bearing the bates range Pfizer_LLaMoreaux_009076 - 145.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7091 | Memorandum with attachments from Meisenhelder to Wallace.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7092 | Gabapentin NDA/FDA Questions/Requests: Responses to FDA Requests Book 1 bearing the bates range Pfizer_LAlphs_0082420 - 908.                                 | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7093 | Record of FDA Contact to discuss December 15, 1992 Advisory Committee Meeting to review the Gabapentin NDA bearing the bates range WLC_JTurner_000698 - 701. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7094 | Letter to Leber bearing the bates range Pfizer_LAlphs_0087261 - 62.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7095 | Letter to Paul Leber bearing the bates range   | Plaintiffs Lack Sufficient Information To Admit Or Deny   |                       |

| Ex#    | Description   | Authenticity  | Substantive Objection |
|--------|---|---|-----------------------|
|        | Pfizer_CPacella_0015510 - 11.   | Authenticity of Documents From Defendants Files   |                       |
| DX7096 | Gabapentin NDA/FDA Questions/Requests: Responses to FDA Requests Book 2 bearing the bates range Pfizer_LAlphs_0082979 - 98.                                 | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7097 | Response to FDA Question 101 bearing the bates range Pfizer_LAlphs_0083351 - 56.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7098 | Record of FDA Contact bearing the bates range NDA20235_MISC_001_0102 - 236.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7099 | Summary Basis of Approval of Gabapentin bearing the bates range Pfizer_LAlphs_0020290 - 383.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7100 | Memorandum to Gabapentin task force bearing the bates range WLC_JTurner_002441 - 47.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7101 | Combined Medical Statistical Review NDA-20-235 bearing the bates range Pfizer_LAlphs_0084359 - 479.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7102 | Supervisory Overview of Safety & Efficacy Data for NDA 20-235 bearing the bates range Pfizer_LLaMoreaux_0031287 - 304.                                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7103 | Epilepsy Pediatric ISS bearing the bates range WLC_CBU_061841 - 2079.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7104 | Gabapentin NDA/FDA Questions and Requests. Item 8 & 10: Clinical and Statistical bearing the bates range WLC_JTurner_000583 - 602.                          | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7105 | Record of FDA Contact bearing the bates range WLC_JTurner_000702 - 703.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7106 | Cover Letter Providing Neurontin Promotion Materials to Paul Leber from Janeth Turner bearing the bates range NDA20235_MISC_008_004 - 5.                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7107 | Approvable Action Memorandum for NDA 20-235 from Paul Leber bearing the bates range Pfizer_LAlphs_0059749 - 54.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7108 | Record of FDA Contact bearing the bates range WLC_JTurner_000813 - 15.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7109 | Fax from Jan Turner to Chamberlain bearing the bates range WLC_JTurner_002828 - 29.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7110 | Letter from Robert Temple to Janeth Turner bearing the bates range Pfizer_JMarino_0004515 - 49.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7111 | Memorandum from Janeth Turner to Distribution bearing the bates range Pfizer_LLaMoreaux_0031285 - 498.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7112 | Letter from Russell Katz to Janeth Turner bearing the bates range Pfizer_MPatel_0202536 - 39.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7113 | Email from Drusilla Scott to Anne Giordani et al. bearing the bates range Pfizer_LKnapp_0053774 - 79.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7114 | Email from Paula Sparks bearing the bates range Pfizer_AGarrity_0002518.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7115 | Center for Drug Evaluation and Research. Division Director Review and Basis for Approval Action for NDAs 21-397, 21-423, and 21-424. Dr. Cynthia McCormick. | Admit   |                       |
| DX7116 | Minutes of Teleconference with FDA bearing the bates range Pfizer_LCastro_0011772 - 76.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7117 | Review and Evaluation of Clinical Data for NDAs 21-397, 21-423, and 21-424 by Sharon Hertz.   | Admit   |                       |
| DX7118 | "Gabapentin & Suicide" report by Tina Ho bearing the bates range Pfizer_BParsons_0123117 - 27.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7119 | Gabapentin: Response to FDA Requests on Suicide and Suicide Attempts for Phase 2-4 Studies with Comparators, September                                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
|        | 2004 bearing the bates range Pfizer_MPatel_0064566 - 67.  |   |   |
| DX7120 | Appendix I to September 2004 Response (Gabapentin Clinical Study & Solicited Cases Reporting Completed Suicide) bearing the bates range Pfizer_GGribko_0011915 - 12475. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7121 | Letter from Janeth Turner to FDA Document and Records Section.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7122 | Explanation of Changes in Neurontin Label bearing the bates range WLC_JTurner_001685 - 87.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7123 | Record of FDA Contact bearing the bates range Pfizer_LAlphs_0087185 - 86.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7124 | Record of Contact bearing the bates range WLC_JTurner_000900 - 01.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7125 | Letter from Janeth Turner to Paul Leber bearing the bates range Pfizer_LCastro_0004858 - 947.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7126 | Record of FDA Contact bearing the bates range WLC_JTurner_002804.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7127 | Record of FDA Contact bearing the bates range WLC_JTurner_000948 - 49.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7128 | Record of FDA Contact bearing the bates range WLC_JTurner_000717 - 18.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7129 | Record of FDA Contact bearing the bates range WLC_JTurner_000688 - 89.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7130 | Record of FDA Contact bearing the bates range WLC_JTurner_000694 - 95.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7131 | Record of FDA Contact bearing the bates range WLC_Turner_000794 - 95.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7132 | Letter from Janeth Turner to Paul Leber bearing the bates range WLC_CBU_119649 - 720.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7133 | Record of FDA Contact bearing the bates range WLC_JTurner_000826 - 28.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7134 | Letter from Tim Paget to Stuart Dombey bearing the bates range WLC_CBU_102997- 3014.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7135 | Minutes of Meeting with FDA.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7136 | Letter from Janeth Turner to Michael Weintraub.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7137 | Neurontin PSUR for period 5/22/1995 - 11/22/1996.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7138 | Neurontin PSUR for period 2/2/1997 - 12/31/1997.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7139 | Neurontin PSUR for period 8/1/1998 - 1/21/1999.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7140 | Neurontin PSUR for period 2/2/1999 - 7/31/1999.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7141 | Neurontin PSUR for period 8/1/1999 - 1/31/2000.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7142 | Neurontin PSUR for period 8/1/2000 - 1/31/2001.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7143 | Neurontin PSUR for period 2/1/2001 - 7/31/2001.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7144 | (PSUR) Periodic Safety Update Report.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |



| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
| DX7145 | (PSUR) Periodic Safety Update Report (5-year) bearing the bates range Pfizer_MPate1_0022406 - 23226.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7146 | (PSUR) Periodic Safety Update Report (1-year) bearing the bates range Pfizer_LLaMoraux_0011734 - 817.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7147 | Psychiatric Event from 2004-2005 PSUR bearing the bates range Pfizer_LKnapp_0063282 - 83.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7148 | Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1 January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEvertz_00131185 - 00131202. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7149 | Parke-Davis Record of FDA Contact bearing the bates range WLC_JTurner_000459.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7150 | Parke-Davis Marketing Assessment: Neurontin in Psychiatric Disorders bearing the bates range V090836.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7151 | Letter and comments bearing the bates range Pfizer_LLaMoreaux_0025272.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7152 | Letter from Dr. Dieck to Dr. Gribko bearing the bates range Pfizer_GGribko_0025081 - 87.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7153 | Email from Allison Fannon to Leslie Tive et al. bearing the bates range Pfizer_LeslieTive_0079307.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7154 | Email from Allison Fannon to Leslie Tive et al. bearing the bates range Pfizer_LKnapp_0137046 - 84.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7155 | Letter from Drusilla Scott to Russell Katz bearing the bates range Pfizer_AGarrity_0002519 - 20.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7156 | Letter from Drusilla Scott to Cynthia McCormick bearing the bates range Pfizer_LKnapp_0025817 - 18.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7157 | Summary of Neurontin Pre-NDA Meeting for the "Management of Neuropathic Pain" bearing the bates range Pfizer_AGarrity_0002490 - 97.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7158 | Minutes of Meeting with FDA and addendum bearing the bates range Pfizer_LCastro_0005616 - 28.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7159 | Letter from Drusilla Scott to FDA with draft labeling bearing the bates range Pfizer_LCastro_0072351 - 403.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7160 | Pfizer Pharmaceuticals' search of adverse events bearing the bates range Pfizer_CPacella_0029534-0029639;0029859-0029864;0129716-0129720;0129799-0129801;0129813-0129818;0129829-0129834;0130032-0130038.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7161 | Email from Lester Reich to Manfred Hauben and attachment bearing the bates range Pfizer_MHauben_0000122 - 25.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7162 | Email from Chris Pacella to Cynthia de Luise bearing the bates range Pfizer_CPacella_0029869 - 71.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7163 | Email from Tina Ho to Cathy Sigler, et al. bearing the bates range Pfizer_THO_0012051 - 66.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7164 | Email from Cathy Sigler to Tina Ho bearing the bates range Pfizer_THO_0001633.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7165 | Email from Lesia Tontisakis to Michael Campbell et al. bearing the bates range Pfizer_THO_0001634 - 35.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7166 | Email and Attachment from Cathy Sigler to Christopher Pacella bearing the bates range Pfizer_CPacella_0022941 - 43.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7167 | Email from Julia Su to Claire Wohlhuter bearing the bates range Pfizer_SDoft_0055892 - 93.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7168 | Email from Suzanne Doft to Jill Bruzga, et al. bearing the bates   | Plaintiffs Lack Sufficient Information To Admit Or Deny   |                       |



| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
|        | range Pfizer_SDofT_0056764.  | Authenticity of Documents From Defendants Files   |                       |
| DX7169 | Email from Ed Whalen to Claire Wohlhuter, et al. bearing the bates range Pfizer_SDofT_0055890.                       | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7170 | Email from Tina Ho to Claire Wohlhuter bearing the bates range Pfizer_SDofT_56200.                                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7171 | Email from Bruce Parsons to Claire Wohlhuter bearing the bates range Pfizer_BParsons_0134014.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7172 | Email from Linda LaMoreaux to Julia Su bearing the bates range Pfizer_JSu_0026449.                                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7173 | Email from Manini Patel to Lucy Castro, et al. bearing the bates range Pfizer_BParsons_0155116 - 17.                 | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7174 | FDA Contact Report April 26, 2004 bearing the bates range Pfizer_BParsons_0141815 - 16.                              | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7175 | FDA Contact Report bearing the bates range Pfizer_LCastro_0019922 - 23.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7176 | Email from Manini Patel bearing the bates range Pfizer_LCastro_0020155.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7177 | Proposal for Search Methodology and Information to be Provided bearing the bates range Pfizer_BParsons_0141988 - 89. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7178 | FDA Contact Report bearing the bates range Pfizer_SDofT_001125 - 26.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7179 | Suicide and Suicide Related Events Analysis Plan Proposal bearing the bates range Pfizer_LCastro_0023878 - 79.       | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7180 | Email from Manini Patel bearing the bates range Pfizer_MPatel_0007960.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7181 | Email from Jacqueline Ware bearing the bates range Pfizer_SDofT_0000886 - 89.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7182 | Detailed Analysis Plan bearing the bates range Pfizer_MPatel_0008631 - 36.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7183 | Email from Lucy Castro bearing the bates range Pfizer_MPatel_0008627 - 30.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7184 | Email from Jacqueline Ware bearing the bates range Pfizer_LCastro_0031551 - 58.                                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7185 | Letter from Jacqueline Ware to Manini Patel, et al. bearing the bates range Pfizer_LCastro_0031246 - 52.             | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7186 | Email from Jacqueline Ware to Manini Patel, et al. bearing the bates range Pfizer_LCastro_0036078 - 86.              | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7187 | Adverse Event Listing for FDA Request.   | Admit   |                       |
| DX7188 | Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_MPatel_0023743 - 44.                         | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7189 | Proposed Suicide Analysis Plan bearing the bates range Pfizer_MPatel_0023745 - 52.                                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7190 | September 2004 Submission (with appendices) bearing the bates range Pfizer_MEvertsz_0141890 - 3416.                  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7191 | September 2004 Submission bearing the bates range Pfizer_MPatel_039110 - 68.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7192 | Appendix B1.4 (September 2004 Submission) bearing the bates range Pfizer_MPatel_0172206 - 09.                        | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7193 | Appendix D to September 2004 Submission.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7194 | Letter from Jane Axelrad to Keith Altman.   | Admit   |   |
| DX7195 | Parsons November 16, 2004 Response to FDA bearing the bates range Pfizer_Regulatory_000955 - 88.                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7196 | November 2004 Submission bearing the bates range Pfizer_MPatel_0045143 - 76.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7197 | Letter from Russell Katz to Manini Patel bearing the bates range Pfizer_LKnapp_0062278 - 85.                          | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7198 | Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_LKnapp_0062717 - 23.                          | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7199 | Letter from FDA to all AED Sponsors about March 16, 2005 Request bearing the bates range Pfizer_CTaylor_0015011 - 18. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7200 | Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_Regulatory_000486 - 95.                       | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7201 | Courtney Calder email to Molly Powers bearing the bates range Pfizer_Regulatory_000001.                               | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7202 | Courtney Calder email to Manini Patel bearing the bates range Pfizer_Regulatory_000002.                               | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7203 | Email from Manini Patel to Courtney Calder bearing the bates range Pfizer_Regulatory_000031 - 32.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7204 | Email from Courtney Calder to Manini Patel bearing the bates range Pfizer_Regulatory_000003.                          | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7205 | Letter from Russell Katz to Manini Patel bearing the bates range Pfizer_Regulatory_000473 - 75.                       | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7206 | Letter from Russell Katz to Mary Ann Evertsz bearing the bates range Pfizer_MEvertsz_0109461 - 63.                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7207 | Letter from Mary Ann Evertsz to Russell Katz bearing the bates range Pfizer_MEvertsz_0125701 - 05.                    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7208 | Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.   | Admit   |   |
| DX7209 | Letter from Russell Katz to Andrew Finkelstein.   | Admit   |   |
| DX7210 | Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.   | Admit   |   |
| DX7211 | Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.   | Admit   |   |
| DX7212 | Plaintiff Lawyer Ads.   | Deny  | Relevance   |
| DX7213 | Greylock McKinnon Associates Bill for Charles King.   | Admit   |   |
| DX7214 | Retention Letter from Greylock McKinnon Associates to Andrew Finkelstein.   | Admit   |   |
| DX7215 | Complete June 2006 Submission bearing the bates range Pfizer_Regulatory_000510 - 954.                                 | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7216 | June 2006 Submission correspondence bearing the bates range Pfizer_MEvertsz_0079431 - 35.                             | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7217 | Advisory Committee discussion.  | Admit   | Relevance   |
| DX7218 | Presentation slides.  | Admit   | Relevance   |
| DX7219 | Briefing document provided to the Advisory Committee.   | Admit   | Relevance except for page 317 (Postmarketing Experience)  |
| DX7220 | Letter from Robin Pitts to Cynthia McCormick.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7221 | Letter to DDMAC from Lucy Castro bearing the bates range Pfizer_LCastro_0085961.                                      | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7222 | Email from Burch to RON Specialty Sales Force bearing the bates range Pfizer_MBrown_00374 - 75.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7223 | Letter to DDMAC from Lucy Castro bearing the bates range Pfizer_LCastro_0085964 - 65.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7224 | Memorandum from Rick Burch to RON Sales Force bearing the bates range Pfizer_RGlanzman_0065616 - 17.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7225 | Letter to DDMAC from Manini Patel bearing the bates range Pfizer_MPatel_0145892.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7226 | Marketing Policies at Parke-Davis bearing the bates range WLC_FRANKLIN_0000128133 - 53.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7227 | Memorandum from R.W. Doyle to Distribution bearing the bates range WLC_FRANKLIN_0000128131 - 32.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7228 | Memorandum from R.W. Doyle to Distribution bearing the bates range WLC_FRANKLIN_0000097026 - 28.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7229 | Standard Operating Procedure for Consultant Meetings bearing the bates range WLC_FRANKLIN_0000111217 - 20.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7230 | Standard Operating Procedure for Continuing Medical Education Grants bearing the bates range WLC_FRANKLIN_0000111224 - 26.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7231 | Standard Operating Procedure for Speakers Bureau/Promotional Events bearing the bates range WLC_FRANKLIN_0000111221 - 23.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7232 | Standard Operating Procedure for the Utilization of Medical Groups at Customer Business Units bearing the bates range WLC_FRANKLIN_0000111227 - 29.                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7233 | Memorandum from Karen Katen to Joe Feczko, et al. bearing the bates range Pfizer_LeslieTive_0063878 - 80.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7234 | Memorandum from Pat Kelly to PPG - Marketing Personnel bearing the bates range Pfizer_LeslieTive_0063876 - 78.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7235 | Standard Response Letter bearing the bates range Pfizer_JSu_0018794.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7236 | Bipolar Standard Response Document.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7237 | Neurontin Speaker Training Guidelines bearing the bates range Pfizer_AZeuscher_0024845 - 46.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7238 | Neurontin Fact Sheet bearing the bates range Pfizer_SDoft_0015171 - 74.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7239 | Listing of Neurontin Worldwide Approvals and Indications bearing the bates range Pfizer_MDL_0008409 - 74.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7240 | Advisory Committee Meeting Transcript.  | Admit   |   |
| DX7241 | FDA Briefing Document from 1992 Advisory Committee Meeting.   | Admit   |   |
| DX7242 | Parke-Davis briefing document to FDA for Peripheral and Central Nervous System (PCNS) Advisory Committee Meeting bearing the bates range Pfizer_LAlphs_0041754 - 820. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7243 | Briefing Materials for Dec. 15, 1992 Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting on NDA 20-235.                                     | Admit   |   |
| DX7244 | Peripheral and Central Nervous System (PCNS) Advisory Committee Meeting Transcript.   | Admit   | Defendant Document Lacks Bates Number And Was Not Produced In Accordance With Rule 26 Or Plaintiff Discovery Demand |
| DX7245 | December 1992 Advisory Committee Meeting Transcript Vol. II.  | Admit   |   |

| Ex#    | Description   | Authenticity  | Substantive Objection |
|--------|---|---|-----------------------|
| DX7246 | May 16, 2002 Advisory Committee Transcript bearing the bates range Pfizer_LCastro_0083167 - 541.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7247 | CDER Office of Translational Sciences & Office of Biostatistics. Statistical Review of Evaluation titled Antiepileptic Drugs and Suicidality.   | Admit   |                       |
| DX7248 | Information for Healthcare Professionals - Suicidality and Antiepileptic Drugs (FDA Alert).   | Admit   |                       |
| DX7249 | Suicidal Thoughts and Behavior Antiepileptic Drugs (FDA Alert).   | Admit   |                       |
| DX7250 | Pfizer Slide presentation to Columbia University Antiepileptic Drug Meeting.  | Admit   |                       |
| DX7251 | FDA. Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee July 10, 2008. Questions 2008-437b-01-FDA-Katz.pdf.   | Admit   |                       |
| DX7252 | Russell Katz Memorandum. Briefing Document for the July 10, 2008 FDA Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality.  | Admit   |                       |
| DX7253 | FDA Amicus Brief.   | Admit   | Hearsay               |
| DX7254 | Pfizer Lyrica & Neurontin slide presentation presented at FDA Advisory Committee.   | Admit   |                       |
| DX7255 | FDA Advisory Committee meeting slide presentation by Dr. J Cramer.  | Admit   | Hearsay               |
| DX7256 | Pfizer Briefing Documents dated July 10, 2008.  | Admit   |                       |
| DX7257 | Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee Transcript.  | Admit   |                       |
| DX7258 | GlaxoSmithKline Lamictal slide presentation at FDA Advisory Committee Meeting on July 10, 2008.   | Admit   |                       |
| DX7259 | Letter from Katz to Clark.  | Admit   |                       |
| DX7260 | Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1 January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEvertsz_0013185 - 202. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7261 | Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067211 - 55.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7262 | Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067016 - 50.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7263 | Attachment 1 (List of Procedural Documents) to Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067051 - 57.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7264 | Pfizer U.S. Medical Information, Standard Response Document, Suicidal and Suicide Gesture bearing the bates range Pfizer_BParsons_008288 - 92.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7265 | Letter from Medicines Control Agency to Parke-Davis bearing the bates range WLC_CBU_103013-14.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7266 | Memorandum from Joe Feczko to PPG - US Medical Personnel bearing the bates range Pfizer_LCastro_0000054 - 58.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
| DX7267 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022305 - 11.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7268 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0047972 - 79.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7269 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022322 - 29.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7270 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022606 - 12.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7271 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LTive_0009939 - 43.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7272 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0047987 - 92.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7273 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0166311 - 14.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7274 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0022069 - 72.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7275 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022344 - 50.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7276 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0022073 - 75.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7277 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0048002 - 08.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7278 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0061212 - 17.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7279 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_MEvertsz_0015747 - 48.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7280 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LCastro_0084739 - 41.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7281 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_MEvertsz_0015747 - 48.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7282 | Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LCastro_0084739 - 41.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7283 | Risk Management Working Group Minutes bearing the bates range Pfizer_RGlanzman_0036788 - 92.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7284 | Risk Management Working Group Minutes bearing the bates range Pfizer_LKnapp_0025486 - 90.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7285 | Risk Management Working Group Minutes bearing the bates range Pfizer_LCastro_0076898 - 900.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7286 | Email string from Linda LaMoreaux to Julia Su bearing the bates range Pfizer_JSu_0017563 - 70.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7287 | Plots of PRR over time.  | Admit   |                       |
| DX7288 | Brock's handwritten notes.   | Admit   | Relevance; Hearsay    |
| DX7289 | International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; Guideline for Industry: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A). | Admit   | Relevance             |
| DX7290 | International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials (E8).  | Admit   | Relevance             |
| DX7291 | International Conference on Harmonization (ICH); Guideline for Industry: The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions (ICH E1A).           | Admit   | Relevance             |



| Ex#    | Description   | Authenticity  | Substantive Objection              |
|--------|---|---|------------------------------------|
| DX7292 | International Conference on Harmonisation Tripartite Guideline - Revision Of The ICH Guideline On Clinical Safety Data Management: Data Elements For Transmission Of Individual Case Safety Reports (E2b(R)).   | Admit   | Relevance                          |
| DX7293 | International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Pharmacovigilance Planning (E2e).   | Admit   |                                    |
| DX7294 | International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Structure And Content Of Clinical Study Reports (E3).   | Admit   | Relevance                          |
| DX7295 | International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Guideline For Good Clinical Practice (E6(R1)).  | Deny- Exhibit Does Not Match Description  | Exhibit Does Not Match Description |
| DX7296 | Neurontin Periodic Adverse Drug Experience Reports and Periodic Reports.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7297 | Email from Maribeth to Carriero bearing the bates range Pfizer_LKnapp_0062000 - 02.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7298 | MedDRA Release Archive.   | Admit   | Relevance                          |
| DX7299 | Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1: January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEvertsz_00131185 - 202. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7300 | Appendix 5, Pfizer Safety and Risk Management Literature Review: Gabapentin Use Among Persons with a History of Psychotic Disorder bearing the bates range Pfizer_Regulatory_261.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7301 | Statement by Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce U.S. House of Representatives.                  | Admit   |                                    |
| DX7302 | Summary of Minutes of Joint Meeting of Endocrine and Metabolic Drugs AC and Drug Safety and Risk Management AC.   | Admit   | Relevance                          |
| DX7303 | Report by Kenneth Petronis, Literature Review: Gabapentin Use Among Persons with a History of a Psychotic Disorder bearing the bates range Pfizer_Regulatory_000260 - 61.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7304 | Tabular Summary of the Indications and Medical History in Cases Reporting Patients Who Committed Suicide or Attempted Suicide While Receiving Gabapentin, by Jigna Shaw, Pharm. D. bearing the bates range Pfizer_MEvertsz_0091472 - 78.                  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7305 | Bipolar and Gabapentin Sensitivity Analysis.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay                            |
| DX7306 | Pfizer Response to CHMP's List of Questions bearing the bates range Pfizer_LKnapp_0127238.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7307 | FDA Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products; www.fda.gov/cder/guidance/1397fnl.pdf.   | Admit   |                                    |
| DX7308 | U.S. FDA, Reviewer Guidance: Evaluating the Risks of Drug Exposure in Human Pregnancies.  | Admit   | Relevance                          |



| Ex#    | Description   | Authenticity  | Substantive Objection |
|--------|---|---|-----------------------|
| DX7309 | Response Assessment Report on List of Outstanding Issues Neurontin and associated trade names (Gabapentin) EMEA/H/A-30/616 MAH: Pfizer Ltd. UK bearing the bates range Pfizer_Regulatory_000262 - 73.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7310 | Rapporteurs' Joint Response Assessment Report in the Referral under Article 30 of Directive 2001/83/EC concerning Neurontin (and associated names) (INN: Gabapentin) EMEA/H/A-30/616 bearing the bates range Pfizer_MPatel_0208552 - 647.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7311 | Response to EMEA List of Outstanding Issues dated 23 June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin), EMEA Procedure No: EMEA/H/A-30/616 bearing the bates range Pfizer_MEvertsz_0084390 - 479.                            | Admit   |                       |
| DX7312 | Appendix 4, Response to EMEA List of Outstanding Issues dated 23 June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin), EMEA Procedure No.: EMEA/H/A-30/616 bearing the bates range Pfizer_JMohan_0000479.                       | Admit   |                       |
| DX7313 | European Union Referral, Response to EMEA, List of Outstanding Issues dated 23, June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin) EMEA Procedure No.: EMEA/H/A-30-616 bearing the bates range Pfizer_MEvertsz_0084480 - 569. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7314 | Joint Response Assessment Report on List of Outstanding Issues Neurontin and associated trade names (Gabapentin) EMEA/H/A-30/616 MAH: Pfizer Ltd. UK bearing the bates range Pfizer_MPatel_0252359 - 95.  | Admit   |                       |
| DX7315 | EMA Guidance on Use of Statistical Signal Detection Methods.  | Admit   |                       |
| DX7316 | CHMP List of Questions bearing the bates range Pfizer_MPatel_0074999 - 5036.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7317 | CHMP Day 180 List of Outstanding Issues Neurontin and Associated names (Gabapentin) EMEA/H/A-30/616 bearing the bates range Pfizer_EGarofalo_001107 - 31.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7318 | CHMP 90-Day List of Remaining Issues bearing the bates range Pfizer_Regulatory_000033 - 36.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7319 | CHMP Summary on Referral Opinion bearing the bates range Pfizer_Regulatory_000062.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7320 | Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0029393 - 96.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7321 | Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0061978 - 81.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7322 | Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0061982 - 84.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7323 | Email from Christopher Pacella to Phillip Arena et al. bearing the bates range Pfizer_CPacella_0061231.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7324 | UK Summary of Product Characteristics 2004 bearing the bates range Pfizer_MPatel_0042959 - 70.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7325 | UK Summary of Product Characteristics for Neurontin Capsules and Tablets.   | Admit   |                       |
| DX7326 | Proposed Summary of Product Characteristics (International Label) bearing the bates range Pfizer_Regulatory_000228 - 46.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7327 | Summary of Product Characteristics 2006 bearing the bates range Pfizer_Regulatory_000215 - 27.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description  | Authenticity  | Substantive Objection              |
|--------|--|---|------------------------------------|
| DX7328 | Neurontin SPC viewed online at <a href="http://vwww.nelms.nhs.uk/Record20Viewinq/viewRecord.aspx?id=580399">http://vwww.nelms.nhs.uk/Record20Viewinq/viewRecord.aspx?id=580399</a> . | Deny- Exhibit Does Not Match Description  | Exhibit Does Not Match Description |
| DX7329 | Pfizer Inc Core Data Sheet bearing the bates range Pfizer_CPacella_0030209 - 20.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7330 | JNDA Summary of Clinical Safety bearing the bates range Pfizer_LAlphs_0002867 - 3074.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7331 | Investigator's Brochure Addendum for Epilepsy Studies in Japan bearing the bates range Pfizer_Mpatel_0017578 - 672.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7374 | FDA Talk Paper on Antidepressants.   | Admit   | Relevance                          |
| DX7375 | Statement from American Epilepsy Society.  | Admit   | Hearsay                            |
| DX7376 | Worsening Depression and Suicidality in Patients Being Treated with Antidepressants.   | Admit   | Relevance                          |
| DX7377 | Gabapentin Comprehensive Summary bearing the bates range Pfizer_LAlphs_0061807 - 1963.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7378 | Charlie Taylor 2003 MOA Report bearing the bates range Pfizer_CTaylor_0001365 - 76.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7379 | An Update on the Possible Mechanisms of Action of Gabapentin. By: Charles Taylor bearing the bates range Pfizer_CTaylor_0008905 - 23.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Rule 403;                          |
| DX7380 | Clinical Development in the Slipstream of Gabapentin bearing the bates range Pfizer_CTaylor_0000204 - 220.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7381 | PowerPoint presentation entitled: Drug Target A2D--The Biology and Pharmacology of Calcium Channel A2D Proteins bearing the bates range Pfizer_CTaylor_0000094 - 121.                | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7382 | Report by Dr. Stephen Brown, "Gabapentin and Psychosis" bearing the bates range MDL_LABL_0000002 - 04.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay                            |
| DX7383 | Report from Dr. Stephen Brown to Dr. Tim Paget bearing the bates range Pfizer_CPacella_0009440 - 49.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay                            |
| DX7384 | Medicines Control Agency Draft Response bearing the bates range Pfizer_LKnapp_0135264 - 65.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay                            |
| DX7385 | Email from James Leonard to Elizabeth Garofalo bearing the bates range Pfizer_LKnapp_0135257 - 58.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7386 | Email from Fiona Sellwood to Thomas Bradley et al. bearing the bates range Pfizer_CPacella_009588 - 89.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7387 | Email from Patricia Carlson to Fiona Sellwood bearing the bates range Pfizer_CPacella_009561 - 62.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7388 | Email from Patricia Carlson to James Leonard et al. bearing the bates range Pfizer_CPacella_009559 - 60.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7389 | Suicide Rates in Neurontin-Treated Populations bearing the bates range Pfizer_MPatel_0039743.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7390 | Email from Larry Alps to Cathy Sigler bearing the bates range Pfizer_LeslieTive_0041009-17.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7391 | Email from Dr. Alexander Ruggieri to Dr. Steven Galson.  | Admit   | Hearsay                            |
| DX7392 | Email from Donald Dobbs to Dr. Alexander Ruggieri.   | Deny  | Hearsay                            |
| DX7393 | Letter from Dr. Roder to Prof. Heller bearing the bates range Pfizer Leslie Tive 0020885-921.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7394 | Letter from Dr. Roder to Dr. Waldhausl bearing the bates range Pfizer Leslie Tive 0020844-79.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |
| DX7395 | Memorandum from Dr. Roder to Leslie Tive bearing the bates range Pfizer_LeslieTive_0020834 - 79.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                                    |

| Ex#    | Description  | Authenticity  | Substantive Objection   |
|--------|--|---|---|
| DX7396 | FDA Staff Manual Guides, Vol. II, § 1410.10.   | Admit   |   |
| DX7397 | Excerpts from Pfizer 2000 SEC form 10K.  | Deny  |   |
| DX7398 | Excerpts from Pfizer 2002 SEC form 10K.  | Deny  |   |
| DX7399 | COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms (2nd Edition).   | Admit   | Relevance   |
| DX7400 | COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms (5th Edition).   | Admit   |   |
| DX7401 | Pharmacist's Letter/Prescriber's Letter bearing the bates range Pfizer JSu_0017853 - 56.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay   |
| DX7402 | Office of Drug Safety Annual Report: 2002.   | Admit   |   |
| DX7403 | The FDA Guidance to Industry, Good Pharmacovigilance Practices and Pharmacoepidemiology Assessment.  | Admit   |   |
| DX7404 | FDA Guidance for Industry: E2E Pharmacovigilance Planning .  | Admit   |   |
| DX7405 | Adverse Event Reporting System (AERS) Office of Pharmacoepidemiology and Statistical Science Brief Description with Caveats of System.       | Admit   |   |
| DX7406 | Druglogic Qscan 3.2 User's Guide. User Manual. Version 3.2.2006..  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay   |
| DX7407 | The Guide to Off-Label Prescription Drugs: New Uses for FDA-Approved Prescription Drugs.   | Documents Are Self-Authenticating Under F.R.E. 902  | Relevance; Hearsay  |
| DX7408 | FDA's Guidance for Industry, Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products - Content and Format. | Admit   |   |
| DX7409 | Letter to Editor of Drug Safety.   | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay   |
| DX7410 | MedDRA Term Selection: Points to Consider. Release 3.10 (Based on MedDRA Version 11.0. April 1,2008.).                                       | Admit   |   |
| DX7411 | Affidavit of Dr. Cynthia McCormick, M.D. with exhibits.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7412 | Alexander Ruggieri, M.D. Expert Report.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7413 | Affidavit of Alexander Ruggieri, M.D.  | Admit   | Hearsay   |
| DX7414 | Alexander Ruggieri, M.D. Supplemental Expert Report.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7415 | Alexander Ruggieri, M.D. CV.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7416 | Charles P. Taylor, Ph.D. Expert Report.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7417 | Charles P. Taylor, Ph.D. CV.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7418 | Gerard Sanacora, Ph.D. M.D. Expert Report.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7419 | Gerard Sanacora, Ph.D. M.D. Supplemental Expert Report.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7420 | Charles P. Taylor, Ph.D. Supplemental Expert Report.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7421 | Gerard Sanacora, Ph.D. M.D. CV.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7422 | Janet Arrowsmith-Lowe, M.D. Expert Report.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7423 | Janet Arrowsmith, M.D. Supplemental Expert Report.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |

| Ex#    | Description  | Authenticity   | Substantive Objection   |
|--------|--|--|---|
| DX7424 | Janet Arrowsmith-Lowe, M.D. Expert Report.                                 | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7425 | Janet Arrowsmith-Lowe, M.D. Supplemental Expert Report.                    | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7426 | Janet Arrowsmith-Lowe, M.D. CV.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7427 | Sheila Weiss Smith, Ph.D. Expert Report.                                   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7428 | Sheila Weiss Smith, Ph.D. Supplemental Expert Report.                      | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7429 | Sheila Weiss Smith, Ph.D. CV.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7430 | Robert D. Gibbons, Ph.D. Expert Report.                                    | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7431 | Robert D. Gibbons, Ph.D. Supplemental Expert Report.                       | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7432 | Robert D. Gibbons, Ph.D. Supplemental Expert Report.                       | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7433 | Robert D. Gibbons, Ph.D. Supplemental Expert Report.                       | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7434 | Robert D. Gibbons, Ph.D. CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7435 | Atul C. Pande, M.D. CV bearing the bates range Pfizer_APande_0000352 - 54. | Plaintffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7436 | Janeth Turner CV.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7437 | Gary Brenner Ph.D., CV.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7438 | Gary Brenner Ph.D., Expert Report.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7439 | Edward Boyer, M.D. CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7440 | Edward Boyer, M.D. Expert Report.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7441 | Anthony Rothschild, M.D. CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7442 | Anthony Rothschild, M.D. Expert Report.                                    | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7443 | Anthony Rothschild, M.D. Expert Report.                                    | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7444 | Douglas Jacobs, M.D. CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7445 | Douglas Jacobs, M.D. Expert Report.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7446 | Douglas Jacobs, M.D. Expert Report.  | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7447 | Henry Grabowski, Ph.D. CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7448 | Henry Grabowski, Ph. D Expert Report.                                      | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7449 | Manfred Hauben, M.D., M.P.H., D.T.M.&H CV.                                 | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7450 | Lloyd Knapp, Pharm.D CV.   | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value  |
| DX7451 | Bentson McFarland M.D., Ph.D, Expert Report.                               | Admit  | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7452 | Sander Greenland, M.A., M.S., Ph.D. Expert Report.                         | Admit  |   |

| Ex#    | Description   | Authenticity  | Substantive Objection  |
|--------|---|---|--|
| DX7453 | Richard Mattson, M.D. CV.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7454 | Declaration of Richard Mattson.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7455 | Declaration of Miroslav Backonja, M.D.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7456 | Declaration of Dr. Kenneth Gorson.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7457 | Declaration of Dr. Edward Vieta.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7458 | Declaration of Robert Gerner, M.D.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7459 | Declaration of Carol A. Janney, M. S.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7460 | Declaration of Dr. Ninan T. Mathew.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7461 | Dr. Mark Mengel, M.D., M.P.H. CV.   | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value |
| DX7462 | Deposition of Benston McFarland.  | Admit   | Hearsay  |
| DX7463 | Figure A "Modulation of K <sup>+</sup> -induced synaptosomal calcium influx by Gabapentin." 875 Brain Res. 157, 158 (2000).   | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7464 | Figure A, "Stimulus-Dependent Modulation of [3H] Norepinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin," 295 J. Pharmacology and Experimental Therapeutics 1086, 1089 (2000). | Deny- Incomplete Document   | Hearsay  |
| DX7465 | Figure 3, "Inhibition of Neuronal Ca <sup>2+</sup> Influx by Gabapentin and Subsequent Reduction of Neurotransmitter Release from Rat Neocortical Slices," 130 Brit. J. Pharmacology 900, 902 (2000).   | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7466 | Figure A, "Stimulus-Dependent Modulation of [3H] Norepinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin," 295 J. Pharmacology and Experimental Therapeutics 1086, 1089 (2000). | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7467 | Figure 1, "Gabapentin Inhibits the Substance P-Facilitated K <sup>+</sup> Evoked Release of [3H] Glutamate from Rat Caudal Trigeminal Nucleus Slices," 93 Pain, 191, 193 (2001).                        | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7468 | Figure from "Pregabalin and Gabapentin Reduce Release of Substance P and CGRP from Rat Spinal Tissues Only After Inflammation or Activation of Protein Kinase C," 105 Pain 133, 136 (2003).             | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7469 | Figure titled "Gabapentin Reduces DAP-Stimulated but not Basal Monoamines" from Pugsley TA, Whetzel SZ, Dooley DJ, Psychopharmacology 137:74-80.  | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7470 | Figure titled "Neurontin/Gabapentin Prescriptions and Promotional Expenditures".  | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay  |
| DX7471 | Over-the-Counter Labeling Rule.   | Admit   | Relevance  |
| DX7472 | Letter to Dr. Robert Gibbons from Archives of General Psychiatry.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |  |
| DX7473 | Research Report 4192-0166.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |  |
| DX7474 | Research Report 720-02801, Study Protocol 945-5-1 Appendix A.2.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |  |
| DX7475 | Research Report 720-02455.  | Plaintiffs Lack Sufficient Information To Admit Or Deny   |  |



| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
|        |  | Authenticity of Documents From Defendants Files   |                       |
| DX7476 | Research Report 877-078 bearing the bates range Pfizer_LAlphs_0016276 - 514.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7477 | Research Report 4301-00066, Study Protocol 879-200 bearing the bates range Pfizer_LeslieTive_0045750 - 6674.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7478 | Research Report Memo 4301-00121, Study Protocol 877-035 bearing the bates range Pfizer_LAlphs_0016093 - 275.                     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7479 | Research Report 4301-00024, Study Protocol 877-210P.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7480 | Research Report 4301-00024: Appendix A.2 (Protocol 877-210 and Amendments 1 and 2, Blank CRFS).                                  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7481 | Research Report 720-02455 Correction Memorandum.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7482 | Research Report 720-02455 Correction Memorandum.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7483 | Research Report 720-04231, Study Protocol 945-094 bearing the bates range Pfizer_MEverts_0052019 - 3246.                         | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7484 | Research Report 720-02883, Study Protocol 945-13 bearing the bates range Pfizer_LAlphs_0031572 - 2276.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7485 | Research Report 4301-00077, Study Protocol 945-006.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7486 | Research Report 4301-00077, Study Protocol 945-006 Appendix A.2.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7487 | Research Report 4301-00103, Study Protocol 945-9/10 bearing the bates range Pfizer_LAlphs_0022558 - 609.                         | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7488 | Research Report 4301-00103: Appendix A.2 (Protocol 945-9/10 and Amendments) bearing the bates range Pfizer_LAlphs_0022558 - 609. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7489 | Research Report 4301-00126, Study Protocol 945-11 bearing the bates range Pfizer_LAlphs_0030388 - 692.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7490 | Research Report 720-02801, Study Protocol 945-005.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7491 | Research Report 720-02801, Study Protocol 945-005 Appendix A.2.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7492 | Research Report 720-02957.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7493 | Research Report 720-03092.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7494 | Research Report 720-03079.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7495 | Research Report 745-02070 bearing the bates range Pfizer_MPatel_0008714 - 34.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7496 | Research Report 720-03322 (Fourth Safety Update).  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7497 | Research Report 720-03362.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7498 | Research Report 720-03362: Correction Memorandum.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7499 | Research Report 720-03381.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7500 | Research Report 720-03366, Study Protocol 945-210G bearing the bates range Pfizer_LAlphs_0016627 - 99.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |



| Ex#    | Description  | Authenticity  | Substantive Objection |
|--------|--|---|-----------------------|
| DX7501 | Research Report 995-0070 Appendix A.3.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7502 | Research Report 720-03908, Study Protocol 945-210.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7503 | Research Report 720-03908, Study Protocol 945-210 Appendix A.2.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7504 | Research Report 720-03495 Study Protocol 945-082 bearing the bates range WLC_CBU_112771 - 887.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7505 | Research Report 720-03675, Study Protocol 945-088.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7506 | Research Report 720-03365, Study Protocol 945-213 bearing the bates range Pfizer_LAlphs_0036546 - 807.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7507 | Gabapentin monotherapy: an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7508 | Gabapentin monotherapy: II. A 26-Week, Double-Blind, Dose-Controlled, Multicenter Study of Conversion from Polytherapy in Outpatients with Refractory Complex Partial or Secondarily Generalized Seizures. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay               |
| DX7509 | Research Report 720-03779, Study Protocol 945-077 bearing the bates range Pfizer_LCastro_0057483 - 8337.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7510 | Research Report Memo 720-03847 Safety Protocol 945-077 bearing the bates range Pfizer_MPate1_0088542 - 60.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7511 | Research Report 720-03480 Neurontin Investigator's Brochure bearing the bates range WLC_CBU_030414 - 79.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7512 | Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_TMF_CRF_006931.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7513 | Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_TMF_CRF_006868.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7514 | Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_LAlphs_0048193.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7515 | Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_LAlphs_0048190.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Incomplete Document   |
| DX7516 | Research Report 720-03891, Study Protocol 945-086/186.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7517 | Research Report 995-00057, Study Protocols 945-193 and 945-200 bearing the bates range Pfizer_LeslieTive_0069995 - 70300.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7518 | Research Report 995-00070, Study Protocol 945-211.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7519 | Research Report 995-00072, Study Protocol 945-195.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7520 | Research Report 720-03851, Study Protocol 945-203.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7521 | Research Report 720-03851, Study Protocol 945-203 Appendix B.82 bearing the bates range Pfizer_EDukes_0009835 - 37.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7522 | Research Report 720-03851, Study Protocol 945-203 Appendix B.86.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7523 | Research Report 720-03851, Study Protocol 945-203 Appendix C.92.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7524 | Research Report 720-04174, Study Protocol 945-209.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7525 | Research Report 720-04174, Study Protocol 945-209 Appendix C.46 bearing the bates range Pfizer_LKnapp_0001212.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description   | Authenticity  | Substantive Objection |
|--------|---|---|-----------------------|
| DX7526 | Research Report 720-03851, Study Protocol 945-204.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7527 | Research Report 995-00074, Study Protocol 945-220 bearing the bates range Pfizer_LTive_0015139 - 294.     | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7528 | Research Report 720-04130, Study Protocol 945-224.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7529 | Research Report 720-04130, Study Protocol 945-224 Appendix 2.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7530 | Research Report for Study 945-092 bearing the bates range Pfizer_LCastro_0021988 - 0023071.               | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7531 | Research Report 430-00124, Study Protocol 945-430-295.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7532 | Research Report 720-04378, Study Protocol 1032-001.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7533 | RR 720-04223, Study Protocol 945-213.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7534 | Research Report 430-00125, Study Protocol 945-430-306.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7535 | Research Report 430-00125, Study Protocol 945-430-306.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7536 | Research Report 720-04455, Study Protocol 1035-001.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7537 | Research Report 720-04481, Study Protocol 1032-004.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7538 | Research Report No. 720-04479, Study Protocol 1032-002.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7539 | Research Report 720-04483, Study Protocol 1035-001B.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7540 | Research Report 995-00085, Study Protocol 945-217 bearing the bates range Pfizer_LeslieTive_0020213 - 69. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7541 | Research Report 720-04471, Study Protocol 1035-002.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7542 | Research Report 720-30049, Study Protocol 1035-003 bearing the bates range Pfizer_LAlphs_0078114.         | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7543 | Research Report 720-30049, Study Protocol 1035-003, p. 8 bearing the bates range Pfizer_LAlphs_0078121.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7544 | Research Report 744-00621 bearing the bates range Pfizer_SDoft_0001945 - 2002.                            | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7545 | Research Report 720-9450222, Study Protocol 945-421-222.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7546 | Research Report 934-0324, Study Protocol 934-324 bearing the bates range Pfizer_MPatel_0193581 - 4549.    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7547 | Research Report 934-0325, Study Protocol 934-325 bearing the bates range Pfizer_MPatel_0195037 - 6187.    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7548 | Research Report 720-30154, Study Protocol 945-411 bearing the bates range Pfizer_MPatel_0140560 - 703.    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7549 | Research Report 957-0233, Study Protocol 934-335 bearing the bates range Pfizer_MPatel_0194550 - 5036.    | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7550 | Final Taiwan Report, Study Protocol 945-468-429 bearing the bates range Pfizer_BParsons_0119335 - 120449. | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |
| DX7551 | Study Protocol 945-420-276 bearing the bates range Pfizer_LKnapp_0108138 - 398.                           | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |                       |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7552 | Final Report, Study Protocol 945-475-283 bearing the bates range Pfizer_MPate1_0245758 - 882.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7553 | Research Report 724-20013, Study Protocol 945-439.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7554 | Research Report 720-03930 bearing the bates range Pfizer_EGarofalo_0000498 - 517.   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7555 | Behavioral Disturbance with Gabapentin (Trimble, M. Institute of Neurology, London, Report for Parke, Davis & Company) bearing the bates range Pfizer_CPacella_0009404 - 21.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7556 | Psychosis with Gabapentin (Trimble, M. Institute of Neurology, London, Report for Warner Lambert) bearing the bates range WLC_CBU_102999 - 3014.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7557 | Summary of post-marketing reports for gabapentin through 3/31/02 Pfizer_CPacella_0061232 - 1257   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7558 | Information for Healthcare Professionals Suicidal Behavior and Ideation and Antiepileptic Drugs.<br><a href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm</a> | Admit   |   |
| DX7559 | Statistical review and evaluation.<br><a href="http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf">http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf</a> ,   | Admit   |   |
| DX7560 | Gibbons R.D., Duan N., Meltzer D., Pope, A., Penhoet E.D., Dubler N.N., Francis C.K., Gill, B., Guinan E., Henderson M., Ildstad S.T., King, P.A., Martinez-Maldonado M., McLain G.E., Murray J.E., Nelkin D. Spellman M.W, and Pitluck S. Waiting for Organ T  | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay   |
| DX7561 | Cynthia G. McCormick, M.D., FDA Division of Neuropharmacological Drug Products, Review of Third Safety Update (5/12/92)   | Admit   |   |
| DX7562 | Cynthia G. McCormick, M.D., FDA Division of Neuropharmacological Drug Products, Review of Fourth Safety Update (12/15/93)   | Admit   |   |
| DX7563 | Cynthia G. McCormick, M.D., Combined Medical-Statistical Review of NDA 20-235 (10/13/93)  | Admit   |   |
| DX7564 | Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry. 2007 Jul; 164(7):989-91.  | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay   |
| DX7565 | Böhning D, Schlattmann P, Lindsay BG. Re: "A statistical method for evaluating suicide clusters and implementing cluster surveillance". Am J Epidemiol. 1992 Jun; 135(11):1310-4.   | Documents Are Self-Authenticating Under F.R.E. 902  | Hearsay   |
| DX7566 | Charles Taylor 8/27/09 Deposition Exhibit 1   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7567 | Charles Taylor 8/27/09 Deposition Exhibit 2   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7568 | Charles Taylor 8/27/09 Deposition Exhibit 3   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7569 | Charles Taylor 8/27/09 Deposition Exhibit 4   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7570 | Charles Taylor 8/27/09 Deposition Exhibit 5   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7571 | Charles Taylor 8/27/09 Deposition Exhibit 6   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7572 | Charles Taylor 8/27/09 Deposition Exhibit 7   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |

| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7573 | Charles Taylor 8/27/09 Deposition Exhibit 8   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7574 | Charles Taylor 8/27/09 Deposition Exhibit 9   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7575 | Charles Taylor 8/27/09 Deposition Exhibit 10  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7576 | Charles Taylor 8/27/09 Deposition Exhibit 11  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7577 | Charles Taylor 8/27/09 Deposition Exhibit 12  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7578 | Charles Taylor 8/27/09 Deposition Exhibit 13  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7579 | Charles Taylor 8/27/09 Deposition Exhibit 14  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay; Chart Not Provided As Part of Expert Report In Advance Of Deposition; Incomplete Document; Calls For Expert Testimony; |
| DX7580 | David Franklin 12/18/09 Deposition Exhibit 1  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance   |
| DX7581 | David Franklin 12/18/09 Deposition Exhibit 2  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance   |
| DX7582 | David Franklin 12/18/09 Deposition Exhibit 3  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance   |
| DX7583 | David Franklin 12/18/09 Deposition Exhibit 4  | Deny  | Relevance   |
| DX7584 | David Franklin 12/18/09 Deposition Exhibit 5  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance   |
| DX7732 | Final Study Report: Gabapentin Protocol A945-1008 A 15 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Neurontin for Efficacy and Quality of Life in Patients with Painful, Diabetic Peripheral Neuropathy Pfizer_LKn | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7733 | Email from John Marino to Allison Fannon et al. bearing bates range Pfizer_CGrogan_0012251 - 52.  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance; Rule 403   |
| DX7734 | Memorandum from R.W. Doyle to Distribution, re: Marketing Policies & Procedures, dated Dec. 6, 1994   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Rule 403  |
| DX7735 | Document titled Promostudy Report, RE: Neurontin Merritt-Putnam Symposium, Mar. 1995  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Hearsay;  |
| DX7736 | Document titled "Medical Education, Non-Speakers Bureau, Independent Programs, Grants and Promotional Programs, dated Jan. 1, 1996  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Rule 403  |
| DX7737 | Contract Addendum   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance; Rule 403   |
| DX7738 | Draft Internal PD Memorandum from P. Reichenberger to all TMs and ABMs, re: Emerging Applications Programs, dated Aug. 26, 1996   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403  |
| DX7739 | Letter from Tracie L. Kelley (MES) to John Knoop (PD), dated Feb. 27, 1997  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay;  |
| DX7740 | Memo re: Neurontin for Neuropathic Pain in Diabetic Neuropathy  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance; Rule 403   |
| DX7741 | Itr from Vervack to Aquino  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance; Rule 403; Hearsay  |
| DX7742 | Memorandum from Pat Kelly to PPG - US Marketing Personnel, dated Mar. 2001, bearing the bates range Pfizer_DProbert_0019738-42  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance; Rule 403   |
| DX7743 | E-mail from Marino Garcia to Angela Crespo, et al., re: Please Read - Article: "Emerging Therapies in Chronic Pain", dated  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;  |

| Ex#    | Description   | Authenticity  | Substantive Objection  |
|--------|---|---|--|
|        | Apr. 27, 2001, bearing the bates range Pfizer_LCastro_0004053-054   |   |  |
| DX7744 | Email From: Burch To: DL-K All Managers, DL-K All Reps<br>Cc: several recipients  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7745 | Email from Marino Garcia to Timothy Hsu and Robert Glanzman, re: Neurontin For Ne Pain in Germany, dated July 18, 2001 bearing the bates range Pfizer_RGlanzman_0037380-381   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;   |
| DX7746 | Submission cover letter with attachments from Beate Roder to the journal Diabetic Medicine, dated Feb. 14, 2002, bearing the bates range Pfizer_LeslieTive_0020880-0020921  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay;   |
| DX7747 | Press release titled "PFIZER RECEIVES FDA APPROVAL TO MARKET NEURONTIN FOR POST-HERPETIC NEURALGIA", dated May 28, 2002, bearing the bates range Pfizer_KSiegler_0004997-998  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7748 | Email from Allison Fannon to Howard Bockbrader, Brian Corrigan re: Gabapentin Pk/pd Abstract and manuscript, dated June 10, 2002, bearing the bates range Pfizer_RGlanzman_014062-063   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7749 | Email from Steve Piron to John Marino, et al., re: NEU-0032591_DDMAC Materials, dated June 13, 2002, bearing the bates range Pfizer_CGrogan_0007124-169   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;   |
| DX7750 | Email from Leslie Tive to Allison Fannon, re: Key Messages, dated Oct. 17, 2002, bearing the bates range Pfizer_RGlanzman_0125037-039   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7751 | Email from Robert Glanzman to Allison Fannon, Suzanne Doft and Angela Crespo, re: Key Messages, dated Oct. 17, 2002, bearing the bates range Pfizer_RGlanzman_0161613-614   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7752 | Submission cover letter with attachments from Beate Roder to the journal DIABETOLOGIA, dated Oct. 21, 2002, bearing the bates range Pfizer_LeslieTive_0020840-0020879   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay;   |
| DX7753 | Email from Bruce Parsons to Mariann Caprino and Jennifer Stamp, DL-Neurontin MM PM & PP, DL-PPG Neurology Group, AA DDEV 945 Neuro Team List, re: Neurontin: NeP Dosing Manuscript Printed Copy Available, dated Jan. 27, 2003, bearing the bates range Pfizer  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7754 | Letter from Rober M. Sutherland M.D., Co-Director Center for Pain Medicine, Allegheny General Hospital to Carlos Gorrio, Territory Manager, Parke Davis, Northeast Customer Business Unit, re: June 4, 1995 letter from Sherwood Richardson to Anthony Wild, da | Deny  | Hearsay;Unfairly Prejudicial- Prejudice Outweighs Probative Value; |
| DX7755 | Email chain sent from Janney Carol to Atul Pande and Debra Gmerek, re: 945-209, dated Feb., 1998  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7756 | Parke-Davis Investigator's Meeting Protocol 945-209, The Ritz Carlton, Chicago, IL., Meeting Minutes, dated Mar. 8-9, 1996  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7757 | Email from Hank McRorie to DL-All_Field_Force, dated Nov. 30, 2000, bearing the bates range Pfizer_MBrown_0000336-38  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Relevance;Rule 403   |
| DX7758 | NDA 21-397 Item 6 Table of Contents - Human Pharmacokinetics and Bioavailability  | Deny  | Exhibit Not Provided   |
| DX7759 | Pfizer RR: RR-Reg 740-03550, bearing bates range Pfizer_LCastro_0007627-94  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |  |
| DX7760 | Proceedings of the Third International Conference on Bipolar Disorder 1999  | Deny  | Exhibit Not Provided   |



| Ex#    | Description   | Authenticity  | Substantive Objection   |
|--------|---|---|---|
| DX7761 | Atul Pande presentation slides titled "Combination Treatment in Bipolar Disorder"<br>(http://www.wpic.pitt.edu/stanley/3rdbipconf/pptslides/pande_files/slide0030.htm, accessed 10/24/2008)                   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7762 | Transcript of A. Pande's Presentation at the Third International Conference on Bipolar Disorder, "New Pharmacotherapies."   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7763 | Chart Titled "Neurontin / Gabapentin Prescriptions and Promotional Expenditures" (Dec. 15, 2008, Michael C. Keeley Expert Report, p. 28)  | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay;Rule 403  |
| DX7764 | Memorandum from B. Roder to L. Tive re: Publication of 945-224 results, bearing bates range Pfizer_LeslieTive_0020834-921   | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files | Hearsay;Rule 403  |
| DX7765 | Response to FDA Regarding Suicide and Suicide Attempt in Neurontin (gabapentin) Clinical Trials and Postmarketing Surveillance, bearing bates range Pfizer_Regulatory_001621-79.                              | Plaintiffs Lack Sufficient Information To Admit Or Deny Authenticity of Documents From Defendants Files |   |
| DX7766 | FDA Ctr. for Drug Eval. And Research, Div. of Neuropharmacological Drug Products, Review and Eval. Of Clinical Data, NDA Supp. 20-235 (Safety Update #4). Review of the World Literature, dated Dec. 15, 1993 | Admit   |   |
| DX7767 | Research Protocol-945-224-A Double Blind Placebo-Controlled Trial with 3 Doses of Gabapentin for Treatment of Painful Diabetic Neuropathy   | Deny  | Exhibit Not Provided  |
| DX7768 | 21 C.F.R. 314.105   | Admit   | Relevance;Rule 403;Foundation   |
| DX7769 | 21 U.S.C. 301   | Admit   | Relevance;Rule 403;Foundation   |
| DX7770 | 21 U.S.C. 352   | Admit   | Relevance;Rule 403;Foundation   |
| DX7771 | 21 U.S.C. 355   | Admit   | Relevance;Rule 403;Foundation   |
| DX7772 | 21 U.S.C. 393   | Admit   | Relevance;Rule 403;Foundation   |
| DX7773 | 51 Fed. Reg. 43900  | Admit   | Relevance;Rule 403;Foundation   |
| DX7774 | 71 Fed. Reg. 3922-29 (Jan. 24, 2006)  | Admit   | Relevance;Rule 403;Foundation   |
| DX7775 | 21 C.F.R. 201.57 (April 2002)   | Admit   | Rule 403;Foundation   |
| DX7776 | 21 C.F.R. 202.1   | Admit   | Relevance;Rule 403;Foundation   |
| DX7777 | 21 C.F.R. 312.20  | Admit   | Relevance;Rule 403;Foundation   |
| DX7778 | 21 C.F.R. 312.22  | Admit   | Relevance;Rule 403;Foundation   |
| DX7779 | 21 C.F.R. 314.50  | Admit   | Relevance;Rule 403;Foundation   |
| DX7780 | 21 C.F.R. 314.80  | Admit   | Relevance;Rule 403;Foundation   |
| DX7781 | Daubert Hearing Transcript (6-20-08)  | Admit   | Relevance;Hearsay;Unfairly Prejudicial- Prejudice Outweighs Probative Value;Rule 403;Foundation   |
| DX7782 | Daubert Hearing Transcript(7-23-08)   | Admit   | Relevance;Hearsay;Unfairly Prejudicial- Prejudice Outweighs Probative Value;Rule 403;Foundation   |
| DX7783 | Daubert Hearing Transcript (6-19-08)  | Admit   | Relevance;Hearsay;Unfairly Prejudicial- Prejudice Outweighs Probative Value;Rule 403;Foundation   |
| DX7784 | Robert D. Gibbons, Ph.D. Supplemental Expert Report.  | Admit   | Untilmely Disclosure; Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7785 | Robert D. Gibbons, Ph.D. Supplemental Expert Report.  | Admit   | Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703                       |
| DX7786 | Henry Grabowski, Ph. D Supplemental Expert Report.  | Admit   | Untimely;Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703              |



| Ex#    | Description  | Authenticity | Substantive Objection  |
|--------|--|--------------|--|
| DX7787 | Henry Grabowski, Ph. D Supplemental Expert Report.   | Admit        | Untimely;Hearsay; Unfairly Prejudicial- Prejudice Outweighs Probative Value; Fails To Meet The Requirments of FRE 702 And/Or FRE 703 |
| DX7788 | Levetiracetam (Keppra) 2006  | Admit        | Relevance  |
| DX7789 | FDA-Approved U.S. Professional Package Insert for Trileptal (Physician's Desk Reference (2006))      | Admit        | Relevance  |
| DX7790 | FDA-Approved U.S. Professional Package Insert for Lyrica (Physician's Desk Reference (2006))         | Admit        | Relevance  |
| DX7791 | FDA-Approved U.S. Professional Package Insert for Gabitril (Physician's Desk Reference (2005))       | Admit        | Relevance  |
| DX7792 | FDA-Approved U.S. Professional Package Insert for Topamax (Physician's Desk Reference (2007))        | Admit        | Relevance  |
| DX7793 | FDA-Approved U.S. Professional Package Insert for Depakote (Physician's Desk Reference (2006))       | Admit        | Relevance  |
| DX7794 | FDA-Approved U.S. Professional Package Insert for Zonegran (Physician's Desk Reference (2007))       | Admit        | Relevance  |
| DX7795 | FDA-Approved U.S. Professional Package Insert for Tegretol (Physician's Desk Reference (2006))       | Admit        | Relevance  |
| DX7796 | FDA-Approved U.S. Professional Package Insert for Equetro (Physician's Desk Reference (2005))        | Admit        | Relevance  |
| DX7797 | FDA-Approved U.S. Professional Package Insert for Felbatol (Physician's Desk Reference (2002))       | Admit        | Relevance  |
| DX7798 | FDA-Approved U.S. Professional Package Insert for Lamictal (Physician's Desk Reference (2006))       | Admit        | Relevance  |
| DX7799 | Amitriptyline Hydrochloride Package Insert   | Admit        | Relevance  |
| DX7800 | Nortriptyline Hydrochloride Package Insert   | Admit        | Relevance  |
| DX7801 | Desipramine Hydrochloride Package Insert   | Admit        | Relevance  |
| DX7802 | Carbamazepine Package Insert   | Admit        | Relevance  |
| DX7803 | Valproate Sodium Package Insert  | Admit        | Relevance  |
| DX7804 | FDA-Approved U.S. Professional Package Insert for Amitriptyline (Physician's Desk Reference (2001))  | Admit        | Relevance  |
| DX7805 | FDA-Approved U.S. Professional Package Insert for Bextra (Physician's Desk Reference (2004))         | Admit        | Relevance  |
| DX7806 | FDA-Approved U.S. Professional Package Insert for Celestone (Physician's Desk Reference (2001))      | Admit        | Relevance  |
| DX7807 | FDA-Approved U.S. Professional Package Insert for Celestone (Physician's Desk Reference (2002))      | Admit        | Relevance  |
| DX7808 | FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (1998)) | Admit        | Relevance  |
| DX7809 | FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (1999)) | Admit        | Relevance  |
| DX7810 | FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2000)) | Admit        | Relevance  |
| DX7811 | FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2001)) | Admit        | Relevance  |
| DX7812 | FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2003)) | Admit        | Relevance  |
| DX7813 | FDA-Approved U.S. Professional Package Insert for Demerol (Physician's Desk Reference (2003))        | Admit        | Relevance  |
| DX7814 | FDA-Approved U.S. Professional Package Insert for Desipramine (Physician's Desk Reference (2003))    | Admit        | Relevance  |

| Ex#    | Description  | Authenticity | Substantive Objection |
|--------|--|--------------|-----------------------|
| DX7815 | FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2000))   | Admit        | Relevance             |
| DX7816 | FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2003))   | Admit        | Relevance             |
| DX7817 | FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2004))   | Admit        | Relevance             |
| DX7818 | FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (1998))  | Admit        | Relevance             |
| DX7819 | FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2000))  | Admit        | Relevance             |
| DX7820 | FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2003))  | Admit        | Relevance             |
| DX7821 | FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2004))  | Admit        | Relevance             |
| DX7822 | FDA-Approved U.S. Professional Package Insert for Imipramine (Physician's Desk Reference (2003)) | Admit        | Relevance             |
| DX7823 | FDA-Approved U.S. Professional Package Insert for Lexapro (Physician's Desk Reference (2003))    | Admit        | Relevance             |
| DX7824 | FDA-Approved U.S. Professional Package Insert for Lortab (Physician's Desk Reference (2003))     | Admit        | Relevance             |
| DX7825 | FDA-Approved U.S. Professional Package Insert for Lortab (Physician's Desk Reference (2004))     | Admit        | Relevance             |
| DX7826 | FDA-Approved U.S. Professional Package Insert for Marcaine (Physician's Desk Reference (2001))   | Admit        | Relevance             |
| DX7827 | FDA-Approved U.S. Professional Package Insert for Marcaine (Physician's Desk Reference (2002))   | Admit        | Relevance             |
| DX7828 | FDA-Approved U.S. Professional Package Insert for Medrol (Physician's Desk Reference (2000))     | Admit        | Relevance             |
| DX7829 | FDA-Approved U.S. Professional Package Insert for Naprosyn (Physician's Desk Reference (1999))   | Admit        | Relevance             |
| DX7830 | FDA-Approved U.S. Professional Package Insert for Naprosyn (Physician's Desk Reference (2001))   | Admit        | Relevance             |
| DX7831 | FDA-Approved U.S. Professional Package Insert for Neurontin (Physician's Desk Reference (2003))  | Admit        | Relevance             |
| DX7832 | FDA-Approved U.S. Professional Package Insert for Neurontin (Physician's Desk Reference (2004))  | Admit        | Relevance             |
| DX7833 | FDA-Approved U.S. Professional Package Insert for Percocet (Physician's Desk Reference (1998))   | Admit        | Relevance             |
| DX7834 | FDA-Approved U.S. Professional Package Insert for Phenergan (Physician's Desk Reference (2003))  | Admit        | Relevance             |
| DX7835 | FDA-Approved U.S. Professional Package Insert for Tylenol (Physician's Desk Reference (2003))    | Admit        | Relevance             |
| DX7836 | FDA-Approved U.S. Professional Package Insert for Vioxx (Physician's Desk Reference (2000))      | Admit        | Relevance             |
| DX7837 | FDA-Approved U.S. Professional Package Insert for Vioxx (Physician's Desk Reference (2001))      | Admit        | Relevance             |
| DX7838 | FDA-Approved U.S. Professional Package Insert for Vioxx (Physician's Desk Reference (2003))      | Admit        | Relevance             |
| DX7839 | FDA-Approved U.S. Professional Package Insert for Keppra (Physician's Desk Reference (2007))     | Admit        | Relevance             |